WO2007079605A2 - Template-fixed peptidomimetics with antimicrobial activity - Google Patents

Template-fixed peptidomimetics with antimicrobial activity Download PDF

Info

Publication number
WO2007079605A2
WO2007079605A2 PCT/CH2007/000017 CH2007000017W WO2007079605A2 WO 2007079605 A2 WO2007079605 A2 WO 2007079605A2 CH 2007000017 W CH2007000017 W CH 2007000017W WO 2007079605 A2 WO2007079605 A2 WO 2007079605A2
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
chr
alkenyl
alkyl
conr
Prior art date
Application number
PCT/CH2007/000017
Other languages
French (fr)
Other versions
WO2007079605A3 (en
Inventor
Frank Gombert
Daniel Obrecht
Wim Vrijbloed
Ricardo Dias
Steve J. Demarco
John Anthony Robinson
Nityakalyana Srinivas
Original Assignee
Polyphor Ltd.
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200730882T priority Critical patent/SI1979374T1/en
Priority to KR1020087020026A priority patent/KR101352829B1/en
Application filed by Polyphor Ltd., Universität Zürich filed Critical Polyphor Ltd.
Priority to CA2637377A priority patent/CA2637377C/en
Priority to DK07700115.4T priority patent/DK1979374T3/en
Priority to PL07700115T priority patent/PL1979374T3/en
Priority to AU2007204547A priority patent/AU2007204547B2/en
Priority to NZ570245A priority patent/NZ570245A/en
Priority to JP2008549738A priority patent/JP5237826B2/en
Priority to BRPI0707144-2A priority patent/BRPI0707144B1/en
Priority to EA200801710A priority patent/EA015991B1/en
Priority to CN2007800080521A priority patent/CN101395173B/en
Priority to AT07700115T priority patent/ATE538131T1/en
Priority to ES07700115T priority patent/ES2381846T3/en
Priority to US12/161,065 priority patent/US8685922B2/en
Priority to EP07700115A priority patent/EP1979374B1/en
Publication of WO2007079605A2 publication Critical patent/WO2007079605A2/en
Publication of WO2007079605A3 publication Critical patent/WO2007079605A3/en
Priority to IL192816A priority patent/IL192816A/en
Priority to NO20083485A priority patent/NO341875B1/en
Priority to HK09105497.8A priority patent/HK1127957A1/en
Priority to US14/074,251 priority patent/US9521846B2/en
Priority to US14/175,160 priority patent/US9538752B2/en
Priority to US14/175,193 priority patent/US9596852B2/en
Priority to US15/392,586 priority patent/US10730912B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Definitions

  • the present invention provides template-fixed ⁇ -hairpin peptidomimetics incorporating a template-fixed chain of 12 ⁇ -amino acid residues which, depending on their positions in the chain, are GIy or Pro, or of certain types, as defined herein below. These template-fixed ⁇ - hairpin mimetics have a selective antimicrobial activity.
  • the present invention provides efficient synthetic processes by which these compounds can, if desired, be made in parallel library-format.
  • These ⁇ -hairpin peptidomimetics show improved efficacy, bioavailability, half-life and most importantly a significantly enhanced ratio between antibacterial activity on the one hand, and hemolysis of red blood cells on the other.
  • tachyplesins [T. Nakamura, H. Furunaka, T. Miyata, F. Tokunaga, T. Muta, S. Iwanaga, M. Niwa, T. Takao, Y. Shimonishi, Y. J. Biol. Chem. 1988, 263, 16709-16713], and the defensins [R. I. Lehrer, A. K. Lichtenstein, T. Ganz, Annu. Rev. Immunol. 1993, 11, 105-128], amphipathic ⁇ -helical peptides (e.g. cecropins, dermaseptins, magainins, and mellitins [A. Tossi, L.
  • cationic peptides such as protegrin 1 (A. Aumelas, M. Mangoni, C. Roumestand, L. Chiche, E.
  • Gramicidin S is a backbone-cyclic peptide with a well defined ⁇ -hairpin structure (S. E. Hull, R. Karlsson, P. Main, M. M. Woolfson, E. J. Dodson, Nature 1978, 275, 206-275) that displays potent antimicrobial activity against gram-positive and gram-negative bacteria (L. H. Kondejewski, S. W. Farmer, D. S. Wishart, R. E. Hancock, R. S. Hodges, Int. J. Peptide Prot. Res. 1996, 47, 460-466).
  • the high hemolytic activity of gramicidin S has, however, hindered its widespread use as an antibiotic.
  • protegrin analogues such as IB367 (J. Chen, T. J. Falla, H. J. Liu, M. A. Hurst, C. A. Fujii, D. A. Mosca, J. R. Embree, D. J. Loury, P. A. Radel, C. C. Chang, L. Gu, J. C. Fiddes,
  • protegrin 1 This broad antimicrobial activity combined with a rapid mode of action, and their ability to kill bacteria resistant to other classes of antibiotics, make them attractive targets for development of clinically useful antibiotics.
  • the activity against gram-positive bacteria is typically higher than against gram- negative bacteria.
  • protegrin 1 also exhibits a high hemolytic activity against human red blood cells, and hence a low selectivity towards microbial cells.
  • Oriented CD experiments W. T. Heller, A. J. Waring, R. I. Lehrer, H. W. Huang, Biochemistry 1998, 37, 17331- 17338) indicate that protegrin 1 may exist in two different states as it interacts with membranes, and these states are strongly influenced by lipid composition.
  • Studies of cyclic protegrin analogues J.-P. Tam, C.
  • Protegrin 1 is an 18 residues linear peptide, with an amidated carboxyl terminus and two disulfide bridges.
  • Tachyplesin I contains 17 residues, also has an amidated carboxyl terminus and contains two disulfide bridges.
  • Recently described backbone-cyclic protegrin and tachyplesin analogues typically contain 18 residues and up to three disulfide bridges (J. P. Tam, C. Wu, J.-L. Yang, Eur. J. Biochem. 2000, 267, 3289-3300; J. P. Tam, Y.-A. Lu, J.-L. Yang, Biochemistry 2000, 39, 7159-7169; N. Sitaram, R. Nagaraij, Biochem. Biophys. Res. Comm. 2000, 267, 783-790).
  • Cathelicidin a 37-residue linear helical-type cationic peptide, and analogues are currently under investigation as inhaled therapeutic agents for cystic fibrosis (CF) lung disease
  • CF cystic fibrosis
  • pseudomonas aeruginosa C. A. Demko, P. J. Biard, P. B. Davies, J. Clin.
  • a new strategy is introduced to stabilize ⁇ -hairpin conformations in backbone-cyclic cationic peptide mimetics exhibiting selective antimicrobial activity. This involves transplanting the cationic and hydrophobic hairpin sequence onto a template, whose function is to restrain the peptide loop backbone into a hairpin geometry.
  • the methods described herein allow the synthesis and screening of large hairpin mimetic libraries, which in turn considerably facilitates structure-activity studies, and hence the discovery of new molecules with potent selective antimicrobial and very low hemolytic activity to human red blood cells.
  • the present strategy allows to synthesize ⁇ -hairpin peptidomimetics with novel selectivities towards various multi-drug resistant pseudomonas- strains.
  • ⁇ -hairpin peptidomimetics of the present invention are compounds of the general formula
  • R 1 is H; lower alkyl; or aryl-lower alkyl
  • R 2 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s SR 56 ;
  • R 3 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s SR 56 ;
  • R 4 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s SR 56 ;
  • R 5 is alkyl; alkenyl; -(CH 2 ) O (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ;
  • R 6 is H; alkyl; alkenyl; -(CH 2 ) 0 (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ;
  • R 7 is alkyl; alkenyl; -(CH 2 ) q (CHR 61 ) s OR 55 ; -(CH 2 ) q (CHR 61 ) s NR 33 R 34 ;
  • R 8 is H; Cl; F; CF 3 ; NO 2 ; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl;
  • R 9 is alkyl; alkenyl; -(CH 2 ) O (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ;
  • R 10 is alkyl; alkenyl; -(CH 2 ) O (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ;
  • R 11 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 6I ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s NR 33 R 34 ;
  • R 12 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s SR 56 ;
  • R 13 is alkyl; alkenyl; -(CH 2 ) q (CHR 61 ) s OR 55 ; -(CH 2 ) q (CHR 61 ) s SR 56 ;
  • R 14 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s NR 33 R 34 ; -(CH 2 ) m (CHR 61 ) s OCONR 33 R 75 ; -(CH 2 ) m (CHR 61 ) s NR 20 CONR 33 R 82 ; -(CH 2 ) q (CHR 61 ) s COOR 57 ; -(CH 2 ) q (CHR 61 ) s CONR 58 R 59 ; -(CH 2 ) q (CHR 61 ) s PO(OR 60 ) 2 ; -(CH 2 ) q (CHR 61 ) s SO 2 R 62 ; or -(CH 2 ) q (CHR 6I ) s C 6 H 4 R 8 ;
  • R 14 is H; al
  • R 15 is alkyl; alkenyl; -(CH 2 ) O (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ; -(CH 2 ) O (CHR 6I ) S NR 33 R 34 ;
  • R 16 is alkyl; alkenyl; -(CH 2 ) O (CHR 6! ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ; -(CH 2 ) O (CHR 61 ) S NR 33 R 34 ;
  • R 17 is alkyl; alkenyl; -(CH 2 ) q (CHR 61 ) s OR 55 ; -(CH 2 ) q (CHR 6I ) s SR 56 ; -(CH 2 ) q (CHR 61 ) s NR 33 R 34 ;
  • R 18 is alkyl; alkenyl; -(CH 2 ) P (CHR 6I ) S OR 55 ; -(CH 2 ) P (CHR 61 ) S SR 56 ; -(CH 2 ) P (CHR 6I ) S NR 33 R 34 ;
  • R 19 is lower alkyl; -(CH 2 ) P (CHR 61 ) S OR 55 ; -(CH 2 ) P (CHR 61 ) S SR 56 ; -(CH 2 ) P (CHR 61 XNR 33 R 34 ; -(CH 2 ) P (CHR 61 ) S OCONR 33 R 75 ; -(CH 2 )P(CHR 61 XNR 20 CONR 33 R 82 ; -(CH 2 ) P (CHR 61 XCOOR 57 ; -(CH 2 ) P (CHR 61 XCONR 58 R 59 ; -(CH 2 ) P (CHR 61 XPO(OR 60 ) 2 ; -(CH 2 ) P (CHR 61 X SO 2 R 62 ; or -(CH 2 ) O (CHR 61) s C 6 H 4 R 8 ; or R 18 and R 19 taken together can form: -(CH 2 ) 2
  • R 20 is H; alkyl; alkenyl; or aryl-lower alkyl;
  • R 21 is H; alkyl; alkenyl; -(CH 2 ) 0 (CHR 6I ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ; -(CH 2 ) O (CHR 61 ) S NR 33 R 34 ;
  • R 22 is H; alkyl; alkenyl; -(CH 2 ) O (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ; -(CH 2 ) O (CHR 61 ) S NR 33 R 34 ;
  • R 23 is alkyl; alkenyl; -(CH 2 ) 0 (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ; -(CH 2 ) O (CHR 61 ) S NR 33 R 34 ;
  • R 24 is alkyl; alkenyl; -(CH 2 ) 0 (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ; -(CH 2 ) O (CHR 61 ) S NR 33 R 34 ;
  • R 25 is H; alkyl; alkenyl; -(CH 2 ) ffl (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s SR 56 ; -(CH 2 ) m (CHR 61 XNR 33 R 34 ; -(CH 2 ) m (CHR 61 ) 5 OCONR 33 R 75 ; -(CH 2 ) m (CHR 61 ) NR 20 CONR 33 R 82 ; -(CH 2 ) o (CHR 61 ) s COOR 57 ; -(CH 2 ) 0 (CHR 61 XCONR 58 R 59 ; -(CH 2 ) 0 (CHR 61 XPO(OR 60 ) 2 ; -(CH 2 ) O (CHR 61 XSO 2 R 62 ; or -(CH 2 ) O (CHR 61 ) S C 6 H 4 R
  • R 26 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s SR 56 ; -(CH 2 ) m (CHR 61 ) s NR 33 R 34 ; -(CH 2 ) m (CHR 61 ) s OCONR 33 R 75 ; -(CH 2 ) m (CHR 61 ) NR 20 CONR 33 R 82 ; -(CH 2 ) o (CHR 61 ) s COOR 57 ; -(CH 2 ) 0 (CHR 61 ) S CONR 58 R 59 ; -(CH 2 ) 0 (CHR 61 XPO(OR 60 ) 2 ; -(CH 2 ) O (CHR 61 ) S SO 2 R 62 ; or -(CH 2 ) O (CHR 61 ) S C
  • R 25 and R 26 taken together can form: -(CH 2 ) 2 . 6 -; -(CH 2 ) r O(CH 2 ) r -; -(CH 2 ) r S(CH 2 ) r -; or -(CH 2 ) r NR 57 (CH 2 ) r -;
  • R 27 is H; alkyl; alkenyl; -(CH 2 ) 0 (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 6I ) S SR 56 ;
  • R 28 is alkyl; alkenyl; -(CH 2 ) O (CHR 61 ) S -OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ; -(CH 2 ) O (CHR 6I ) S
  • R 29 is alkyl; alkenyl; -(CH 2 ) O (CHR 61 ) S OR 55 ; -(CH 2 ) O (CHR 61 ) S SR 56 ;
  • R 30 is H; alkyl; alkenyl; or aryl-lower alkyl;
  • R 31 is H; alkyl; alkenyl; -(CH 2 ) P (CHR 61 ) S OR 55 ; -(CH 2 ) P (CHR 61 ) S NR 33 R 34 ; -(CH 2 )p(CHR 61 ) s OCONR 33 R 75 ; -(CH 2 ) P (CHR 61 ) S NR 20 CONR 33 R 82 ;
  • R 32 is H; lower alkyl; or aryl-lower alkyl;
  • R 33 is H; alkyl, alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s NR 34 R 63 ; -(CH 2 ) m (CHR 61 ) s OCONR 75 R 82 ; -(CH 2 ) m (CHR 61 ) s NR 20 CONR 78 R 82 ;
  • R 34 is H; lower alkyl; aryl, or aryl-lower alkyl;
  • R 33 and R 34 taken together can form: -(CH 2 ) 2 . 6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -;
  • R 35 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR ⁇ l ) s NR 33 R 34 ;
  • R 36 is H, alkyl; alkenyl; -(CH 2 ) 0 (CHR 61 ) S OR 55 ; -(CH 2 ) P (CHR 61 ) S NR 33 R 34 ;
  • R 37 is H; F; Br; Cl; NO 2 ; CF 3 ; lower alkyl; -(CH 2 ) P (CHR 61 ) S OR 55 ; -(CH 2 ) P (CHR 61 ) S NR 33 R 34 ;
  • R 38 is H; F; Br; Cl; NO 2 ; CF 3 ; alkyl; alkenyl; -(CH 2 ) P (CHR 61 ) S OR 55 ;
  • R 39 is H; alkyl; alkenyl; or aryl-lower alkyl;
  • R 40 is H; alkyl; alkenyl; or aryl-lower alkyl;
  • R 41 is H; F; Br; Cl; NO 2 ; CF 3 ; alkyl; alkenyl; -(CH 2 ) P (CHR 61 ) S OR 55 ;
  • R 42 is H; F; Br; Cl; NO 2 ; CF 3 ; alkyl; alkenyl; -(CH 2 ) P (CHR 61 ) S OR 55 ;
  • R 43 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ⁇ NR 33 R 34 ;
  • R 44 is alkyl; alkenyl; -(CH 2 ) r (CHR 61 ) s OR 55 ; -(CH 2 ) r (CHR 61 ) s SR 56 ; -(CH 2 ) r (CHR 61 ) 5 NR 33 R 34 ;
  • R 45 is H; alkyl; alkenyl; -(CH 2 ) O (CHR 61 ) S OR 55 ; -(CH 2 J 0 (CHR 61 JsSR 56 ;
  • R 46 is H; alkyl; alkenyl; or -(CH 2 J 0 (CHR 61 J p C 6 H 4 R 8 ;
  • R 47 is H; alkyl; alkenyl; or -(CH 2 ) O (CHR 61 ) S OR 55 ;
  • R 48 is H; lower alkyl; lower alkenyl; or aryl-lower alkyl;
  • R 49 is H; alkyl; alkenyl; -(CHR 61 ) S COOR 57 ; (CHR 6I ) S CONR 58 R 59 ; (CHR 61 ) S PO(OR 60 ) 2 ;
  • R 50 is H; lower alkyl; or aryl-lower alkyl;
  • R 51 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 J 5 SR 56 ; -(CH 2 ) ra (CHR 61 ) s NR 33 R 34 ; -(CH 2 ) m (CHR 61 ) s OCONR 33 R 75 ;
  • R 52 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 ) s SR 56 ; -(CH 2 ) m (CHR 61 ) s NR 33 R 34 ; -(CH 2 ) m (CHR 61 ) s OCONR 33 R 75 ;
  • R 53 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) s OR 55 ; -(CH 2 ) m (CHR 61 J 8 SR 56 ; -(CH 2 ) m (CHR 61 ) s NR 33 R 34 ; -(CH 2 ) ra (CHR 61 ) s OCONR 33 R 75 ;
  • R 54 is H; alkyl; alkenyl; -(CH 2 ) m (CHR 61 ) 8 OR 55 ; -(CH 2 J 1n (CHR 61 J 8 NR 33 R 34 ; -(CH 2 J 1n (CHR 61 J 8 OCONR 33 R 75 ; -(CH 2 J 1n (CHR 61 J 8 NR 20 CONR 33 R 82 ;
  • R 55 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH 2 ) m (CHR 61 ) s OR 57 ;
  • R 56 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH 2 ) m (CHR 6I ) s OR 57 ; -(CH 2 ) m (CHR 61 ) s NR 34 R 63 ; -(CH 2 ) m (CHR 61 ) s OCONR 75 R 82 ;
  • R 57 is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl;
  • R 58 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl;
  • R 59 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or
  • R 58 and R 59 taken together can form: -(CH 2 ) 2 . 6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) r ; or
  • R 60 is H; lower alkyl; lower alkenyl; aryl; or aryl-lower alkyl;
  • R 61 is H, alkyl; alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; - (CH 2 ) P OR 55 ;
  • R 62 is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl-lower alkyl;
  • R 63 is H; lower alkyl; lower alkenyl; aryl, heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl;
  • R 34 and R 63 taken together can form: -(CH 2 ) 2 . 6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -;
  • R 64 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; -(CH 2 ) P (CHR 61 ) S OR 65 ; -(CH 2 ) P (CHR 61 ) S SR 66 ; or -(CH 2 ) P (CHR 6I ) S NR 34 R 63 ; -(CH 2 )P(CHR 61 ) S OCONR 75 R 82 ; -(CH 2 )P(CHR 61 ) S NR 20 CONR 78 R 82 ;
  • R 65 is H; lower alkyl; lower alkenyl; aryl, aryl-lower alkyl; heteroaryl-lower alkyl; -COR 57 ; -COOR 57 ; or -CONR 58 R 59 ;
  • R 66 is H; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; heteroaryl-lower alkyl; or -
  • R 67 being H; Cl; Br; F; NO 2 ; -NR 34 COR 57 ; lower alkyl; or lower alkenyl; R 68 being H; Cl; Br; F; NO 2 ; -NR 34 COR 57 ; lower alkyl; or lower alkenyl; R 69 being H; Cl; Br; F; NO 2 ; -NR 34 COR 57 ; lower alkyl; or lower alkenyl; and R 70 being H; Cl; Br; F; NO 2 ; -NR 34 COR 57 ; lower alkyl; or lower alkenyl; with the proviso that at least two of R 67 , R 68 , R 69 and R 70 are H; and
  • Z is a chain of 12 ⁇ -amino acid residues, the positions of said amino acid residues in said chain being counted starting from the N-terminal amino acid, whereby these amino acid residues are, depending on their position in the chain, GIy or Pro, or of formula -A-CO-, or of formula -B-CO-, or of one of the types
  • R 71 is H; lower alkyl; lower alkenyl; -(CX 2 ) P (CHR 61 ) S OR 75 ; -(CX 2 ) P (CHR 61 ) S SR 75 ; -(CX 2 ) P (CHR 61 ) S NR 33 R 34 ; -(CX 2 ) P (CXR 61 ) S OCONR 33 R 75 ; -(CX 2 ) P (CHR 61 ) S NR 20 CONR 33 R 82 ;
  • R 72 is H; lower alkyl; lower alkenyl; -(CX 2 ) p (CHR 86 ) s OR 85 ; or
  • R 73 is -(CX 2 ) O R 77 ; -(CX 2 ) r O(CH 2 ) o R 77 ; -(CX 2 ) r S(CH 2 ) 0 R 77 ; or
  • XX 1 -CH 3 where XX is -O-; -NR 20 -, or -S-; u is 1-3, and t is 1-6;
  • R 75 is lower alkyl; lower alkenyl; or aryl-lower alkyl;
  • R 33 and R 75 taken together can form: -(CX 2 ) 2 . 6 -; -(CX 2 ) 2 O(CX 2 ) 2 -; -(CX 2 ) 2 S(CX 2 ) 2 -; or
  • -(CX 2 ) 2 NR 57 (CX 2 ) 2 -; R 75 and R 82 taken together can form: -(CX 2 ) 2 . 6 -; -(CX 2 ) 2 O(CX 2 ) 2 -; -(CX 2 ) 2 S(CX 2 ) 2 -; or
  • R 76 isH; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CX 2 ) O OR 72 ; -(CX 2 ) O SR 72 ; -(CXz) 0 NR 33 R 34 ; -(CX 2 ) 0 OCONR 33 R 75 ; -(CX 2 ) o NR 20 CONR 33 R 82 ; -(CX 2 ) o COOR 75 ; -(CX 2 ) o CONR 58 R 59 ; -(CX 2 ) o PO(OR 60 ) 2 ; -(CX 2 ) P SO 2 R 62 ; or -(CX 2 ) o COR 64 ;
  • R 77 is -C 6 R 67 R 68 R 69 R 70 R 76 ; or a heteroaryl group of one of the formulae
  • R 78 is H; lower alkyl; aryl; or aryl-lower alkyl;
  • R 78 and R 82 taken together can form: -(CX 2 ) 2 . 6 -; -(CX 2 ) 2 O(CX 2 )2-; -(CXa) 2 S(CXa) 2 -; or
  • R 79 is H; lower alkyl; aryl; or aryl-lower alkyl; or
  • R 78 and R 79 taken together, can be -(CX 2 ) 2-7 -; -(CX 2 ) 2 O(CX 2 ) 2 -; or -(CX 2 ) 2 NR 57 (CX 2 ) 2 -; R 80 is H; or lower alkyl;
  • R 81 is H; lower alkyl; or aryl-lower alkyl
  • R 82 is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;
  • R 33 and R 82 taken together can form: -(CX 2 ) 2 . 6 -; -(CXz) 2 O(CXz) 2 -; -(CX 2 ) 2 S(CX 2 ) 2 -; or
  • R 83 is H; lower alkyl; aryl; or -NR 78 R 79 ;
  • R 84 is -(CX 2 ) m (CHR 61 ) s OH; -(CX 2 ) P CONR 78 R 79 ; -(CX 2 ) P NR 80 CONR 78 R 79 ;
  • R 85 is lower alkyl; or lower alkenyl; R 86 is H, alkyl; alkenyl; -(CX 2 ) P OR 85 ;-(CX 2 ) P SR 85
  • R 87 is H; alkyl; alkenyl; heteroaryl, aryl-lower alkyl; -(CX 2 ) P OR 55 ; -(CX 2 ) p OCONR 75 R 82 ; -(CX 2 ) P NR 20 CONR 78 R 82 ; -(CX 2 ) P COOR 57 , or -(CX 2 ) P PO(OR 60 ) 2 ;
  • X is H; or optionally halogen; with the proviso that in said chain of 12 ⁇ -amino acid residues Z the amino acid residues in positions 1 to 12 are, in a preferred embodiment:
  • P2 oftype D or oftype E;
  • P3 of type C or of type D, or the residue is GIy or Pro;
  • P4 of type C or oftype E or oftype F, or the residue is GIy or Pro;
  • P5 of type E or of type D or of type C, or the residue is GIy or Pro
  • - P6 of type E or of type F or of type C or of formula -A-CO-, or the residue is GIy or Pro
  • P7 of type C or of type E or of type F or of formula -B-CO-;
  • P8 of type D or of type C, or of Type F, or the residue is Pro;
  • P9 of type C or of type E or of type D or of type F;
  • - PlO of type E;
  • PI l of type C or of type F, or the residue is Pro or GIy
  • Pl 2 of type C or of type D or of type E or of type F, or the residue is Pro
  • P4 and P9 and/or P2 and Pl 1 taken together, can form a group of type H; and at P6, PlO and Pl 1 also D-isomers being possible; or, alternatively, but in a less preferred embodiment: Pl : of type C or of type D or of type E or of type F, or the residue is
  • P2 of type C or of type F, or the residue is Pro or GIy ;
  • P3 of type E
  • - P4 of type C or of type E or of type D or of type F;
  • P5 of type D or of type C, or of type F, or the residue is Pro;
  • P6 of type C or of type E or of type F or of formula -B-CO-;
  • P7 of type E or of type F or of type C or of formula -A-CO-, or the residue is GIy or Pro
  • - P8 of type E or of type D or of type C, or the residue is GIy or Pro
  • P9 of type C or of type E or of type F; or the residue is GIy or Pro;
  • PlO of type C or of type D, or the residue is GIy or Pro;
  • Pl 1 of type D or of type E;
  • P12 of type C or of type D or of type E or of type F, or the residue is Pro;
  • P4 and P9 and/or P2 and Pl 1, taken together, can form a group of type H; and at P2, P3, and P7 also D-isomers being possible;
  • ⁇ -hairpin peptidomimetics can be prepared by a process which comprises
  • X is an N-protecting group or, if
  • step (fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula
  • the peptidomimetics of the present invention can be prepared by
  • step (b 1 ) removing the N-protecting group from the product obtained in step (a 1 ) or
  • the peptidomimetics of the present invention can also be enantiomers of the compounds of formula I. These enantiomers can be prepared by a modification of the above processes in which enantiomers of all chiral starting materials are used.
  • alkyl designates saturated, straight-chain or branched hydrocarbon radicals having up to 24, preferably up to 12, carbon atoms, ioptionally substituted with halogen.
  • alkenyl designates straight chain or branched hydrocarbon radicals having up to 24, preferably up to 12, carbon atoms and containing at least one or, depending on the chain length, up to four olefinic double bonds, optionally substituted with halogen.
  • lower designates radicals and compounds having up to 6 carbon atoms.
  • lower alkyl designates saturated, straight-chain or branched hydrocarbon radicals having up to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl and the like.
  • aryl designates aromatic carbocyclic hydrocarbon radicals containing one or two six-membered rings, such as phenyl or naphthyl, which may be substituted by up to three substituents such as Br, Cl, F, CF 3 , NO 2 , lower alkyl or lower alkenyl.
  • heteroaryl designates aromatic heterocyclic radicals containing one or two five- and/or six-membered rings, at least one of them containing up to three heteroatoms selected from the group consisting of O, S and N and said ring(s) being optionally substituted; representative examples of such optionally substituted heteroaryl radicals are indicated hereinabove in connection with the definition of R 77 .
  • the structural element -A-CO- designates amino acid building blocks which in combination with the structural element -B-CO- form templates (al) and (a2).
  • Templates (a) through (p) constitute building blocks which have an N-terminus and a C-terminus oriented in space in such a way that the distance between those two groups may lie between 4.0-5.5A.
  • a peptide chain Z is linked to the C-terminus and the N-terminus of the templates (a) through (p) via the corresponding N- and C-termini so that the template and the chain form a cyclic structure such as that depicted in formula I.
  • template and peptide chain form a ⁇ -hairpin mimetic.
  • the ⁇ -hairpin conformation is highly relevant for the anti-bacterial activity of the ⁇ -hairpin mimetics of the present invention.
  • the ⁇ -hairpin stabilizing conformational properties of the templates (a) through (p) play a key role not only for the selective antibacterial activity but also for the synthetic processes defined hereinabove, as incorporation of the templates at the beginning or near the middle of the linear protected peptide precursors enhances cyclization yields significantly.
  • Building blocks A1-A69 belong to a class of amino acids wherein the N-terminus is a secondary amine forming part of a ring. Among the genetically encoded amino acids only proline falls into this class.
  • the configuration of building block Al through A69 is (D), and they are combined with a building block -B-CO- of (L)-configuration.
  • Preferred combinations for templates (al) are- D Al-CO- L B-CO- to D A69-CO- L B-CO-.
  • D Pro- L Pro constitutes the prototype of templates (al).
  • Mores preferred, but possible are combinations- L Al-CO- D B-CO- to L A69-CO- D B-CO- forming templates (a2).
  • L Pro- D Pro constitutes the prototype of template (a2).
  • building blocks -Al-CO- to -A69-CO- in which A has (D)- configuration are carrying a group R 1 at the ⁇ -position to the N-terminus.
  • the preferred values for R 1 are H and lower alkyl with the most preferred values for R 1 being H and methyl.
  • Al- A69 are shown in (D)- conflguration which, for R 1 being H and methyl, corresponds to the (R) -configuration.
  • this configuration may also have to be expressed as (S).
  • R 2 building blocks -Al-CO- to -A69-CO- can carry an additional substituent designated as R 2 to R 17 .
  • This additional substituent can be H, and if it is other than H, it is preferably a small to medium-sized aliphatic or aromatic group. Examples of preferred values for R 2 to R 17 are:
  • -R 2 H; lower alkyl; lower alkenyl; (CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); (CH 2 ) m SR 56 (where R 56 : lower alkyl; or lower alkenyl); (CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • -R 3 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) ra SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) M -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) m OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75
  • R 4 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) M -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) m OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alky
  • R 5 lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) M -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) O OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33
  • R 6 H; lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2-6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) 0 OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl
  • R 7 lower alkyl; lower alkenyl; -(CH 2 ) q OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) q SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) q NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 8 H; F; Cl; CF 3 ; lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); (CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 9 lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 10 lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 11 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 12 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 13 lower alkyl; lower alkenyl; -(CH 2 ) q OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) q SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) q NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R u H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 )JSlR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 )W-; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) m OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl
  • R" lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CHz) 0 SR 56 (where R 36 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) M -; -(CH 2 ) 2 O(CH 2 )z-; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) r ; where R 57 : H; or lower alkyl); -(CH 2 ) Q OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R
  • R 16 lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 )MS -(CH 2 ) 2 O(CHz) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) O OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R 75 taken
  • R 17 lower alkyl; lower alkenyl; -(CH 2 ) q OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) q SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) q NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • building blocks Al to A69 the following are preferred: A5 with R 2 being H, A8, A A2222,, A A22f5, A38 with R 2 being H, A42, A47, and A50. Most preferred are building blocks of type A8':
  • R 20 is H or lower alkyl; and R 64 is alkyl; alkenyl; aryl; aryl-lower alkyl; or heteroaryl-lower alkyl; especially those wherein R 64 is n-hexyl (A8'-l); n-heptyl (A8'-2); 4- (phenyl)benzyl (A8'-3); diphenylmethyl (A8'-4); 3-amino-propyl (A8'-5); 5-amino-pentyl (A8 ?
  • Building block A70 belongs to the class of open-chain ⁇ -substituted ⁇ -amino acids, building blocks A71 and A72 to the corresponding ⁇ -amino acid analogues and building blocks A73- A104 to the cyclic analogues of A70.
  • Such amino acid derivatives have been shown to constrain small peptides in well defined reverse turn or U-shaped conformations (C. M. Venkatachalam, Biopolymers, 1968, 6, 1425-1434; W. Kabsch, C Sander, Biopolymers 1983, 22, 2577).
  • Such building blocks or templates are ideally suited for the stabilization of ⁇ - hairpin conformations in peptide loops (D. Obrecht, M. Altorfer, J. A.
  • templates (al) can also consist of -A70-CO- to A104-CO- where building block A70 to Al 04 is of either (D)- or (L)-configuration, in combination with a building block -B-CO- of (L)- configuration.
  • Preferred values for R 20 in A70 to A104 are H or lower alkyl with methyl being most preferred.
  • Preferred values for R 18 , R 19 and R 21 -R 29 in building blocks A70 to A104 are the following: - R 18 : lower alkyl.
  • R 19 lower alkyl; lower alkenyl; -(CH 2 ) P OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) P SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) P NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CHa) 2-6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) P OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33
  • R 21 H; lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) M -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) 0 OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl;
  • R 22 lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 35 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) M -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) 0 OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R
  • R 23 H; lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 W; -(CH 2 ) 2 O(CH 2 ) r ; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) 0 OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and
  • R 25 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2-6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) m OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R 75 taken together form: -(CH 2 ) 2-6 -; -(CH 2
  • R 26 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2-6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) m OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R 75 taken together form: -(CH 2 ) 2-6 -; -
  • R 82 (where R 20 : H; or lower lower alkyl; R 33 : H; or lower alkyl; or lower alkenyl; R 82 : H; or lower alkyl; or R 33 and R 82 taken together form: -(CH 2 ) 2 .
  • R 25 and R 26 taken together can be -(CH 2 ) 2 - 6 -; -(CH 2 )2 ⁇ (CH 2 )2-; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl).
  • R 27 H; lower alkyl; lower alkenyl; -(CH 2 ) 0 OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 28 lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 29 lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) M -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) O OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33
  • R s H; F; Cl; CF 3 ; lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34
  • R 33 lower alkyl; or lower alkenyl
  • R 34 H; or lower alkyl
  • R 33 and R 34 taken together form: -(CH 2 ) M S -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) O OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl;
  • R 75 lower alkyl; or R 33 and R 75 taken together form: -(CH 2 ) 2 . 6 -; -(CH 2 ) 2 O(CH 2 ) 2 -;
  • R 30 H, methyl.
  • R 3J H; lower alkyl; lower alkenyl; -(CH 2 ) P OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) P NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R" H, methyl. - R 33 : lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 34 R 63 (where R 34 : lower alkyl; or lower alkenyl; R 63 : H; or lower alkyl; or R 34 and R 63 taken together form: -(CH 2 ) 2 .
  • R 78 R 82 (where R 20 : H; or lower lower alkyl; R 78 : H; or lower alkyl; or lower alkenyl; R 82 : H; or lower alkyl; or R 78 and R 82 taken together form: -(CH 2 ) 2 . 6 -; -(CH 2 ) 2 O(CH 2 ) r ; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl);
  • R 20 H; or lower alkyl
  • R 64 lower alkyl; or lower alkenyl
  • R 34 H; or lower alkyl.
  • R 35 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 82 (where R 20 : H; or lower lower alkyl; R 33 : H; or lower alkyl; or lower alkenyl; R 82 : H; or lower alkyl; or R 33 and R 82 taken together form: -(CH 2 ) 2-6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl);
  • R 20 H; or lower alkyl
  • R 64 lower alkyl; or lower alkenyl
  • R 36 lower alkyl; lower alkenyl; or aryl-lower alkyl.
  • R 37 H; lower alkyl; lower alkenyl; -(CH 2 ) P OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) P NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or
  • R 33 and R 34 taken together form: -(CH 2 W; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) P OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R 75 taken together form: -(CH 2 ) 2 . 6 -;
  • R 82 (where R 20 : H; or lower alkyl; R 33 : H; or lower alkyl; or lower alkenyl; R 82 : H; or lower alkyl; or R 33 and R 82 taken together form: -(CH 2 ) 2 .
  • R 38 H; lower alkyl; lower alkenyl; -(CH 2 ) P OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) P NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2-6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) P OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R 78 taken together form: -(CH 2 ) 2 .
  • R 39 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m N(R 20 )COR 64 (where: R 20 : H; or lower alkyl; R 64 : lower alkyl; or lower alkenyl); -(CH 2 ) O COOR 57 (where R 57 : lower alkyl; or lower alkenyl); -(CH 2 ) 0 CONR 58 R 59 (where R 58 : lower alkyl; or lower alkenyl; and R 59 : H; lower alkyl; or R 58 and R 59 taken together form: -(CH 2 ) 2 .
  • R 10 lower alkyl; lower alkenyl; or aryl-lower alkyl.
  • R" H; lower alkyl; lower alkenyl; -(CH 2 ) P OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) P NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 42 H; lower alkyl; lower alkenyl; -(CH 2 ) P OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) P NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2-6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) P OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R 75 taken together form: -(CH 2 ) 2-6 -; -(CH 2 )
  • R 43 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 )JMR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) M -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) r ; where R 57 : H; or lower alkyl); -(CH 2 ) m OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl
  • R 44 lower alkyl; lower alkenyl; -(CH 2 ) P OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) P SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) P NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 3 taken together form: -(CH 2 ) M S -(CH 2 ) 2 O(CH 2 ) r ; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) P OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R
  • R 45 H; lower alkyl; lower alkenyl; -(CH 2 ) O OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) O SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) O NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 46 H; lower alkyl; lower alkenyl; -(CH 2 ) S OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) S SR 56 (where R 56 : lower alkyl; or lower alkenyl); -(CH 2 ) S NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 W; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) S OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R
  • R 57 H; or lower alkyl
  • R 8 H; F; Cl; CF 3 ; lower alkyl; lower alkenyl; or lower alkoxy
  • R 47 H; or OR 55 (where R 55 : lower alkyl; or lower alkenyl).
  • R 48 H; or lower alkyl.
  • R 49 H;lower alkyl; -(CH 2 ) 0 COOR 57 (where R 57 : lower alkyl; or lower alkenyl);
  • R 58 lower alkyl; or lower alkenyl; and R 59 : H; lower alkyl; or R 58 and R 59 taken together form: -(CH 2 ) 2 . 6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or
  • R 57 H; or lower alkyl
  • R 8 H; F; Cl; CF 3 ; lower alkyl; lower alkenyl; or lower alkoxy
  • R 50 H; methyl.
  • R 51 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 82 (where R 20 : H; or lower lower alkyl; R 33 : H; or lower alkyl; or lower alkenyl; R 82 : H; or lower alkyl; or R 33 and R 82 taken together form: -(CH 2 ) 2-6 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl);
  • R 20 H; or lower alkyl
  • R 64 lower alkyl; or lower alkenyl
  • R 52 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 ) m NR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 ) 2 .
  • R 82 (where R 20 : H; or lower lower alkyl; R 33 : H; or lower alkyl; or lower alkenyl; R 82 : H; or lower alkyl; or R 33 and R 82 taken together form: -(CH 2 ) 2-5 -; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; R 57 : H; or lower alkyl);
  • R 20 H; or lower alkyl
  • R 64 lower alkyl; or lower alkenyl
  • R 53 H; lower alkyl; lower alkenyl; -(CH 2 ) m OR 55 (where R 55 : lower alkyl; or lower alkenyl); -(CH 2 )JSTR 33 R 34 (where R 33 : lower alkyl; or lower alkenyl; R 34 : H; or lower alkyl; or R 33 and R 34 taken together form: -(CH 2 W; -(CH 2 ) 2 O(CH 2 ) 2 -; -(CH 2 ) 2 S(CH 2 ) 2 -; or -(CH 2 ) 2 NR 57 (CH 2 ) 2 -; where R 57 : H; or lower alkyl); -(CH 2 ) m OCONR 33 R 75 (where R 33 : H; or lower alkyl; or lower alkenyl; R 75 : lower alkyl; or R 33 and R 75 taken together form: -(CH 2 ) 2 .
  • R 54 lower alkyl; lower alkenyl; or aryl-lower alkyl.
  • building blocks A70 to Al 04 the following are preferred: A74 with R 22 being H, A75, A76, A77 with R 22 being H, A78 and A79.
  • the building block -B-CO- within templates (al) and (a2) designates an L-amino acid residue.
  • Preferred values for B are: -NR 20 CH(R 71 )- and enantiomers of groups A5 with R 2 being H, A8, A22, A25, A38 with R 2 being H, A42, A47, and A50. Most preferred are
  • phenylbenzyl (A8"-23); diphenylmethyl (A8"-24); 3-amino-propyl (A8"-25); 5- amino-pentyl (A8"-26); methyl (A8"-27); ethyl (A8"-28); isopropyl (A8"-29); isobutyl (A8"-30); n-propyl (A8"-31); cyclohexyl (A8"-32); cyclohexylmethyl (A8"-33); n- butyl (A8"-34); phenyl (A8"-35); benzyl (A8"-36); (3-indolyl)methyl (A8"-37); 2-(3- indolyl)ethyl (A8"-38); (4-phenyl)phenyl (A8"-39); n-nonyl (A8"-40); CH 3 -OCH 2 CH 2 -
  • the peptidic chain Z of the ⁇ -hairpin mimetics described herein is generally defined in terms of amino acid residues belonging to one of the following groups: - Group C -NR 20 CH(R 72 )CO-; "hydrophobic: small to medium-sized"
  • amino acid residues in chain Z can also be of formula -A-CO- or of formula -B-CO- wherein A and B are as defined above.
  • GIy can also be an amino acid residue in chain Z
  • Pro can be an amino acid residue in chain Z, too, with the exception of positions where interstrand linkages (H) are possible.
  • Group C comprises amino acid residues with small to medium-sized hydrophobic side chain groups according to the general definition for substituent R 72 .
  • a hydrophobic residue refers to an amino acid side chain that is uncharged at physiological pH and that is repelled by aqueous solution.
  • these side chains generally do not contain hydrogen bond donor groups, such as (but not limited to) primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, phosphonates, phosphates, ureas or thioureas.
  • ethers such as ethers, thioethers, esters, tertiary amides, alkyl- or aryl phosphonates and phosphates or tertiary amines.
  • Genetically encoded small-to-medium-sized amino acids include alanine, isoleucine, leucine, methionine and valine.
  • Group D comprises amino acid residues with aromatic and heteroaromatic side chain groups according to the general definition for substituent R 73 .
  • An aromatic amino acid residue refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated ⁇ -electron system (aromatic group).
  • hydrogen bond donor groups such as (but not limited to) primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, phosphonates, phosphates, ureas or thioureas, and hydrogen bond acceptor groups such as (but not limited to) ethers, thioethers, esters, tetriary amides, alkyl- or aryl phosphonates -and phosphates or tertiary amines.
  • Genetically encoded aromatic amino acids include phenylalanine and tyrosine.
  • a heteroaromatic amino acid residue refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated ⁇ -system incorporating at least one heteroatom such as (but not limited to) O, S and N according to the general definition for substituent R 77 .
  • residues may contain hydrogen bond donor groups such as (but not limited to) primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, phosphonates, phosphates, ureas or thioureas, and hydrogen bond acceptor groups such as (but not limited to) ethers, thioethers, esters, tetriary amides, alkyl- or aryl phosphonates -and phosphates or tertiary amines.
  • Hydro bond donor groups such as (but not limited to) primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, phosphonates, phosphates, ureas or thioureas, and hydrogen bond acceptor groups such as (but not limited to) ethers, thioethers, esters, tetriary amides, alkyl- or aryl phosphonates
  • Group E comprises amino acids containing side chains with polar-cationic, acylamino- and urea-derived residues according to the general definition for substituen R 74 .
  • Polar-cationic refers to a basic side chain which is protonated at physiological pH.
  • Genetically encoded polar-cationic amino acids include arginine, lysine and histidine. Citrulline is an example for an urea derived amino acid residue.
  • Group F comprises amino acids containing side chains with polar-non-charged or anionic residues according to the general definition for substituent R 84 .
  • a polar-non-charged or anionic residue refers to a hydrophilic side chain that is uncharged and, respectively anionic at physiological pH (carboxylic acids being included), but that is not repelled by aqueous solutions.
  • Such side chains typically contain hydrogen bond donor groups such as (but not limited to) primary and secondary amides, carboxyclic acids and esters, primary and secondary amines, thiols, alcohols, phosphonates, phosphates, ureas or thioureas. These groups can form hydrogen bond networks with water molecules.
  • polar-non-charged amino acids include asparagine, cysteine, glutamine, serine and threonine, but also aspartic acid and glutamic acid.
  • Group H comprises side chains of preferably (L)-amino acids at opposite positions of the ⁇ - strand region that can form an interstrand linkage.
  • the most widely known linkage is the disulfide bridge formed by cysteines and homo-cysteines positioned at opposite positions of the ⁇ -strand.
  • Various methods are known to form disulfide linkages including those described by: J. P. Tam et al. Synthesis 1979, 955-957; Stewart et al. , Solid Phase Peptide Synthesis, 2d Ed., Pierce Chemical Company, III., 1984; Ahmed et al. J. Biol. Chem.
  • disulfide linkages can be prepared using acetamidomethyl (Acm)- protective groups for cysteine.
  • a well established interstrand linkage consists in linking ornithines and lysines, respectively, with glutamic and aspartic acid residues located at opposite ⁇ -strand positions by means of an amide bond formation.
  • Preferred protective groups for the side chain amino- groups of ornithine and lysine are allyloxycarbonyl (Alloc) and allylesters for aspartic and glutamic acid.
  • interstrand linkages can also be established by linking the amino groups of lysine and ornithine located at opposite ⁇ -strand positions with reagents such as N,N-carbonylimidazole to form cyclic ureas.
  • positions for interstrand linkages are positions P4 and P 9 and/or P2 and Pl 1 taken together.
  • Such interstrand linkages are known to stabilize the ⁇ -hairpin conformations and thus constitute an important structural element for the design of ⁇ -hairpin mimetics.
  • amino acid residues in chain Z are those derived from natural ⁇ -amino acids.
  • amino acids which, or the residues of which, are suitable for the purposes of the present invention, the abbreviations corresponding to generally adopted usual practice:
  • ⁇ -amino acids which, or the residues of which, are suitable for the purposes of the present invention include: C Ciitt L-Citrulline
  • arly preferrei i residues for group D are:
  • residues for group E are Arg L-Arginine Lys L-Lysine
  • residues for group F are Asn L-Asparagine
  • the peptidic chain Z within the ⁇ -hairpin mimetics of the invention comprises 12 amino acid residues.
  • the positions Pl to P12 of each amino acid residue in the chain Z are unequivocally defined as follows: Pl represents the first amino acid in the chain Z that is coupled with its N-terminus to the C-terminus of the templates (b)-(p), or of group -B-CO- in template (al), or of group -A-CO- in template (a2); and P12 represents the last amino acid in the chain Z that is coupled with its C-terminus to the N-terminus of the templates (b)-(p), or of group -A-CO- in template (al), or of group -B-CO- in template (a2).
  • Each of the positions Pl to P12 will preferably contain an amino acid residue belonging to one of the above types C, D, E, F, H, or of formula -A-CO- or of formula -B-CO-, or being GIy, or Pro as follows:
  • the ⁇ -amino acid residues in positions 1 to 12 of the chain Z are preferably: - Pl : of type C or of type D or of type E or of type F;
  • P3 of type C, or the residue is GIy or Pro;
  • P4 of type C or of type E or of type F, or the residue is GIy or Pro;
  • P5 of type E, or the residue is GIy or Pro
  • - P6 of type E, of type C or of type F or of formula -A-CO-, or the residue is GIy or Pro
  • P7 of type C or of type E or of type F or of formula -B-CO-;
  • P8 of type D, or of type F;
  • P9 oftype E or oftype F or oftype C;
  • PI l of type F or of type C, or the residue is GIy or Pro
  • - P12 of type C or of type D or of type E, or of type F; or
  • P4 and P9 and/or P2 and Pl 1 taken together, can form a group of type H; and at P6, PlO and PI l also D-isomers being possible; or, alternatively, within the less preferred embodiment mentioned earlier herein above: - Pl : of type C or of type D or of type E, or of type F;
  • P2 of type F or of type C, or the residue is GIy or Pro;
  • P4 of type E or of type F or of type C;
  • P5 of type D, or of Type F
  • - P6 of type C or of type E or of type F or of formula -B-CO-;
  • P7 of type C or of type F or of formula -A-CO-, or the residue is GIy or Pro;
  • P8 of type E, or the residue is GIy or Pro;
  • P9 of type C or of type E or of type F, or the residue is GIy or Pro
  • - PlO of type C, or the residue is GIy or Pro
  • P12 of type C or of type D or of type E or of type F; or
  • P4 and P9 and/or P2 and PI l taken together, can form a group of type H; and at P2, P3, and P7 also D-isomers being possible.
  • the ⁇ -amino acid residues in positions 1 to 12 are most preferably: Pl : Ala, Cit, Thr, Thr, Asp, GIu;
  • P2 Trp, Tyr; - P3: Ile, Val, Nle, Chg, Cha;
  • P7 His, Lys, GIn, Dab;
  • Pl 1 Ala, Abu, Thr, GIy, Pro, Hse, lie, Nva, 0 AIa, 0 VaI, Aib, NIe, Chg,
  • P12 Dab, Lys, GIn, Ser; at P6, PlO and Pl 1 are D-Isomers being possible.
  • Particularly preferred ⁇ -hairpin peptidomimetics of the invention include those described in Examples 1, 2, 6, 16, 19, 22, 24, 25, 28, 29, 32, 35, 40, 41, 49, 50.
  • the processes of the invention can advantageously be carried out as parallel array syntheses to yield libraries of template-fixed ⁇ -hairpin peptidomimetics of the above general formula I.
  • Such parallel syntheses allow one to obtain arrays of numerous (normally 24 to 192, typically 96) compounds of general formula I in high yields and defined purities, minimizing the formation of dimeric and polymeric by-products.
  • the proper choice of the functionalized solid-support (i.e. solid support plus linker molecule), templates and site of cyclization play thereby key roles.
  • the functionalized solid support is conveniently derived from polystyrene crosslinked with, preferably 1-5%, divinylbenzene; polystyrene coated with polyethyleneglycol spacers (Tentagel R ); and polyacrylamide resins (see also Obrecht, D.; Villalgordo, J. -M, "Solid- Supported Combinatorial and Parallel Synthesis of Small-Molecular- Weight Compound Libraries", Tetrahedron Organic Chemistry Series, Vol. 17, Pergamon, Elsevier Science, 1998).
  • the solid support is functionalized by means of a linker, i.e. a bifunctional spacer molecule which contains on one end an anchoring group for attachment to the solid support and on the other end a selectively cleavable functional group used for the subsequent chemical transformations and cleavage procedures.
  • a linker i.e. a bifunctional spacer molecule which contains on one end an anchoring group for attachment to the solid support and on the other end a selectively cleavable functional group used for the subsequent chemical transformations and cleavage procedures.
  • linkers i.e. a bifunctional spacer molecule which contains on one end an anchoring group for attachment to the solid support and on the other end a selectively cleavable functional group used for the subsequent chemical transformations and cleavage procedures.
  • Type 1 linkers are designed to release the amide group under acidic conditions (Rink H, Tetrahedron Lett. 1987, 28, 3783-3790).
  • Linkers of this kind form amides of the carboxyl group of the amino acids; examples of resins functionalized by such linker structures include 4-[(((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) aminomethyl] PS resin, 4-[(((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) aminomethyl] -4- methylbenzydrylamine PS resin (Rink amide MBHA PS Resin), and 4-[(((2,4- dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) aminomethyl] benzhydrylamine PS-resin (Rink amide BHA PS resin).
  • the support is derived from polystyrene crosslinked with, most preferably 1-5%, divinylbenzene and functionalized by means of the 4- (((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) linker.
  • Type 2 linkers are designed to eventually release the carboxyl group under acidic conditions.
  • Linkers of this kind form acid-labile esters with the carboxyl group of the amino acids, usually acid-labile benzyl, benzhydryl and trityl esters; examples of such linker structures include 2-methoxy-4-hydroxymethylphenoxy (Sasrin R linker), 4-(2,4-dimethoxyphenyl- hydroxymethyl)-phenoxy (Rink linker), 4-(4-hydroxymethyl-3-methoxyphenoxy)butyric acid (HMPB linker), trityl and 2-chlorotrityl.
  • the support is derived from polystyrene crosslinked with, most preferably 1-5%, divinylbenzene and functionalized by means of the 2-chlorotrityl linker.
  • a number of reaction vessels (normally 24 to 192, typically 96), equal to the total number of compounds to be synthesized by the parallel method, are loaded with 25 to 1000 mg, preferably 100 mg, of the appropriate functionalized solid support, preferably 1 to 3% cross- linked polystyrene or Tentagel resin.
  • the solvent to be used must be capable of swelling the resin and includes, but is not limited to, dichloromethane (DCM), dimethylformamide (DMF), N-methylpyrrolidone (NMP), dioxane, toluene, tetrahydrofuran (THF), ethanol (EtOH), trifluoroethanol (TFE), isopropylalcohol and the like.
  • Solvent mixtures containing as at least one component a polar solvent are beneficial for ensuring high reactivity and solvation of the resin-bound peptide chains ( Fields, G. B., Fields, C. G., J. Am. Chem. Soc. 1991, 113, 4202-4207).
  • Suitable protecting groups for amino acids and, respectively, for their residues are, for example,
  • guanidino group (as is present e. g. in the side-chain of arginine)
  • Ts tosyl i. e. p-toluenesulfonyl
  • the 9-fluorenylmethoxycarbonyl- (Fmoc)-protected amino acid derivatives are preferably used as the building blocks for the construction of the template-fixed ⁇ -hairpin loop mimetics of formula I.
  • For the deprotection, i. e. cleaving off of the Fmoc group 20% piperidine in DMF or 2% DBU/2% piperidine in DMF can be used.
  • the quantity of the reactant i. e. of the amino acid derivative, is usually 1 to 20 equivalents based on the milliequivalents per gram (meq/g) loading of the functionalized solid support (typically 0.1 to 2.85 meq/g for polystyrene resins) originally weighed into the reaction tube. Additional equivalents of reactants can be used, if required, to drive the reaction to completion in a reasonable time.
  • the reaction tubes, in combination with the holder block and the manifold, are reinserted into the reservoir block and the apparatus is fastened together. Gas flow through the manifold is initiated to provide a controlled environment, for example, nitrogen, argon, air and the like. The gas flow may also be heated or chilled prior to flow through the manifold.
  • Heating or cooling of the reaction wells is achieved by heating the reaction block or cooling externally with isopropanol/dry ice and the like to bring about the desired synthetic reactions. Agitation is achieved by shaking or magnetic stirring (within the reaction tube).
  • the preferred workstations are Labsource's Combi-chem station and MultiSyn Tech's-Syro synthesizer.
  • Amide bond formation requires the activation of the ⁇ -carboxyl group for the acylation step.
  • this activation is being carried out by means of the commonly used carbodiimides such as dicyclohexylcarbodiimide (DCC, Sheehan & Hess, J. Am. Chem. Soc. 1955, 77, 1067- 1068) or diisopropylcarbodiimide (DIC, Sarantakis et al Biochem. Biophys. Res. Commun.1976, 73, 336-342), the resulting dicyclohexylurea and diisopropylurea is insoluble and, respectively, soluble in the solvents generally used.
  • DCC dicyclohexylcarbodiimide
  • DIC Diisopropylcarbodiimide
  • 1-hydroxybenzotriazole (HOBt, Konig & Geiger, Chem. Ber 1970, 103, 788-798) is included as an additive to the coupling mixture.
  • HOBt prevents dehydration, suppresses racemization of the activated amino acids and acts as a catalyst to improve the sluggish coupling reactions.
  • Certain phosphonium reagents have been used as direct coupling reagents, such as benzotriazol-l-yl-oxy-tris-(dimethylamino)-phos ⁇ honium hexafluorophosphate (BOP, Castro et al., Tetrahedron Lett 1975, 14, 1219-1222; Synthesis, 1976, 751-752), or benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexaflurophoshate (Py-BOP, Coste et al., Tetrahedron Lett.
  • BOP benzotriazol-l-yl-oxy-tris-(dimethylamino)-phos ⁇ honium hexafluorophosphate
  • Py-BOP Coste et al., Tetrahedron Lett.
  • DPPA diphenoxyphosphoryl azide
  • TATU O-(7- aza-benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
  • HATU O-(7-aza- benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • HOAt Carpino et al., Tetrahedron Lett. 1994, 35, 2279-2281
  • reaction wells are filled with solvent (preferably 5 ml), the reaction tubes, in combination with the holder block and manifold, are immersed and agitated for 5 to 300 minutes, preferably 15 minutes, and drained by gravity followed by gas pressure applied through the manifold inlet (while closing the outlet) to expel the solvent; 2) The manifold is removed from the holder block, aliquots of solvent
  • reaction tubes preferably 5 ml
  • a filter preferably 5 ml
  • Both of the above washing procedures are repeated up to about 50 times (preferably about 10 times), monitoring the efficiency of reagent, solvent and by-product removal by methods such as TLC, GC, or inspection of the washings.
  • IPegK IPegK
  • SPegK a solution of 5 equivalents of HATU (N-[(dimethylamino)-lH- l,2,3-triazolo[4,5- ⁇ ]pyridin-l-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide) in dry DMF and a solution of 10 equivalents of DIPEA (Diisopropyl ethaylamine) in dry DMF and 5 equivalents of 2-[2-(2-methoxyethoxy)ethoxy] acetic acid (IPeg) and, respectively, 2-(2-methoxyethoxy)acetic acid (sPeg), is applied to the liberated amino group of the appropiate amino acid side chain for 3 h.
  • DIPEA Diisopropyl ethaylamine
  • Interstrand linkages and their formation have been discussed above, in connection with the explanations made regarding groups of the type H which can, for example, be disulfide bridges formed by cysteine and homocysteine residues at opposite positions of the ⁇ -strand; or lactam bridges formed by glutamic and aspartic acid residues linking ornithine and, respectively, lysine residues, or by glutamic acid residues linking 2,4-diaminobutyric acid residues located at opposite ⁇ -strand positions by amide bond formation.
  • groups of the type H which can, for example, be disulfide bridges formed by cysteine and homocysteine residues at opposite positions of the ⁇ -strand; or lactam bridges formed by glutamic and aspartic acid residues linking ornithine and, respectively, lysine residues, or by glutamic acid residues linking 2,4-diaminobutyric acid residues located at opposite ⁇ -strand positions by amide bond formation.
  • a solution of 10 equivalents of iodine solution is applied in DMF or in a mixture OfCH 2 Cl 2 /MeOH for 1.5 h which is repeated for another 3h with a fresh iodine solution after filtering of the iodine solution, or in a mixture of DMSO and acetic acid solution, buffered with 5% with NaHCOsto pH 5-6 for 4h, or in water after having been adjusted to pH 8 with ammonium hydroxide solution by stirring for 24h or ammonium acetate buffer adjusted to pH 8 in the presence of air, or in a solution of NMP and tri-n- butylphosphine (preferably 50 eq.).
  • Detachment of the fully protected linear peptide from the solid support is achieved by immersion of the reaction tubes, in combination with the holder block and manifold, in reaction wells containing a solution of the cleavage reagent (preferably 3 to 5 ml). Gas flow, temperature control, agitation and reaction monitoring are implemented as described above and as desired to effect the detachment reaction.
  • the reaction tubes, in combination with the holder block and manifold are disassembled from the reservoir block and raised above the solution level but below the upper lip of the reaction wells, and gas pressure is applied through the manifold inlet (while closing the outlet) to efficiently expel the final product solution into the reservoir wells.
  • the resin remaining in the reaction tubes is then washed 2 to 5 times as above with 3 to 5 ml of an appropriate solvent to extract (wash out) as much of the detached product as possible.
  • the product solutions thus obtained are combined, taking care to avoid cross-mixing.
  • the individual solutions/extracts are then manipulated as needed to isolate the final compounds. Typical manipulations include, but are not limited to, evaporation, concentration, liquid/liquid extraction, acidification, basification, neutralization or additional reactions in solution.
  • the solvent is removed by evaporation, the fully protected cyclic peptide derivative is dissolved in a solvent which is not miscible with water, such as DCM, and the solution is extracted with water or a mixture of water-miscible solvents, in order to remove any excess of the coupling reagent.
  • a solvent which is not miscible with water such as DCM
  • the fully protected peptide derivative is treated with 95% TFA, 2.5% H 2 O, 2.5% TIS or another combination of scavengers for effecting the cleavage of protecting groups.
  • the cleavage reaction time is commonly 30 minutes to 12 hours, preferably about 2.5 hours.
  • the volatiles are evaporated to dryness and the crude peptide is dissolved in 20% AcOH in water and extracted with isopropyl ether or other solvents which are suitable therefor.
  • the aqueous layer is collected and evaporated to dryness, and the fully deprotected cyclic peptide derivative of formula I is obtained as end-product.
  • this peptide derivative can be used directly for biological assays, or it has to be further purified, for example by preparative HPLC.
  • the detachment, cyclisation and complete deprotection of the fully protected peptide from the solid support can be achieved manually in glass vessels.
  • the ⁇ -hairpin peptidomimetics of the invention can be used in a wide range of applications in order to inhibit the growth of or to kill microorganisms.
  • they can be used to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa.
  • ⁇ -hairpin peptidomimetics of the invention can also be used to treat or prevent diseases related to microbial infection in plants and animals.
  • the ⁇ -hairpin peptidomimetics can be added to the desired material singly, as mixtures of several ⁇ -hairpin peptidomimetics or in combination with other antimicrobial agents.
  • the ⁇ -hairpin peptidomimetics may be administered per se or may be applied as an appropriate formulation together with carriers, diluents or excipients well known in the art.
  • infections related to respiratory diseases such as cystic fibrosis, emphysema and asthma
  • infections related to skin or soft tissue diseases such as surgical wounds, traumatic wounds and burn wounds
  • infections related to gastrointestinal diseases such as epidemic diarrhea, necrotizing enterocolitis and typhlitis
  • infections related to eye diseases such as keratitis and endophthalmitis
  • infections related to ear diseases such as otitis, infections related to CNS diseases such as brain abscess and meningitis
  • infections related to bone diseases such as osteochondritis and osteomyelitis
  • infections related to cardiovascular diseases such as endocartitis and pericarditis
  • gastrourinal diseases such as epididymitis, prostatitis and urethritis
  • the ⁇ -hairpin peptidomimetics can be administered singly, as mixtures of several ⁇ -hairpin peptidomimetics, in combination with other antimicrobial or antibiotic agents, or anti cancer agents, or anti
  • compositions comprising ⁇ -hairpin peptidomimetics of the invention may be manufactured by means of conventional mixing, dissolving, granulating, coated tablet- making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active ⁇ -hairpin peptidomimetics into preparations which can be used pharmaceutically. Proper formulation depends upon the method of administration chosen.
  • ⁇ -hairpin peptidomimetics of the invention may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.
  • Systemic formulations include those designed for administration by injection, e.g. subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.
  • the ⁇ -hairpin peptidomimetics of the invention may be formulated in adequate solutions, preferably in physiologically compatible buffers such as Hink's solution, Ringer's solution, or physiological saline buffer.
  • the solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the ⁇ -hairpin peptidomimetics of the invention may be in powder form for combination with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • penetrants appropriate to the barrier to be permeated are used in the formulation as known in the art.
  • the compounds can be readily formulated by combining the active ⁇ - hairpin peptidomimetics of the invention with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the ⁇ -hairpin peptidomimetics of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions etc., for oral ingestion of a patient to be treated.
  • suitable excipients include fillers such as sugars, such as lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents.
  • desintegrating agents may be added, such as cross-linked polyvinylpyrrolidones, agar, or alginic acid or a salt thereof, such as sodium alginate.
  • solid dosage forms may be sugar-coated or enteric-coated using standard techniques.
  • suitable carriers, excipients or diluents include water, glycols, oils, alcohols, etc.
  • flavoring agents, preservatives, coloring agents and the like may be added.
  • the composition may take the form of tablets, lozenges, etc. formulated as usual.
  • the ⁇ -hairpin peptidomimetics of the invention are conveniently delivered in form of an aeorosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifmoromethane, trichlorofluromethane, carbon dioxide or another suitable gas.
  • a suitable propellant e.g. dichlorodifmoromethane, trichlorofluromethane, carbon dioxide or another suitable gas.
  • the dose unit may be determined by providing a valve to deliver a metered amount.
  • gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the ⁇ -hairpin peptidomimetics of the invention and a suitable powder base such as lactose or starch.
  • the compounds may also be formulated in rectal or vaginal compositions such as suppositories together with appropriate suppository bases such as cocoa butter or other glycerides.
  • the ⁇ -hairpin peptidomimetics of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection.
  • the ⁇ -hairpin peptidomimetics of the invention may be formulated with suitable polymeric or hydrophobic materials (e.g. as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble salts.
  • ⁇ -hairpin peptidomimetics of the invention may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent.
  • sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic agent, additional strategies for protein stabilization may be employed.
  • ⁇ -hairpin pepdidomimetics of the invention may contain charged residues, they may be included in any of the above-described formulations as such or as pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.
  • ⁇ -hairpin peptidomimetics of the invention will generally be used in an amount effective to achieve the intended purpose. It is to be understood that the amount used will depend on a particular application.
  • an antimicrobially effective amount of a ⁇ -hairpin peptidomimetic of the invention, or a composition thereof is applied or added to the material to be desinfected or preserved.
  • antimicrobially effective amount is meant an amount of a ⁇ -hairpin peptidomimetic of the invention, or a composition thereof, that inhibits the growth of, or is lethal to, a target microbe population. While the antimicrobially effective amount will depend on a particular application, for use as desinfectants or preservatives the ⁇ -hairpin peptidomimetics of the invention, or compositions thereof, are usually added or applied to the material to be desinfected or preserved in relatively low amounts.
  • the ⁇ -hairpin peptidomimetics of the invention comprise less than about 5% by weight of a desinfectant solution or material to be preserved, preferably less than 1% by weight and more preferably less than 0.1% by weight.
  • a desinfectant solution or material to be preserved preferably less than 1% by weight and more preferably less than 0.1% by weight.
  • An ordinary skilled expert will be able to determine antimicrobially effective amounts of particular ⁇ -hairpin pepdidomimetics of the invention for particular applications without undue experimentation using, for example, the in vitro assays provided in the examples.
  • the ⁇ - hairpin pepidomimetics of the invention, or compositions thereof are administered or applied in a therapeutically effective amount.
  • therapeutically effective amount is meant an amount effective in ameliorating the symptoms of, or in ameliorating, treating or preventing microbial infections or diseases related thereto. Determination of a therapeutically effective amount is well within the capacities of those skilled in the art, especially in view of the detailed disclosure provided herein.
  • a therapeutically effective dose can be determined using, for example, the in vitro assays provided in the examples.
  • the treatment may be applied while the infection is visible, or even when it is not visible.
  • An ordinary skilled expert will be able to determine therapeutically effective amounts to treat topical infections without undue experimentation.
  • a therapeutically effective dose can be estimated initially from in vitro assays.
  • a dose can be formulated in animal models to achieve a circulating ⁇ -hairpin peptidomimetic concentration range that includes the IC 50 as determined in the cell culture (i.e. the concentration of a test compound that is lethal to 50% of a cell culture), the MIC, as determined in cell culture (i.e. the concentration of a test compound that is lethal to 100% of a cell culture).
  • IC 50 as determined in the cell culture
  • the MIC as determined in cell culture
  • Such information can be used to more accurately determine useful doses in humans.
  • Initial dosages can also be determined from in vivo data, e.g. animal models, using techniques that are well known in the art. One having ordinary skills in the art could readily optimize administration to humans based on animal data.
  • Dosage amount for applications as antimicrobial agents may be adjusted individually to provide plasma levels of the ⁇ -hairpin peptidomimetics of the invention which are sufficient to maintain the therapeutic effect.
  • Therapeutically effective serum levels may be achieved by administering multiple doses each day.
  • the effective local concentration of the ⁇ - hairpin peptidomimetics of the invention may not be related to plasma concentration.
  • One having the skills in the art will be able to optimize therapeutically effective local dosages without undue experimentation.
  • the amount of ⁇ -hairpin peptidomimetics administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgement of the prescribing physician.
  • the antimicrobial therapy may be repeated intermittently while infections are detectable or even when they are not detectable.
  • the therapy may be provided alone or in combination with other drugs, such as for example antibiotics or other antimicrobial agents.
  • a therapeutically effective dose of the ⁇ -hairpin peptidomimetics described herein will provide therapeutic benefit without causing substantial toxicity.
  • Hemolysis of red blood cells is often employed for assessment of toxicity of related compounds such as protegrin or tachyplesin. Values are given as %-lysis of red blood cells observed at a concentration of lOO ⁇ g/ml. Typical values determined for cationic peptides such as protegrin and tachyplesin range between 30-40% with average MIC-values of 1- 5 ⁇ g/ml over a wide range of pathogens. Normally, ⁇ -hairpin peptidomimetics of the invention will show hemolysis in a range of 0.5-10%, often in a range of 1-5%, at activity levels comparable to those mentioned above for protegrin and tachyplesin. Thus preferred compounds exhibit low MIC-values and low %-hemolysis of red blood cells observed at a concentration of lOO ⁇ g/ml.
  • Toxicity of the ⁇ -hairpin peptidomimetics of the invention herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD 50 (the dose lethal to 50% of the population) or the LDioo (the dose lethal to 100% of the population).
  • the dose ratio between toxic and therapeutic effect is the therapeutic index. Compounds which exhibit high therapeutic indices are preferred.
  • the data obtained from these cell culture assays and animal studies can be used in formulating a dosage range that is not toxic for use in humans.
  • the dosage of the ⁇ -hairpin peptidomimetics of the invention lies preferably within a range of circulating concentrations that include the effective dose with little or no toxicity.
  • the dosage may vary within the range depending upon the dosage form employed and the route of administration utilized.
  • the exact formulation, route of administration and dose can be chosen by the individual physician in view of the patient's condition (see, e.g. Fingl et al. 1975, In : The Pharmacological Basis of Titer apeutics, Ch.1, p.l).
  • HOBt 1-hydroxybenzotriazole
  • DIEA diisopropylethylamine
  • HOAT 7-aza- 1 -hydroxybenzotriazole
  • HATU O-(7-aza-benzotriazole-l-yl)-N,N,N',N'-tetramethyluronoium hexafluorophosphate (Carpino et al. Tetrahedron Lett. 1994, 35, 2279-2281).
  • the resin was shaken (CH 2 Cl 2 /MeOH/DIEA : 17/2/1), 30 ml for 30 min; then washed in the following order with CH 2 Cl 2 (Ix), DMF (Ix), CH 2 Cl 2 (Ix), MeOH (Ix), CH 2 Cl 2 (Ix), MeOH (Ix), CH 2 Cl 2 (2x), Et 2 O (2x) and dried under vacuum for 6 hours.
  • Loading was typically 0.6-0.7 mMol/g.
  • the following preloaded resin was prepared: Fmoc-Pro-2-chlorotritylresin.
  • the synthesis was carried out using a Syro-peptide synthesizer (Multisyntech) using 24 to 96 reaction vessels. In each vessel were placed 60 mg (weight of the resin before loading) of the above resin. The following reaction cycles were programmed and carried out:
  • Steps 3 to 6 are repeated to add each amino-acid.
  • Aquity UPLC BEH C18 column (1.7 ⁇ m, 100 x 2.1 mm, cod. 186002352 - Waters) with the following solvents A (H 2 O + 0.1% TFA) and B (CH 3 CN + 0.085% TFA) and the gradient: 0 min: 95%A, 5%B; 0.2 min: 95%A 5%B; 4 min: 35%A, 65%B; 4.2 min: 5% A, 95%B; 4.25 min: 95%A, 5%B; 4.9 min: 95%A, 5%B.
  • the resin was suspended in 1 ml (0.39 mMol) of 1% TFA in CH 2 Cl 2 (v/v) for 3 minutes and filtered, and the filtrate was neutralized with ImI (1.17 mMol, 3eq.) of 20% DIEA in CH 2 Cl 2 (v/v). This procedure was repeated twice to ensure completion of the cleavage.
  • the resin was washed with 2ml OfCH 2 Cl 2 .
  • the CH 2 Cl 2 layer was evaporated to dryness.
  • the fully protected linear peptide was solubilised in 8 ml of dry DMF. Then 2 eq. of HATU in dry DMF (ImI) and 4 eq.
  • Examples 1-50 are shown in Table 1.
  • the peptides were synthesized starting with the amino acid L-Pro which was grafted to the resin.
  • Starting resin was Fmoc-Pro-2-chlorotrityl resin, which was prepared as described above.
  • the linear peptides were synthesized on solid support according to the procedure described above in the following sequence: Resin-Pro- D Pro-P12-Pl 1-P10-P9-P8-P7-P6-P5-P4-P3-P2-P1.
  • Ex. 1-50 were cleaved from the resin, cyclized, deprotected and purified as indicated by preparative reverse phase LC-MS.
  • HPLC-retention times were determined using the analytical methods as described above. Examples 1 to 39 were analysed with method I 1 for Examples 40-50 method 2 was used:
  • Ex. 1 (8.87), Ex. 2 (9.26), Ex. 3 (9.34), Ex. 4 (9.45), Ex. 5 (9.48), Ex. 6 (9.44), Ex. 7 (10.11), Ex.8 (9.99), Ex.9 (10.22), Ex.10 (9.76), Ex.11 (10.56), Ex.12 (11.37), Ex.13 (9.13), Ex.
  • Lyophilized peptides were weighed on a Microbalance (Mettler MT5) and dissolved in sterile water to a final concentration of 1 mg/ml unless stated otherwise. Stock solutions were kept at +4 0 C, light protected.
  • the selective antimicrobial activities of the peptides were determined in 96-well plates (Nunclon polystyrene) by the standard NCCLS broth microdilution method (see ref 1, below) with slight modifications. Innocula of the microorganisms were diluted into
  • cytotoxicity of the peptides to HELA cells (Acc57) and COS-7 cells (CRL-1651) was determined using the MTT reduction assay [see ref. 2 and 3, below]. Briefly the method was as follows: HELA cells and COS-7 cells were seeded at 7.OxIO 3 and, respectively, 4.5x10 3 cells per well and grown in 96-well microtiter plates for 24 hours at 37°C at 5% CC" 2 . At this point, time zero (Tz) was determined by MTT reduction (see below). The supernatant of the remaining wells was discarded, and fresh medium and the peptides in serial dilutions of 12.5, 25 and 50 ⁇ M were dispensed into the wells.
  • peptide concentration was assayed in triplicate. Incubation of the cells was continued for 48 hours at 37°C at 5% CO 2 . Wells were then washed once with phosphate buffered saline (PBS) and subsequently 100 ⁇ l MTT reagent (0.5 mg/ml in medium RPMI1640 and, respectively, DMEM) were added to the wells. This was incubated at 37 0 C for 2 hours and subsequently the medium was aspirated and 100 ⁇ l isopropanol were added to each well. The absorbance at 595 nm of the solubilized product was measured (ODs 95 peptide). For each concentration averages were calculated from triplicates.
  • PBS phosphate buffered saline
  • MTT reagent 0.5 mg/ml in medium RPMI1640 and, respectively, DMEM
  • the percentage of growth was calculated as follows: (OD 59 5peptide-OD59 5 Tz-OD 595 Empty well) / (OD 595 Tz- OD 595 Em ⁇ ty well) x 100% and was plotted for each peptide concentration.
  • the LC 50 values Lethal Concentration, defined as the concentration that kills 50% of the cells
  • hRBC fresh hRBC were washed three times with phosphate buffered saline (PBS) by centrifugation for 10 min at 2000 x g. Peptides at a concentration of 100 ⁇ M were incubated with 20% v/v hRBC for 1 hour at 37 0 C. The final erythrocyte concentration was approximately 0.9xl0 9 cells per ml. A value of 0% and, respectively,. 100% cell lysis was determined by incubation of the hRBC in the presence of PBS alone and, respectively, 0.1% Triton X-100 in H 2 O.
  • PBS phosphate buffered saline
  • the filtrates in the receiver PP plate were analysed by LC/MS as follows: Column: Jupiter C18 (Phenomenex), mobile phases: (A) 0.1% formic acid in water and (B) acetonitrile, gradient: 5%-100% (B) in 2 minutes, electrospray ionization, MRM detection (triple quadrupole). The peak areas were determined and triplicate values were averaged. The binding was expressed in percent of the (filtered and not-filtered time point 0 min) control 1 and 2 by: 100-(100 x T 6 o/T 0 ). The average from these values was then calculated.
  • Example 1 Pharmacokinetic study after single intravenous (i.v.) and subcutaneous (s.c.) administration was performed for the compound of Example 1 ("Ex. 1").
  • CD-I mice (20- 25 g) were used in the study.
  • Physiological saline was used a vehicle.
  • the volume was 2 ml/kg i.v., and 5 ml/kg s.c. and the peptide Ex. 1 was injected to give a final intravenous dose of 1 mg/kg, and a subcutaneous dose of 5 mg/kg.
  • the plate containing eluates was introduced into the concentrator system and taken to dryness.
  • the residues were dissolved in 100 ⁇ L of formic acid 0.1%/acetonitrile, 95/5 (v/v) and analysed in the HPLC/MS on a reverse phase analytical column (Jupiter C 18, 50 x 2.0 mm, 5 ⁇ m, Phenomenex), using gradient elution (mobile phases A: 0.1% formic acid in water, B: Acetonitrile; from 5%B to 100%B in 2 min.).
  • Samples coming from animal treatments were pooled in order to obtain an appropriate volume for the extraction. If the total volume obtained was less than 0.2 ml the appropriate amount of "blank" mouse plasma was added in order to keep the matrix identical to the calibration curve. Samples were than spiked with IS and processed as described for the calibration curve.
  • the area under the curve AUC was calculated by the linear trapezoidal rule.
  • Elimination half-life was calculated by the linear regression on at least three data points during the elimination phase.
  • the time intervals selected for the half-life determinations were evaluated by the correlation coefficient (r 2 ), which should be at least above 0.85 and most optimally above 0.96.
  • r 2 correlation coefficient
  • the initial concentration at t zero was determined by extrapolation of the curve through the first two time points.
  • bioavailability after i.p. administration was calculated from the normalised AUCinf_D_obs ration after s.c. versus i.v. administration.
  • Ex. 1 After intravenous administration of Ex. 1 at a dose level of 1 mg/kg body weight, Ex. 1 followed intravenous kinetic characteristics. After PK analysis, Ex. 1 showed an extrapolated Ci n i t j a i of 2174 ng/ml and a C max observed of 1268 ng/ml at 5 min. Plasma levels rapidly decreased to 575 and 177 ng/ml at 15 min and 1 hour respectively. From 0.5 to 2 h plasma levels decreased with an elimination half-life of 0.53 h to 10.6 ng/ml at

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Pain & Pain Management (AREA)

Abstract

Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting firom the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and Solution phase synthetic strategy.

Description

Template - fixed peptidomimetics
The present invention provides template-fixed β-hairpin peptidomimetics incorporating a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain, are GIy or Pro, or of certain types, as defined herein below. These template-fixed β- hairpin mimetics have a selective antimicrobial activity. In addition, the present invention provides efficient synthetic processes by which these compounds can, if desired, be made in parallel library-format. These β-hairpin peptidomimetics show improved efficacy, bioavailability, half-life and most importantly a significantly enhanced ratio between antibacterial activity on the one hand, and hemolysis of red blood cells on the other.
The growing problem of microbial resistance to established antibiotics has stimulated intense interest in developing novel antimicrobial agents with new modes of action (H. Breithaupt, Nat. Biotechnol. 1999, 17, 1165-1169). One emerging class of antibiotics is based on naturally occurring cationic peptides (T. Ganz, R. I. Lehrer, MoI. Medicine Today 1999, J, 292-297; R. M. Epand, H. J. Vogel, Biochim. Biophys. Acta 1999, 1462, 11-28). These include disulfide-bridged β-hairpin and β-sheet peptides (such as the protegrins [V. N.. M.; O. V. Shamova, H. A. Korneva, R. I. Lehrer, FEBS Lett. 1993, 327, 231-236], tachyplesins [T. Nakamura, H. Furunaka, T. Miyata, F. Tokunaga, T. Muta, S. Iwanaga, M. Niwa, T. Takao, Y. Shimonishi, Y. J. Biol. Chem. 1988, 263, 16709-16713], and the defensins [R. I. Lehrer, A. K. Lichtenstein, T. Ganz, Annu. Rev. Immunol. 1993, 11, 105-128], amphipathic α-helical peptides (e.g. cecropins, dermaseptins, magainins, and mellitins [A. Tossi, L. Sandri, A. Giangaspero, Biopolymers 2000, 55, 4-30]), as well as other linear and loop- structured peptides. Although the mechanisms of action of antimicrobial cationic peptides are not yet fully understood, their primary site of interaction is the microbial cell membrane (H. W. Huang, Biochemistry 2000, 39, 8347-8352). Upon exposure to these agents, the cell membrane undergoes permeabilization, which is followed by rapid cell death. However, more complex mechanisms of action, for example, involving receptor-mediated signaling, cannot presently be ruled out (M. Wu, E. Maier, R. Benz, R. E. Hancock, Biochemistry 1999, 35, 7235-7242). The antimicrobial activities of many of these cationic peptides usually correlate with their preferred secondary structures, observed either in aqueous solution or in membrane-like environments (N. Sitaram, R. Nagaraj, Biochim. Biophys. Acta 1999, 1462, 29-54). Structural studies by nuclear magnetic resonance (NMR) spectroscopy have shown that cationic peptides such as protegrin 1 (A. Aumelas, M. Mangoni, C. Roumestand, L. Chiche, E.
Despaux, G. Grassy, B. Calas, A. Chavanieu, A. Eur. J. Biochem. 1996, 237, 575-583; R. L. Fahrner, T. Dieckmann, S. S. L. Harwig, R. I. Lehrer, D. Eisenberg, J. Feigon, J. Chem. Biol. 1996, 3, 543-550) and tachyplesin I (K. Kawano, T. Yoneya, T. Miyata, K. Yoshikawa, F. Tokunaga, Y. Terada, S. J. Iwanaga, S. J. Biol. Chem. 1990, 265, 15365-15367) adopt well defined β-hairpin conformations, due to the constraining effect of two disulfide bridges. In protegrin analogues lacking one or both of these disulfide bonds, the stability of the β-hairpin conformation is diminished, and the antimicrobial activity is reduced (J. Chen, T. J. Falla, H. J. Liu, M. A. Hurst, C. A. Fujii, D. A. Mosca, J. R. Embree D. J. Loury, P. A. Radel, C. C. Chang, L. Gu, J. C. Fiddes, Biopolymers 2000, 55, 88-98; S. L. Harwig, A. Waring, H. J. Yang, Y. Cho, L. Tan, R. I. Lehrer, R. J. Eur. J. Biochem. 1996, 240, 352-357; M. E.
Mangoni, A. Aumelas, P. Charnet, C. Roumestand, L. Chiche, E. Despaux, G. Grassy, B. Calas, A. Chavanieu, FEBS Lett. 1996, 383, 93-98; H. Tamamura, T. Murakami, S. Noriuchi, K. Sugihara, A. Otaka, W. Takada, T. Ibuka, M. Waki, N. Tamamoto, N. Fujii, Chem. Pharm. Bull. 1995, 43, 853-858). Similar observations have been made in analogues of tachyplesin I (H. Tamamura, R. Ikoma, M. Niwa, S. Funakoshi, T. Murakami, N. Fujii,
Chem. Pharm. Bull. 1993, 41, 978-980) and in hairpin-loop mimetics of rabbit defensinNP-2 (S. Thennarasu, R. Nagaraj, Biochem. Biophys. Res. Comm. 1999, 254, 281-283). These results show that the β-hairpin structure plays an important role in the antimicrobial activity and stability of these protegrin-like peptides. In the case of the cationic peptides preferring α- helical structures, the amphililic structure of the helix appears to play a key role in determining antimicrobial activity (A. Tossi, L. Sandri, A. Giangaspero, A. Biopolymers 2000, 55, 4-30). Gramicidin S is a backbone-cyclic peptide with a well defined β-hairpin structure (S. E. Hull, R. Karlsson, P. Main, M. M. Woolfson, E. J. Dodson, Nature 1978, 275, 206-275) that displays potent antimicrobial activity against gram-positive and gram-negative bacteria (L. H. Kondejewski, S. W. Farmer, D. S. Wishart, R. E. Hancock, R. S. Hodges, Int. J. Peptide Prot. Res. 1996, 47, 460-466). The high hemolytic activity of gramicidin S has, however, hindered its widespread use as an antibiotic. Recent structural studies by NMR have indicated that the high hemolytic activity apparently correlates with the highly amphipathic nature of this cyclic β-hairpin-like molecule, but that it is possible to dissociate antimicrobial and hemolytic activities by modulating the conformation and amphiphilicity (L. H. Kondejewski, M. Jelokhani-Niaraki, S. W. Farmer, B. Lix, M. Kay, B. D. Sykes, R. E. Hancock, R. S. Hodges, J. Biol. Chem. 1999, 274, 13181-13192; C. McInnesL. H. Kondejewski, R. S. Hodges, B. D. Sykes, J. Biol. Chem. 2000, 275, 14287-14294).
A new cyclic antimicrobial peptide RTD-I was reported recently from primate leukocytes (Y.-Q. Tang, J. Yuan, G. Osapay, K. Osapay, D. Tran, C. J. Miller, A. J. Oellette, M. E. Selsted, Science 1999, 286, 498-502. This peptide contains three disulfide bridges, which act to constrain the cyclic peptide backbone into a hairpin geometry. Cleavage of the three disulfide bonds leads to a significant loss of antimicrobial activity. Analogues of protegrins (J. P. Tarn, C. Wu, J.-L. Yang, Eur. J. Biochem. 2000, 267, 3289-3300) and tachyplesins (J.- P. Tam, Y. -A. Lu, J.-L. Yang, Biochemistry 2000, 39, 7159-7169; N. Sitaram, R. Nagaraij, Biochem. Biophys. Res. Comm. 2000, 267, 783-790) containing a cyclic peptide backbone, as well as multiple disulfide bridges to enforce a aniphiphilic hairpin structure, have also been reported. In these cases, removal of all the cystine constraints does not always lead to a large loss of antimicrobial activity, but does modulate the membranolytic selectivity (J. P. Tam, C. Wu, J.-L. Yang, Eur. J. Biochem. 2000, 267, 3289-3300).
A key issue in the design of new selective cationic antimicrobial peptides are bioavailability, stability and reduced haemolytic activity. The naturally occurring protegrins and tachyplesins exert a significant hemolytic activity against human red blood cells. This is also the case for protegrin analogues such as IB367 (J. Chen, T. J. Falla, H. J. Liu, M. A. Hurst, C. A. Fujii, D. A. Mosca, J. R. Embree, D. J. Loury, P. A. Radel, C. C. Chang, L. Gu, J. C. Fiddes,
Biopolymers 2000, 55, 88-98; C. Chang, L. Gu, J. Chen, US-Pat: 5,916,872, 1999). This high hemolytic activity essentially obviates its use in vivo, and represents a serious disadvantage in clinical applications. Also, the antibiotic activity of analogues often decreases significantly with increasing salt concentration, such that under in vivo conditions (ca. 100-150 mM NaCl) the antimicrobial activity may be severely reduced. Protegrin 1 exhibits potent and similar activity against gram-positive and gram-negative bacteria as well as fungi in both low- and high-salt assays. This broad antimicrobial activity combined with a rapid mode of action, and their ability to kill bacteria resistant to other classes of antibiotics, make them attractive targets for development of clinically useful antibiotics. The activity against gram-positive bacteria is typically higher than against gram- negative bacteria. However, protegrin 1 also exhibits a high hemolytic activity against human red blood cells, and hence a low selectivity towards microbial cells. Oriented CD experiments (W. T. Heller, A. J. Waring, R. I. Lehrer, H. W. Huang, Biochemistry 1998, 37, 17331- 17338) indicate that protegrin 1 may exist in two different states as it interacts with membranes, and these states are strongly influenced by lipid composition. Studies of cyclic protegrin analogues (J.-P. Tam, C. Wu, J.-L. Yang, Eur. J. Biochem. 2000, 267, 3289-3300) have revealed, that an increase in the conformational rigidity, resulting from backbone cyclization and multiple disulfide bridges, may confer membranolytic selectivity that dissociates antimicrobial activity from hemolytic activity, at least in the series of compounds studied.
Protegrin 1 is an 18 residues linear peptide, with an amidated carboxyl terminus and two disulfide bridges. Tachyplesin I contains 17 residues, also has an amidated carboxyl terminus and contains two disulfide bridges. Recently described backbone-cyclic protegrin and tachyplesin analogues typically contain 18 residues and up to three disulfide bridges (J. P. Tam, C. Wu, J.-L. Yang, Eur. J. Biochem. 2000, 267, 3289-3300; J. P. Tam, Y.-A. Lu, J.-L. Yang, Biochemistry 2000, 39, 7159-7169; N. Sitaram, R. Nagaraij, Biochem. Biophys. Res. Comm. 2000, 267, 783-790).
Cathelicidin , a 37-residue linear helical-type cationic peptide, and analogues are currently under investigation as inhaled therapeutic agents for cystic fibrosis (CF) lung disease (L. Saiman, S. Tabibi, T. D. Starner, P. San Gabriel, P. L. Winokur, H. P. Jia, P. B. McGray, Jr., B. F. Tack, Antimicrob. Agents and Chemother. 2001, 45, 2838-2844; R. E. W. Hancock, R. Lehrer, Trends Biotechnol. 1998, 16, 82-88). Over 80% of CF patients become chronically infected with pseudomonas aeruginosa (C. A. Demko, P. J. Biard, P. B. Davies, J. Clin.
Epidemiol. 1995, 48, 1041-1049; E. M. Kerem, R. Gold, H. Levinson, J. Pediatr. 1990, 116, 714-719). Other antimicrobial peptides against Pseudomonads (Y.H. Yau, B. Ho, N.S. Tan, M.L. Ng, J.L. Ding, Antimicrob. Agents and Chemother. 2001, 45, 2820-2825 and herein cited references), like FALL-39, SMAP-29, and lepidopteran cecropin display a few of the desired attributes like potent antimicrobial activity over a wide range of pH, rapid killing rate, and low hemolytic activity.
In the compounds described below, a new strategy is introduced to stabilize β-hairpin conformations in backbone-cyclic cationic peptide mimetics exhibiting selective antimicrobial activity. This involves transplanting the cationic and hydrophobic hairpin sequence onto a template, whose function is to restrain the peptide loop backbone into a hairpin geometry.
Template-bound hairpin mimetic peptides have been described in the literature (D, Obrecht, M. Altorfer, J. A. Robinson, Adv. Med. Chem. 1999, 4, 1-68; J. A. Robinson, Syn. Lett. 2000, 4, 429-441) and the ability to generate β-hairpin peptidomimetics using combinatorial and parallel synthesis methods has now been established (L. Jiang, K. Moehle, B. Dhanapal, D. Obrecht, J. A. Robinson, HeIv. Chim. Acta. 2000, S3, 3097-3112). Antibacterial template - fixed peptidomimetics and methods for their synthesis have been described in International Patent applications WO02/070547 Al and WO2004/018503 Al but these molecules do not exhibit high plasma stability selectivity and particularly high potency.
The methods described herein allow the synthesis and screening of large hairpin mimetic libraries, which in turn considerably facilitates structure-activity studies, and hence the discovery of new molecules with potent selective antimicrobial and very low hemolytic activity to human red blood cells. The present strategy allows to synthesize β-hairpin peptidomimetics with novel selectivities towards various multi-drug resistant pseudomonas- strains.
The β-hairpin peptidomimetics of the present invention are compounds of the general formula
Figure imgf000007_0001
(I)
wherein
Figure imgf000007_0002
is a group of one of the formulae
Figure imgf000007_0003
(a1) (a2)
Figure imgf000007_0004
Figure imgf000008_0001
Figure imgf000009_0001
is the residue of an L-α-amino acid with B being a residue of formula -NR20CH(R71)- or the enantiomer of one of the groups Al to A69 as defined hereinafter;
is a group of one of the formulae
Figure imgf000009_0003
Figure imgf000009_0002
Figure imgf000010_0001
A5 A6 A7 A8 A9
Figure imgf000010_0002
A10 A11 A12 A13 A14
Figure imgf000010_0003
A15 A16 A17 A18 A19
Figure imgf000010_0004
A20 A21 A22 A23 A24
Figure imgf000010_0005
A25 A26 A27 A28
Figure imgf000011_0001
A48 A49 A50 A51 A52
Figure imgf000012_0001
A74
Figure imgf000013_0001
A80 A81 A82 A83 A84
Figure imgf000013_0002
A90 A91 A92 A93 A94
Figure imgf000013_0003
A95 A96 A97 A98
Figure imgf000013_0004
Figure imgf000014_0001
R1 is H; lower alkyl; or aryl-lower alkyl;
R2 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;
-(CH2)ra(CHR61)sNR33R34; -(CH2)ra(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)0(CHR61)SCOOR57;
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R3 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)O(CHR61)SCOOR57 ;
-(CH2)0(CHR61)SCONR58R59 ; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61^C6H4R8; R4 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; -(CH2)ra(CHR61)sNR20CONR33R82;
-(CH2)p(CHR61)sCOOR57; -(CH2)p(CHR61)sCONR58R59; -(CH2)p(CHR61)sPO(OR60)2;
-(CH2)P(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R5 is alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)O(CHR61)SNR33R34; -(CH2)O(CHR61)SOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R6 is H; alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)O(CHR61)SNR33R34; -(CH2)O(CHR61)SOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR6I)SC6H4R8; R7 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sNR33R34;
-(CH2)q(CHR61)sOCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82;
-(CH2)r(CHR61)sCOOR57; -(CH2)r(CHR61)sCONR58R59; -(CH2)r(CHR61)sPO(OR60)2; -(CH2)r(CHR61)sSO2R62; or -(CH2)r(CHR6I)s C6H4R8;
R8 is H; Cl; F; CF3; NO2; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl;
-(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)NR33R34 ;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)SSO2R62; or -(CH2)0(CHR61)SCOR64;
R9 is alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)o(CHR6I)sCOOR57; -(CH2)o(CHR6I)sCONR58R59; -(CH2)o(CHR6I)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8;
R10 is alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8;
R11 is H; alkyl; alkenyl; -(CH2)m(CHR6I)sOR55; -(CH2)m(CHR61)sNR33R34;
-(CH2)m(CHR61)sOCONR33R75; -(CH2)ra(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)0(CHR61)sSO2R62; or -(CH2)0(CHR6l)s C6H4R8; R12 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR6I)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)r(CHR61)sCOOR57;
-(CH2)r(CHR61)sCONR58R59; -(CH2)r(CHR61)sPO(OR60)2; -(CH2)r(CHR61)s SO2R62; or
-(CH2)r(CHR61)sC6H4R8; R13 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sSR56;
-(CH2)q(CHR61)sNR33R34;
-(CH2)q(CHR61)5OCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82;
-(CH2)q(CHR61)sCOOR57; -(CH2)q(CHR61)sCONR58R59; -(CH2)q(CHR61)sPO(OR60)2; -(CH2)q(CHR61)s SO2R62; or -(CH2)q(CHR6I)sC6H4R8; R14 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)q(CHR61)sCOOR57; -(CH2)q(CHR61)sCONR58R59; -(CH2)q(CHR61)sPO(OR60)2;. -(CH2)q(CHR6I)sSOR62; or -(CH2)q(CHR61)s C6H4R8;
R15 is alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR6I)SNR33R34;
-(CH2)o(CHR6I)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR6I)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8;
R16 is alkyl; alkenyl; -(CH2)O(CHR6!)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR6I)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8;
R17 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR6I)sSR56; -(CH2)q(CHR61)sNR33R34;
-(CH2)q(CHR61)sOCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82; -(CH2)q(CHR61)5COOR57; -(CH2)q(CHR61)sCONR58R59; -(CH2)q(CHR61)5PO(OR60)2; -(CH2)q(CHR61)s SO2R62; or -(CH2)q(CHR61XC6H4R8;
R18 is alkyl; alkenyl; -(CH2)P(CHR6I)SOR55; -(CH2)P(CHR61)SSR56; -(CH2)P(CHR6I)SNR33R34;
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82; -(CH2)P(CHR61)SCOOR57; -(CH2)P(CHR61)sCONR58R59; -(CH2)p(CHR61)sPO(OR60)2; -(CH2)p(CHR61χ SO2R62; or -(CH2)O(CHR61)SC6H4R8;
R19 is lower alkyl; -(CH2)P(CHR61)SOR55; -(CH2)P(CHR61)SSR56; -(CH2)P(CHR61XNR33R34; -(CH2)P(CHR61)SOCONR33R75; -(CH2)P(CHR61XNR20CONR33R82; -(CH2)P(CHR61XCOOR57; -(CH2)P(CHR61XCONR58R59; -(CH2)P(CHR61XPO(OR60)2; -(CH2)P(CHR61X SO2R62; or -(CH2)O(CHR61) sC6H4R8; or R18 and R19 taken together can form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; R20 is H; alkyl; alkenyl; or aryl-lower alkyl; R21 is H; alkyl; alkenyl; -(CH2)0(CHR6I)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8;
R22 is H; alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR6I)sCOOR57; -(CH2)o(CHR6I)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR6I)S SO2R62; or -(CH2)O(CHR61)SC6H4R8;
R23 is alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61XC6H4R8;
R24 is alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR6I)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61XC6H4R8;
R25 is H; alkyl; alkenyl; -(CH2)ffl(CHR61)sOR55; -(CH2)m(CHR61)sSR56; -(CH2)m(CHR61XNR33R34; -(CH2)m(CHR61)5OCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)0(CHR61XCONR58R59; -(CH2)0(CHR61XPO(OR60)2; -(CH2)O(CHR61XSO2R62; or -(CH2)O(CHR61)SC6H4R8;
R26 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)0(CHR61)SCONR58R59; -(CH2)0(CHR61XPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; or
R25 and R26 taken together can form: -(CH2)2.6-; -(CH2)rO(CH2)r-; -(CH2)rS(CH2)r-; or -(CH2)rNR57(CH2)r-; R27 is H; alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)O(CHR6I)SSR56;
-(CH2)o(CHR61)sNR33R34;
-(CH2)o(CHR6I)sCOOR5V(CH2)0(CHR61)sCONR58R59;
-(CH2)O(CHR61)SOCONR33R75; -(CH2)o(CHR6I)sNR20CONR33R82; -(CH2)o(CHR6I)sPO(ORδ0)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61XC6H4R8; R28 is alkyl; alkenyl; -(CH2)O(CHR61)S-OR55; -(CH2)O(CHR61)S SR56; -(CH2)O(CHR6I)S
NR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)s COOR57; -(CH2)O(CHR61)S CONR58R59; -(CH2)O(CHR61)S
PO(OR60)2;
-(CH2)O(CHR6I)S SO2R62; or -(CH2)O(CHR6I)S C6H4R8; R29 is alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)O(CHR61)SNR33R34; -(CH2)o(CHR61)sOCONR33R75; -(CH2)O(CHR61^NR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R30 is H; alkyl; alkenyl; or aryl-lower alkyl;
R31 is H; alkyl; alkenyl; -(CH2)P(CHR61)SOR55; -(CH2)P(CHR61)SNR33R34; -(CH2)p(CHR61)sOCONR33R75; -(CH2)P(CHR61)SNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)SSO2R62; or -(CH2)O(CHR61)S C6H4R8; R32 is H; lower alkyl; or aryl-lower alkyl;
R33 is H; alkyl, alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR34R63; -(CH2)m(CHR61)sOCONR75R82; -(CH2)m(CHR61)sNR20CONR78R82;
-(CH2)o(CHR61)sCOR64; -(CH2)o(CHR61)s-CONR58R59, -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR6I)S SO2R62; or -(CH2)O(CHR61^C6H4R8; R34 is H; lower alkyl; aryl, or aryl-lower alkyl;
R33 and R34 taken together can form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-;
R35 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHRδl)sNR33R34;
-(CH2)m(CHR61)5OCONR33R75; -(CH2)m(CHR61)5NR20CONR33RS2; -(CH2)p(CHR61)sCOOR57; -(CH2)P(CHR61XCONR58R59; -(CH2)P(CHR61)SPO(OR60)2;
-(CH2)P(CHR61)SSO2R62; or -(CH2)P(CHR61)S C6H4R8; R36 is H, alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)P(CHR61)SNR33R34;
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82; -(CH2)P(CHR61)SCOOR57; -(CH2)P(CHR61)SCONR58R59; -(CH2)P(CHR6I)SPO(OR60)2;
-(CH2)p(CHR61)sSO2R62; or -(CH2)O(CHR6I)S C6H4R8; R37 is H; F; Br; Cl; NO2; CF3; lower alkyl; -(CH2)P(CHR61)SOR55; -(CH2)P(CHR61)SNR33R34;
-(CH2)P(CHR61)SOCONR33R75; -(CH2)P(CHR61)SNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR6I)sCONR58R59; -(CH2)o(CHR6I)sPO(OR60)2; -(CH2)O(CHR6I)SSO2R62; or -(CH2)O(CHR61)S C6H4R8;
R38 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)P(CHR61)SOR55;
-(CH2)p(CHR61)sNR33R34;
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)SSO2R62; or -(CH2)O(CHR6I)SC6H4R8;
R39 is H; alkyl; alkenyl; or aryl-lower alkyl; R40 is H; alkyl; alkenyl; or aryl-lower alkyl; R41 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)P(CHR61)SOR55;
-(CH2)P(CHR61)sNR33R34; -(CH2)P(CHR61)sOCONR33R75; -(CH2)P(CHR61 )sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)0(CHR61)sSO2R62; or -(CH2)O(CHR61)S C6H4R8; R42 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)P(CHR61)SOR55;
-(CH2)P(CHR61)SNR33R34; -(CH2)P(CHR61)SOCONR33R75; -(CH2)P(CHR61)5NR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)0(CHR61)sSO2R62; or -(CH2)O(CHR61)S C6H4R8; R43 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61^NR33R34;
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)O(CHR61)SCOOR57; -(CH2)O(CHR61)SCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)SSO2R62; or -(CH2)O(CHR61)S C6H4R8; R44 is alkyl; alkenyl; -(CH2)r(CHR61)sOR55; -(CH2)r(CHR61)sSR56; -(CH2)r(CHR61)5NR33R34;
-(CH2)r(CHR61)sOCONR33R75; -(CH2)r(CHR6I)sNR20CONR33R82; -(CH2)r(CHR61)sCOOR57; -(CH2)r(CHR61)sCONR58R59; -(CH2)r(CHR61)sPO(OR60)2;
-(CH2)r(CHR61)s SO2R62; or -(CH2)r(CHR61)sC6H4R8; R45 is H; alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2J0(CHR61JsSR56;
-(CH2J0(CHR61J5NR33R34; -(CH2)0(CHR6I)SOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)s(CHR61)sCONR58R59; -(CH2)s(CHR61)sPO(OR60)2;
-(CH2)S(CHR61)S SO2R62; or -(CH2)S(CHR6I)SC6H4R8; R46 is H; alkyl; alkenyl; or -(CH2J0(CHR61JpC6H4R8; R47 is H; alkyl; alkenyl; or -(CH2)O(CHR61)SOR55; R48 is H; lower alkyl; lower alkenyl; or aryl-lower alkyl;
R49 is H; alkyl; alkenyl; -(CHR61)SCOOR57; (CHR6I)SCONR58R59; (CHR61)SPO(OR60)2;
-(CHR61)SSOR62; or -(CHR6I)SC6H4R8; R50 is H; lower alkyl; or aryl-lower alkyl;
R51 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61J5SR56; -(CH2)ra(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;
-(CH2)ra(CHR61)sNR20CONR33R82; -(CH2)0(CHR61)sCOOR57;
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)pPO(OR60)2;
-(CH2)p(CHR61)s SO2R62; or -(CH2)P(CHR61)SC6H4R8; R52 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)0(CHR61)SCOOR57;
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)pPO(OR60)2;
-(CH2)P(CHR61)S SO2R62; or -(CH2)P(CHR61)SC6H4R8; R53 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61J8SR56; -(CH2)m(CHR61)sNR33R34; -(CH2)ra(CHR61)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)pPO(OR60)2;
-(CH2)P(CHR61)S SO2R62; or -(CH2)P(CHR61J8C6H4R8; R54 is H; alkyl; alkenyl; -(CH2)m(CHR61)8OR55; -(CH2J1n(CHR61J8NR33R34; -(CH2J1n(CHR61J8OCONR33R75; -(CH2J1n(CHR61J8NR20CONR33R82;
-(CH2J0(CHR61JCOOR57; -(CH2J0(CHR61J5CONR58R59; or -(CH2J0(CHR61J8 C6H4R8; R55 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH2)m(CHR61)sOR57;
-(CH2Jm(CHR61J5NR34R63; -(CH2Jm(CHR61J8OCONR75R82; -(CH2)ra(CHR61)sNR20CONR78R82; -(CH2)o(CHR6I)s-COR64; -(CH2)o(CHR6I)COOR57; or
-(CH2)O(CHR61XCONR58R59;
R56 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH2)m(CHR6I)sOR57; -(CH2)m(CHR61)sNR34R63; -(CH2)m(CHR61)sOCONR75R82;
-(CH2)m(CHR61)sNR20CONR78R82; -(CH2)0(CHR61)S-COR64; or -(CH2)O(CHR61)SCONR58R59;
R57 is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl; R58 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl;
R59 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or
R58 and R59 taken together can form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or
-(CH2)2NR57(CH2)2-; R60 is H; lower alkyl; lower alkenyl; aryl; or aryl-lower alkyl;
R61 is H, alkyl; alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; - (CH2)POR55;
-(CH2)PNR33R34; -(CH2)POCONR75R82; -(CH2)PNR20CONR78R82; -(CH2)OCOOR57; or -(CH2)oPO(COR60)2; R62 is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl-lower alkyl;
R63 is H; lower alkyl; lower alkenyl; aryl, heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl;
-COR64; -COOR57; -CONR58R59; -SO2R62; or -PO(OR60)2;
R34and R63 taken together can form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-;
R64 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; -(CH2)P(CHR61)SOR65; -(CH2)P(CHR61)SSR66; or -(CH2)P(CHR6I)SNR34R63; -(CH2)P(CHR61)SOCONR75R82; -(CH2)P(CHR61)SNR20CONR78R82;
R65 is H; lower alkyl; lower alkenyl; aryl, aryl-lower alkyl; heteroaryl-lower alkyl; -COR57; -COOR57; or -CONR58R59;
R66 is H; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; heteroaryl-lower alkyl; or -
CONR58R59; m is 2-4; o is 0-4; p is 1-4; q is 0-2; r is 1 or 2; s is O or 1; R67 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; R68 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; R69 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; and R70 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; with the proviso that at least two of R67, R68, R69 and R70 are H; and
Z is a chain of 12 α-amino acid residues, the positions of said amino acid residues in said chain being counted starting from the N-terminal amino acid, whereby these amino acid residues are, depending on their position in the chain, GIy or Pro, or of formula -A-CO-, or of formula -B-CO-, or of one of the types
C: -NR20CH(R72)CO-;
D: -NR20CH(R73)CO-; E: -NR20CH(R74)CO-;
F: -NR20CH(R84)CO-;
H: -NR20-CH(CO-)-(CH2)4.7-CH(CO-)-NR20-;
-NR20-CH(CO-)-(CH2)pSS(CH2)p-CH(CO-)-NR20-; -NR20-CH(CO-)-(-(CH2)pNR20CO(CH2)p-CH(CO-)-NR20-; and -NR20-CH(CO-)-(-(CH2)pNR20CONR20(CH2)p-CH(CO-)-NR20-;
R71 is H; lower alkyl; lower alkenyl; -(CX2)P(CHR61)SOR75; -(CX2)P(CHR61)SSR75; -(CX2)P(CHR61)SNR33R34; -(CX2)P(CXR61)SOCONR33R75; -(CX2)P(CHR61)SNR20CONR33R82;
-(CX2)0(CHR61)SCOOR75; -(CX2)PCONR58R59; -(CX2)PPO(OR62)2; -(CX2)PSO2R62; or -(CX2)O-C6R67R68R69R70R76;
R72 is H; lower alkyl; lower alkenyl; -(CX2)p(CHR86)sOR85; or
-(CX2)p(CHR86)5SR85; R73 is -(CX2)OR77; -(CX2)rO(CH2)oR77; -(CX2)rS(CH2)0R77; or
-(CX2)rNR20(CH2)oR77; R74 is -(CX2)PNR78R79; -(CX2)PNR77R80; -(CX2)pC(=NR80)NR78R79; - (CX2)PC(=NOR50)NR78R79; -(CX2)pC(=NNR78R79)NR78R79; -(CX2)pNR80C(=NR80)NR78R79; -(CX2)pN=C(NR78R80)NR79R80;-(CX2)pC6H4NR78R7V(CX2)pC6H4NR77R80;
-(CX2)pC6H4C(=NR80)NR78R79; -(CX2)pC6H4C(=NOR50)NR78R79;
-(CX2)pC6H4C(=NNR78R79)NR78R79; -(CX2)pC6H4NR80C(=NR80)NR78R79;
-(CX2)pC6H4N=C(NR78R80)NR79R80; -(CX2)rO(CX2)mNR78R79; -(CX2)rO(CX2)mNR77R80; -(CX2)rO(CX2)pC(=NR80)NR78R79; -(CX2)rO(CX2)pC(=NOR50)NR78R79;
-(CX2)rO(CX2)pC(=NNR78R79)NR78R79; -(CX2)rO(CH2)mNR80C(=NR80)NR78R79;
-(CX2)rO(CX2)mN=C(NR78R80)NR79R80; -(CX2)rO(CX2)pC6H4CNR78R79;
-(CX2)rO(CX2)pC6H4C(=NR80)NR78R79; -(CX2)rO(CX2)pC6H4C(=NOR50)NR78R79;
-(CX2)rO(CX2)pC6H4C(=NNR78R79)NR78R79; -(CX2)rO(CX2)pC6H4NR80C(=NR80)NR78R79; -(CX2)rS(CX2)mNR78R79;
-(CX2)rS(CX2)raNR77R80;-(CX2)rS(CX2)pC(=NR80)NR78R79;
-(CX2)rS(CX2)pC(=NOR50)NR78R79; -(CX2)rS(CX2)pC(=NNR78R79)NR78R79;
-(CX2)rS(CX2)mNR80C(=NR80)NR78R79; -(CX2)rS(CX2)mN=C(NR78R80)NR79R80;
-(CX2XS(CX2)PC6H4CNR78R79; -(CX2)rS(CX2)pC6H4C(=NR80)NR7SR79; -(CX2)rS(CX2)pC6H4C(=NOR50)NR78R79; -(CX2)rS(CX2)pC6H4C(=NNR78R79)NR78R79;
-(CX2)rS(CX2)pC6H4NR80C(=NR80)NR78R79; -(CX2)PNR80COR64J -(CX2)PNR80COR77;
-(CX2)PNR80CONR78R79; -(CX2)PC6H4NR80CONR78R79; or -(CX2)PNR20CO-[(CX2)U-
XX]1-CH3 where XX is -O-; -NR20-, or -S-; u is 1-3, and t is 1-6;
R75 is lower alkyl; lower alkenyl; or aryl-lower alkyl;
R33 and R75 taken together can form: -(CX2)2.6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-; R75 and R82 taken together can form: -(CX2)2.6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-; R76 isH; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CX2)OOR72; -(CX2)OSR72; -(CXz)0NR33R34; -(CX2)0OCONR33R75; -(CX2)oNR20CONR33R82; -(CX2)oCOOR75; -(CX2)oCONR58R59; -(CX2)oPO(OR60)2; -(CX2)PSO2R62; or -(CX2)oCOR64;
R77 is -C6R67R68R69R70R76; or a heteroaryl group of one of the formulae
Figure imgf000024_0001
H1 H2 H3 H4 H5
Figure imgf000024_0002
H6 H7 H8 H9 H10
Figure imgf000024_0003
H11 H12 H13 H14 H15
Figure imgf000024_0004
H16 H17 H18 H19 H20
Figure imgf000024_0005
H21 H22 H23 H24 H25
Figure imgf000024_0006
H26 H27 H28 H29
Figure imgf000024_0007
H30 H31 H32 H33
Figure imgf000025_0001
H34 H35 H36 H37
Figure imgf000025_0002
H42 H43 H44 H45
Figure imgf000025_0003
H46 H47 H48 H49
Figure imgf000025_0004
H50 H51 H52 H53 H54
R78 is H; lower alkyl; aryl; or aryl-lower alkyl;
R78 and R82 taken together can form: -(CX2)2.6-; -(CX2)2O(CX2)2-; -(CXa)2S(CXa)2-; or
-(CX2)2NR57(CX2)2-;
R79 is H; lower alkyl; aryl; or aryl-lower alkyl; or
R78 and R79, taken together, can be -(CX2)2-7-; -(CX2)2O(CX2)2-; or -(CX2)2NR57(CX2)2-; R80 is H; or lower alkyl;
R81 is H; lower alkyl; or aryl-lower alkyl; R82 is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;
R33 and R82 taken together can form: -(CX2)2.6-; -(CXz)2O(CXz)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-;
R83 is H; lower alkyl; aryl; or -NR78R79; R84 is -(CX2)m(CHR61)sOH; -(CX2)PCONR78R79; -(CX2)PNR80CONR78R79;
-(CX2)PC6H4CONR78R79; or -(CX2)PC6H4NR80CONR78R79; R85 is lower alkyl; or lower alkenyl; R86 is H, alkyl; alkenyl; -(CX2)POR85;-(CX2)PSR85
R87 is H; alkyl; alkenyl; heteroaryl, aryl-lower alkyl; -(CX2)POR55; -(CX2)pOCONR75R82; -(CX2)PNR20CONR78R82; -(CX2)PCOOR57, or -(CX2)PPO(OR60)2;
X is H; or optionally halogen; with the proviso that in said chain of 12 α-amino acid residues Z the amino acid residues in positions 1 to 12 are, in a preferred embodiment:
Pl : of type C or of type D or of type E or of type F, or the residue is Pro;
P2: oftype D or oftype E;
P3: of type C or of type D, or the residue is GIy or Pro;
P4: of type C or oftype E or oftype F, or the residue is GIy or Pro;
P5: of type E or of type D or of type C, or the residue is GIy or Pro; - P6: of type E or of type F or of type C or of formula -A-CO-, or the residue is GIy or Pro;
P7: of type C or of type E or of type F or of formula -B-CO-;
P8: of type D or of type C, or of Type F, or the residue is Pro;
P9: of type C or of type E or of type D or of type F; - PlO: of type E;
PI l: of type C or of type F, or the residue is Pro or GIy ; and Pl 2: of type C or of type D or of type E or of type F, or the residue is Pro; or
P4 and P9 and/or P2 and Pl 1, taken together, can form a group of type H; and at P6, PlO and Pl 1 also D-isomers being possible; or, alternatively, but in a less preferred embodiment: Pl : of type C or of type D or of type E or of type F, or the residue is
Pro;
P2: of type C or of type F, or the residue is Pro or GIy ;
P3: of type E; - P4: of type C or of type E or of type D or of type F;
P5: of type D or of type C, or of type F, or the residue is Pro;
P6: of type C or of type E or of type F or of formula -B-CO-;
P7: of type E or of type F or of type C or of formula -A-CO-, or the residue is GIy or Pro; - P8: of type E or of type D or of type C, or the residue is GIy or Pro;
P9: of type C or of type E or of type F; or the residue is GIy or Pro;
PlO: of type C or of type D, or the residue is GIy or Pro;
Pl 1 : of type D or of type E; and
P12: of type C or of type D or of type E or of type F, or the residue is Pro; or
P4 and P9 and/or P2 and Pl 1, taken together, can form a group of type H; and at P2, P3, and P7 also D-isomers being possible;
and pharmaceutically acceptable salts thereof.
In accordance with the present invention these β-hairpin peptidomimetics can be prepared by a process which comprises
(a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 5, 6 or 7, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(b) removing the N-protecting group from the product thus obtained;
(c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position nearer the N- terminal amino acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected; (d) removing the N-protecting group from the product thus obtained;
(e) repeating steps (c) and (d) until the N-terminal amino acid residue has been introduced;
(f) coupling the product thus obtained with a compound of the general formula
Figure imgf000028_0001
wherein
Figure imgf000028_0002
is as defined above and X is an N-protecting group or, if
Figure imgf000028_0003
is to be group (al) or (a2), above, alternatively
(fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula
HOOC-B-H III or HOOC-A-H IV wherein B and A are as defined above , any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(fb) removing the N-protecting group from the product thus obtained; and
(fc) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(g) removing the N-protecting group from the product obtained in step (f) or (fc);
(h) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(i) removing the N-protecting group from the product thus obtained;
(j) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(k) removing the N-protecting group from the product thus obtained;
(1) repeating steps (j) and (k) until all amino acid residues have been introduced; (m) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
(o) detaching the product thus obtained from the solid support;
(p) cyclizing the product cleaved from the solid support; (q) if desired, forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β-strand region;
(r) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule; and (s) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.
Alternatively, the peptidomimetics of the present invention can be prepared by
(a1) coupling an appropriately functionalized solid support with a compound of the general formula
Figure imgf000029_0001
wherein
Figure imgf000030_0001
is as defined above and X is an N-protecting group or, if
Figure imgf000030_0002
is to be group (al) or (a2), above, alternatively
(a'a) coupling said appropriately functionalized solid support with an appropriately N-protected derivative of an amino acid of the general formula
HOOC-B-H 111 or HOOC-A-H IV wherein B and A are as defined above , any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(a'b) removing the N-protecting group from the product thus obtained; and (a'c) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(b1) removing the N-protecting group from the product obtained in step (a1) or
(a'c);
(c1) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(d1) removing the N-protecting group from the product thus obtained;
(e1) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected; (f ) removing the N-protecting group from the product thus obtained; (g1) repeating steps (e1) and (f ) until all amino acid residues have been introduced;
(h1) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
(i1) detaching the product thus obtained from the solid support;
(j') cyclizing the product cleaved from the solid support;
(k1) if desired forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β-strand region; (I1) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule; and
(m1) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.
The peptidomimetics of the present invention can also be enantiomers of the compounds of formula I. These enantiomers can be prepared by a modification of the above processes in which enantiomers of all chiral starting materials are used.
As used in this description, the term "alkyl", taken alone or in combinations, designates saturated, straight-chain or branched hydrocarbon radicals having up to 24, preferably up to 12, carbon atoms, ioptionally substituted with halogen. Similarly, the term "alkenyl" designates straight chain or branched hydrocarbon radicals having up to 24, preferably up to 12, carbon atoms and containing at least one or, depending on the chain length, up to four olefinic double bonds, optionally substituted with halogen. The term "lower" designates radicals and compounds having up to 6 carbon atoms. Thus, for example, the term "lower alkyl" designates saturated, straight-chain or branched hydrocarbon radicals having up to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl and the like. The term "aryl" designates aromatic carbocyclic hydrocarbon radicals containing one or two six-membered rings, such as phenyl or naphthyl, which may be substituted by up to three substituents such as Br, Cl, F, CF3, NO2, lower alkyl or lower alkenyl. The term "heteroaryl" designates aromatic heterocyclic radicals containing one or two five- and/or six-membered rings, at least one of them containing up to three heteroatoms selected from the group consisting of O, S and N and said ring(s) being optionally substituted; representative examples of such optionally substituted heteroaryl radicals are indicated hereinabove in connection with the definition of R77.
The structural element -A-CO- designates amino acid building blocks which in combination with the structural element -B-CO- form templates (al) and (a2). Templates (a) through (p) constitute building blocks which have an N-terminus and a C-terminus oriented in space in such a way that the distance between those two groups may lie between 4.0-5.5A. A peptide chain Z is linked to the C-terminus and the N-terminus of the templates (a) through (p) via the corresponding N- and C-termini so that the template and the chain form a cyclic structure such as that depicted in formula I. In a case as here where the distance between the N- and C- termini of the template lies between 4.0-5.5 A the template will induce the H-bond network necessary for the formation of a β-hairpin conformation in the peptide chain Z. Thus template and peptide chain form a β-hairpin mimetic.
The β-hairpin conformation is highly relevant for the anti-bacterial activity of the β-hairpin mimetics of the present invention. The β-hairpin stabilizing conformational properties of the templates (a) through (p) play a key role not only for the selective antibacterial activity but also for the synthetic processes defined hereinabove, as incorporation of the templates at the beginning or near the middle of the linear protected peptide precursors enhances cyclization yields significantly.
Building blocks A1-A69 belong to a class of amino acids wherein the N-terminus is a secondary amine forming part of a ring. Among the genetically encoded amino acids only proline falls into this class. The configuration of building block Al through A69 is (D), and they are combined with a building block -B-CO- of (L)-configuration. Preferred combinations for templates (al) are-DAl-CO-LB-CO- to DA69-CO-LB-CO-. Thus, for example, DPro-LPro constitutes the prototype of templates (al). Less preferred, but possible are combinations-LAl-CO-DB-CO- to LA69-CO-DB-CO- forming templates (a2). Thus, for example, LPro-DPro constitutes the prototype of template (a2). It will be appreciated that building blocks -Al-CO- to -A69-CO- in which A has (D)- configuration, are carrying a group R1 at the α-position to the N-terminus. The preferred values for R1 are H and lower alkyl with the most preferred values for R1 being H and methyl. It will be recognized by those skilled in the art, that Al- A69 are shown in (D)- conflguration which, for R1 being H and methyl, corresponds to the (R) -configuration. Depending on the priority of other values for R1 according to the Cahn, Ingold and Prelog- rules, this configuration may also have to be expressed as (S).
In addition to R1 building blocks -Al-CO- to -A69-CO- can carry an additional substituent designated as R2 to R17. This additional substituent can be H, and if it is other than H, it is preferably a small to medium-sized aliphatic or aromatic group. Examples of preferred values for R2 to R17 are:
-R2: H; lower alkyl; lower alkenyl; (CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); (CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); (CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; R57: H; or lower alkyl); (CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR5SR59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 : lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
-R3: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)raSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)r; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R4: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2- ; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyljor lower alkoxy).
R5: lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; R57: where H; or lower alkyl); (CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)oN(R20)COR64(where: R20: H; or lower alkyl; R64: alkyl; alkenyl; aryl; and aryl-lower alkyl; heteroaryl-lower alkyl); -(CH2)0COOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R6: H; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56 : lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0OCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0N(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONRS8R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2)2-5-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 : lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2X1C6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R7: lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55 : lower alkyl; or lower alkenyl); -(CH2)qSR56 (where R56 : lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)r; where R57: H; or lower alkyl); -(CH2)qOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)qNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)rCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)qCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60 : lower alkyl; or lower alkenyl); (CH2)rSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl;or lower alkoxy). - R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); (CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0N(R2Q)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);
-(CH2)OCOOR57 (where R57 : lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CHz)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R9: lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58 : lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)ZNR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R10: lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). - R11: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)raOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R12: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2- ; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)rCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)rCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R13: lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)qSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)rCOO57 (where R57: lower alkyl; or lower alkenyl); -(CH2)qCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl;or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2- ; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)C1C6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
Ru: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)JSlR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)W-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; - (CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H; lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R38 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0PO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R": lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CHz)0SR56 (where R36: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)M-; -(CH2)2O(CH2)z-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)r; where R57: H; or lower alkyl); -(CH2)QOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)0N(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); particularly favoured are NR20COlower alkyl (R20=H; or lower alkyl); -(CH2)0COOR57 (where R57: lower alkyl; or lower alkenyl);
-(CH2)0CONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 : lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). R16: lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)MS -(CH2)2O(CHz)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0N(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR5δR59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). - R17: lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55 : lower alkyl; or lower alkenyl); -(CH2)qSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)rCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)qCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
Among the building blocks Al to A69 the following are preferred: A5 with R2 being H, A8, A A2222,, A A22f5, A38 with R2 being H, A42, A47, and A50. Most preferred are building blocks of type A8':
Figure imgf000042_0001
A81 wherein R20 is H or lower alkyl; and R64 is alkyl; alkenyl; aryl; aryl-lower alkyl; or heteroaryl-lower alkyl; especially those wherein R64 is n-hexyl (A8'-l); n-heptyl (A8'-2); 4- (phenyl)benzyl (A8'-3); diphenylmethyl (A8'-4); 3-amino-propyl (A8'-5); 5-amino-pentyl (A8?-6); methyl (A8'-7); ethyl (A8'-8); isopropyl (A8'-9); isobutyl (A8'-10); n-propyl (A8?- 11); cyclohexyl (A8'-12); cyclohexylmethyl (A8'-13); n-butyl (A8'-14); phenyl (A8'-15); benzyl (A8'-16); (3-indolyl)methyl (A8'-17); 2-(3-indolyl)ethyl (A8'-18); (4-phenyl)phenyl (A8'-19); and n-nonyl (A8'-20).
Building block A70 belongs to the class of open-chain α-substituted α-amino acids, building blocks A71 and A72 to the corresponding β-amino acid analogues and building blocks A73- A104 to the cyclic analogues of A70. Such amino acid derivatives have been shown to constrain small peptides in well defined reverse turn or U-shaped conformations (C. M. Venkatachalam, Biopolymers, 1968, 6, 1425-1434; W. Kabsch, C Sander, Biopolymers 1983, 22, 2577). Such building blocks or templates are ideally suited for the stabilization of β- hairpin conformations in peptide loops (D. Obrecht, M. Altorfer, J. A. Robinson, "Novel Peptide Mimetic Building Blocks and Strategies for Efficient Lead Finding", Adv. Med Chem, 1999, Vol.4, 1-68; P. Balaram, "Non-standard amino acids in peptide design and protein engineering", Curr. Opin. Struct. Biol. 1992, 2, 845-851; M. Crisma, G. Valle, C. Toniolo, S. Prasad, R. B. Rao, P. Balaram, "β-turn conformations in crystal structures of model peptides containing α,α- disubstituted amino acids", Biopolymers 1995, 35, 1-9; V. J. Hruby, F. Al-Obeidi, W. Kazmierski, Biochem. J. 1990, 268, 249-262).
It has been shown that both enantiomers of building blocks -A70-CO- to A104-CO- in combination with a building block -B-CO- of L-configuration can efficiently stabilize and induce β-hairpin conformations (D. Obrecht, M. Altorfer, J. A. Robinson, "Novel Peptide Mimetic Building Blocks and Strategies for Efficient Lead Finding", Adv. Med Chem. 1999, VoU, 1-68; D. Obrecht, C. Spiegler, P. Schδnholzer, K. Mϋller, H. Heimgartner, F. Stierli, HeIv. CMm. Acta 1992, 75, 1666-1696; D. Obrecht, U. Bohdal, J. Daly, C. Lehmann, P. Schδnholzer, K. Mϋller, Tetrahedron 1995, 51, 10883-10900; D. Obrecht, C. Lehmann, C. Ruffieux, P. Schδnholzer, K. Mϋller, HeIv. CMm. Acta 1995, 78, 1567-1587; D. Obrecht, U. Bohdal, C. Broger, D. Bur, C. Lehmann, R. Ruffieux, P. Schonholzer, C. Spiegler, HeIv. CHm. Acta 1995, 78, 563-580; D. Obrecht, H. Karajiannis, C. Lehmann, P. Schonholzer, C. Spiegler, HeIv. CMm. Acta 1995, 78, 703-714).
Thus, for the purposes of the present invention templates (al) can also consist of -A70-CO- to A104-CO- where building block A70 to Al 04 is of either (D)- or (L)-configuration, in combination with a building block -B-CO- of (L)- configuration.
Preferred values for R20 in A70 to A104 are H or lower alkyl with methyl being most preferred. Preferred values for R18, R19 and R21-R29 in building blocks A70 to A104 are the following: - R18: lower alkyl.
R19: lower alkyl; lower alkenyl; -(CH2)POR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)PSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CHa)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)POCONR33R75 (where R33 : H; or lower alkyl; or lower alkenyl; R75 : lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)PN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)PCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)PCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)PSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)OC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). R21: H; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0OCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)M-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R32: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); (CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or (CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R22: lower alkyl; lower alkenyl; -(CH2)OOR55 (where R35: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0OCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)0COOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR37(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF; lower alkyl; lower alkenyl; or lower alkoxy).
R23: H; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2W; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0OCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); particularly favoured are NR20COlower alkyl (R20=H; or lower alkyl); -(CH2)0COOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); - R24: lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); particularly favoured are NR20COlower alkyl (R20=H ; or lower alkyl); -(CH2)0COOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R 58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R25: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)JS[R20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). - R26: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
Alternatively, R25 and R26 taken together can be -(CH2)2-6-; -(CH2)2θ(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl). - R27: H; lower alkyl; lower alkenyl; -(CH2)0OR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-5-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R28 : lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)0OCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2θ(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R29: lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33 : H; or lower alkyl; or lower alkenyl; R75 : lower alkyl; or R33 and R75 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2s where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); particularly favored are NR20COlower-alkyl (R20=H; or lower alkyl); -(CH2)0COOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONR58R39 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)MS -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
For templates (b) to (p), such as (bl) and (cl), the preferred values for the various symbols are the following:
Rs: H; F; Cl; CF3; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34
(where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)MS -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)OOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl;
R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CHz)2O(CHz)2-; -(CHz)2S(CHz)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CHz)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CHz)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2X1C6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). - R20: H; or lower alkyl.
R30: H, methyl.
R3J: H; lower alkyl; lower alkenyl; -(CH2)POR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)POCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CHz)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CHJ)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); (-CHz)0CONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)Z-6-; -(CH2)z0(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)AH4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); most preferred is -CHzCONR58R59 (R58: H; or lower alkyl; R59: lower alkyl; or lower alkenyl). R": H, methyl. - R33: lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mNR34R63 (where R34: lower alkyl; or lower alkenyl; R63: H; or lower alkyl; or R34 and R63 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl) ; (CH2)mOCONR75R82(where R75: lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R75 and R82 taken together form: -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)mNR20CONR78R82 (where R20: H; or lower lower alkyl; R78: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R78 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);
-(CH2)0COOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:
-(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl).
R34: H; or lower alkyl.
R35: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);
-(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:
-(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl).
R36: lower alkyl; lower alkenyl; or aryl-lower alkyl.
R37: H; lower alkyl; lower alkenyl; -(CH2)POR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or
R33 and R34 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)POCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)pNR20CONR33R82 (where R20: H; or lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 : lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CHz)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alky; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). - R38: H; lower alkyl; lower alkenyl; -(CH2)POR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)POCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R78 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)0COOR37 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2),^-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R39: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl).
R10: lower alkyl; lower alkenyl; or aryl-lower alkyl. R": H; lower alkyl; lower alkenyl; -(CH2)POR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)POCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.5-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);
-(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alky; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R42: H; lower alkyl; lower alkenyl; -(CH2)POR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)POCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)PN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). R43: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mSR56 (where R56 : lower alkyl; or lower alkenyl); -(CH2)JMR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)r; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)r; - (CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2^NR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62: lower alkyl; or lower alkenyl); or -(CH2)C1C6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R44: lower alkyl; lower alkenyl; -(CH2)POR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)PSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R3 taken together form: -(CH2)MS -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)POCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R78 taken together form: -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)PN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)PCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)PCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R5S and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or -(CH2)OC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). R45: H; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)SOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)r; where R57: H; or lower alkyl); or -(CH2)AH4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R46: H; lower alkyl; lower alkenyl; -(CH2)SOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)SSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)SNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)SOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)SNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)SN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or -(CH2)AH4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). R47: H; or OR55 (where R55: lower alkyl; or lower alkenyl). R48: H; or lower alkyl. R49: H;lower alkyl; -(CH2)0COOR57 (where R57 : lower alkyl; or lower alkenyl);
-(CH2)OCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or (CH2)AH4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). R50: H; methyl. R51: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)raNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);
-(CH2)PCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)PCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59 : H; lower alkyl; or R58 and R59 taken together form:
-(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or -(CH2)AH4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R52: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)raOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-5-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; R57: H; or lower alkyl);
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);
-(CH2)PCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)PCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CHa)2-6-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or -(CH2)AH4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R53: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower alkenyl); -(CH2)JSTR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R": H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)raN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)pCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)PCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form: -(CH2W; -(CHj)2O(CH2)T; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or -(CH2)rC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
R54: lower alkyl; lower alkenyl; or aryl-lower alkyl.
Among the building blocks A70 to Al 04 the following are preferred: A74 with R22 being H, A75, A76, A77 with R22 being H, A78 and A79.
The building block -B-CO- within templates (al) and (a2) designates an L-amino acid residue. Preferred values for B are: -NR20CH(R71)- and enantiomers of groups A5 with R2 being H, A8, A22, A25, A38 with R2 being H, A42, A47, and A50. Most preferred are
Ala L-Alanine
Arg L-Arginine
Asn L-Asparagine
Cys L-Cysteine GIn L-Glutamine
GIy Glycine
His L-Histidine
He L-Isoleucine Leu L-Leucine
Lys L-Lysine
Met L-Methionine
Phe L-Phenylalanine
Pro L-Proline
Pro(5RPhe) (2S,5R)-5-phenylpyrrrolidine-2-carbocyclic acid
Ser L-Serine
Thr L-Threonine
Trp L-Tryptophan
Tyr L-Tyrosine
VaI L-Valine
Cit L-Citrulline
Orn L-Ornithine tBuA L-t-Butylalanine
Sar Sarcosine t-BuG L-tert.-Butylglycine
4AmPhe L-para-Aminophenylalanine
3AmPhe L-meta-Aminophenylalanine
2AmPhe L-ortho-Aminophenylalanine
Phe(mC(NH2)=NH) L-meta-Amidinophenylalanine
Phe(pC(NH2)=NH) L-para-Amidinophenylalanine
Phe(mNHC (NH2)=NH) L-meta-Guanidinophenylalanine Phe(pNHC (NH2)=NH) L-para-Guanidinophenylalanine
Phg L-Phenylglycine
Cha L-Cyclohexylalanine
C4al L-3-Cyclobutylalanine
C5al L-3-Cyclopentylalanine
NIe L-Norleucine
2-Nal L-2-Naphthylalanine
1-Nal L-I -Naphthylalanine
4C1-Phe L-4-Chlorophenylalanine
3C1-Phe L-3-Chlorophenylalanine
2C1-Phe L-2-Chlorophenylalanine 3,4C12-Phe L-3 ,4-Dichlorophenylalanine
4F-Phe L-4-Fluorophenylalanine
3F-Phe L-3-Fluorophenylalanine
2F-Phe L-2-Fluorophenylalanine
Tic L-1 ,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid
Thi L-β-2-Thienylalanine
Tza L-2-Thiazolylalanine
Mso L-Methionine sulfoxide
AcLys L-N-Acetyllysine
Dpr L-2,3-Diaminopropionic acid
A2Bu L-2,4-Diaminobutyric acid
Dbu (S)-2,3-Diaminobutyric acid
Abu γ-Aminobutyric acid (GABA)
Aha ε-Aminohexanoic acid
Aib α-Aminoisobutyric acid
Y(BzI) L-O-Benzyltyrosine
Bip L-Biphenylalanine
S(BzI) L-O-Benzylserine
T(BzI) L-O-Benzylthreonine hCha L-Homo-cyclohexylalanine hCys L-Homo-cysteine hSer L-Homo-serine hArg L-Homo-arginine hPhe L-Homo-phenylalanine
Bpa L-4-Benzoylphenylalanine
Pip L-Pipecolic acid
OctG L-Octylglycine
MePhe L-N-Methylphenylalanine
MeNIe L-N-Methylnorleucine
MeAIa L-N-Methylalanine
MeIIe L-N-Methylisoleucine
MeVaI L-N-Methvaline MeLeu L-N-Methylleucine
In addition, the most preferred values for B also include groups of type A8" of (L)- configuration:
Figure imgf000059_0001
A8" wherein R20 is H or lower alkyl and R64 is alkyl; alkenyl; -[(CH2)U-X]1-CH3 (where X is -O-; -NR20-, or -S-; u = 1-3, and t = 1-6), aryl; aryl-lower alkyl; or heteroaryl-lower alkyl; especially those wherein R64 is n-hexyl (A8"-21); n-heptyl (A8"-22); 4-
(phenyl)benzyl (A8"-23); diphenylmethyl (A8"-24); 3-amino-propyl (A8"-25); 5- amino-pentyl (A8"-26); methyl (A8"-27); ethyl (A8"-28); isopropyl (A8"-29); isobutyl (A8"-30); n-propyl (A8"-31); cyclohexyl (A8"-32); cyclohexylmethyl (A8"-33); n- butyl (A8"-34); phenyl (A8"-35); benzyl (A8"-36); (3-indolyl)methyl (A8"-37); 2-(3- indolyl)ethyl (A8"-38); (4-phenyl)phenyl (A8"-39); n-nonyl (A8"-40); CH3-OCH2CH2-
OCH2- (A8"-41) and CH3-(OCH2CH2)2-OCH2- (A8"-42).
The peptidic chain Z of the β-hairpin mimetics described herein is generally defined in terms of amino acid residues belonging to one of the following groups: - Group C -NR20CH(R72)CO-; "hydrophobic: small to medium-sized"
Group D -NR20CH(R73)CO-; "hydrophobic: large aromatic or heteroaromatic"
Group E -NR20CH(R74)CO-; "polar-cationic" and "urea-derived" Group F -NR20CH(R84)CO-; "polar-non-charged or anionic" - Group H -NR20-CH(CO-)-(CH2)4.7-CH(CO-)-NR20-;
-NR20-CH(CO-HCH2)pSS(CH-)p-CH(CO-)-NR20-;
-NR20-CH(CO-)-(-(CH2)pNR20CO(CH2)p-CH(CO-)-NR20-; and
-NR20-CH(CO-)-(-(CH2)pNR20CONR20(CH2)p-CH(CO-)-NR20-;
"interstrand linkage" Furthermore, the amino acid residues in chain Z can also be of formula -A-CO- or of formula -B-CO- wherein A and B are as defined above. Finally, GIy can also be an amino acid residue in chain Z, and Pro can be an amino acid residue in chain Z, too, with the exception of positions where interstrand linkages (H) are possible.
Group C comprises amino acid residues with small to medium-sized hydrophobic side chain groups according to the general definition for substituent R72. A hydrophobic residue refers to an amino acid side chain that is uncharged at physiological pH and that is repelled by aqueous solution. Furthermore these side chains generally do not contain hydrogen bond donor groups, such as (but not limited to) primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, phosphonates, phosphates, ureas or thioureas. However, they may contain hydrogen bond acceptor groups such as ethers, thioethers, esters, tertiary amides, alkyl- or aryl phosphonates and phosphates or tertiary amines. Genetically encoded small-to-medium-sized amino acids include alanine, isoleucine, leucine, methionine and valine.
Group D comprises amino acid residues with aromatic and heteroaromatic side chain groups according to the general definition for substituent R73. An aromatic amino acid residue refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated π-electron system (aromatic group). In addition they may contain hydrogen bond donor groups such as (but not limited to) primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, phosphonates, phosphates, ureas or thioureas, and hydrogen bond acceptor groups such as (but not limited to) ethers, thioethers, esters, tetriary amides, alkyl- or aryl phosphonates -and phosphates or tertiary amines. Genetically encoded aromatic amino acids include phenylalanine and tyrosine.
A heteroaromatic amino acid residue refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated π-system incorporating at least one heteroatom such as (but not limited to) O, S and N according to the general definition for substituent R77. In addition such residues may contain hydrogen bond donor groups such as (but not limited to) primary and secondary amides, primary and secondary amines and the corresponding protonated salts thereof, thiols, alcohols, phosphonates, phosphates, ureas or thioureas, and hydrogen bond acceptor groups such as (but not limited to) ethers, thioethers, esters, tetriary amides, alkyl- or aryl phosphonates -and phosphates or tertiary amines. Genetically encoded heteroaromatic amino acids include tryptophan and histidine.
Group E comprises amino acids containing side chains with polar-cationic, acylamino- and urea-derived residues according to the general definition for substituen R74. Polar-cationic refers to a basic side chain which is protonated at physiological pH. Genetically encoded polar-cationic amino acids include arginine, lysine and histidine. Citrulline is an example for an urea derived amino acid residue.
Group F comprises amino acids containing side chains with polar-non-charged or anionic residues according to the general definition for substituent R84. A polar-non-charged or anionic residue refers to a hydrophilic side chain that is uncharged and, respectively anionic at physiological pH (carboxylic acids being included), but that is not repelled by aqueous solutions. Such side chains typically contain hydrogen bond donor groups such as (but not limited to) primary and secondary amides, carboxyclic acids and esters, primary and secondary amines, thiols, alcohols, phosphonates, phosphates, ureas or thioureas. These groups can form hydrogen bond networks with water molecules. In addition they may also contain hydrogen bond acceptor groups such as (but not limited to) ethers, thioethers, esters, tetriary amides, carboxylic acids and carboxylates, alkyl- or aryl phosphonates -and phosphates or tertiary amines. Genetically encoded polar-non-charged amino acids include asparagine, cysteine, glutamine, serine and threonine, but also aspartic acid and glutamic acid.
Group H comprises side chains of preferably (L)-amino acids at opposite positions of the β- strand region that can form an interstrand linkage. The most widely known linkage is the disulfide bridge formed by cysteines and homo-cysteines positioned at opposite positions of the β-strand. Various methods are known to form disulfide linkages including those described by: J. P. Tam et al. Synthesis 1979, 955-957; Stewart et al. , Solid Phase Peptide Synthesis, 2d Ed., Pierce Chemical Company, III., 1984; Ahmed et al. J. Biol. Chem. 1975, 250, 8477- 8482 ; and Pennington et al., Peptides, pages 164-166, Giralt and Andreu, Eds., ESCOM Leiden, The Netherlands, 1990. Most advantageously, for the scope of the present invention, disulfide linkages can be prepared using acetamidomethyl (Acm)- protective groups for cysteine. A well established interstrand linkage consists in linking ornithines and lysines, respectively, with glutamic and aspartic acid residues located at opposite β-strand positions by means of an amide bond formation. Preferred protective groups for the side chain amino- groups of ornithine and lysine are allyloxycarbonyl (Alloc) and allylesters for aspartic and glutamic acid. Finally, interstrand linkages can also be established by linking the amino groups of lysine and ornithine located at opposite β-strand positions with reagents such as N,N-carbonylimidazole to form cyclic ureas.
As mentioned earlier, positions for interstrand linkages are positions P4 and P 9 and/or P2 and Pl 1 taken together. Such interstrand linkages are known to stabilize the β-hairpin conformations and thus constitute an important structural element for the design of β-hairpin mimetics.
Most preferred amino acid residues in chain Z are those derived from natural α-amino acids. Hereinafter follows a list of amino acids which, or the residues of which, are suitable for the purposes of the present invention, the abbreviations corresponding to generally adopted usual practice:
three letter code one letter code
Ala L-Alanine A
Arg L-Arginine R
Asn L-Asparagine N
Asp L- Aspartic acid D
Cys L-Cysteine C
GIu L-Glutamic acid E
GIn L-Glutamine Q
GIy Glycine G
His L-Histidine H lie L-Isoleucine I Leu L-Leucme L
Lys L-Lysine K
Met L-Methionine M
Phe L-Phenylalanine F
Pro L-Proline P
DPro D-Proline Dp
Ser L-Serine S
Thr L-Threonine T
Trp L-Tryptophan W
Tyr L-Tyrosine Y
VaI L-Valine V
Other α-amino acids which, or the residues of which, are suitable for the purposes of the present invention include: C Ciitt L-Citrulline
Om L-Ornithine tBuA L-t-Butylalanine
Sar Sarcosine
Pen L-Penicillamine t-BuG L-tert.-Butylglycine
4AmPhe L-para-Aminophenylalanine
3AmPhe L-meta-Aminophenylalanine
2AmPhe L-ortho-Aminophenylalanine
Phe(mC(NH2)=NH) L-meta-Amidinophenylalanine P Phhee((ppCC((NNHH22))===NNHH)) L-para-Amidinophenylalanine
Phe(mNHC (NH2)=NH) L-meta-Guanidinophenylalanine Phe(pNHC (NH2)=NH) L-para-Guanidinophenylalanine Phg L-Phenylglycine
Cha L-Cyclohexylalanine C4al L-3-Cyclobutylalanine
C5al L-3-Cyclopentylalanine
NIe L-Norleucine 2-Nal L-2-Naphthylalanine
1-Nal L-I -Naphthylalanine
4C1-Phe L-4-Chlorophenylalanine
3C1-Phe L-3 -Chlorophenylalanine
2C1-Phe L-2-Chlorophenylalanine
3,4C12-Phe L-3 ,4-Dichlorophenylalanine
4F-Phe L-4-Fluorophenylalanine
3F-Phe L-3-Fluorophenylalanine
2F-Phe L-2-Fluorophenylalanine
Tic 1 ,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid
Thi L-β-2-Thienylalanine
Tza L-2-Thiazolylalanine
Mso L-Methionine sulfoxide
AcLys N-Acetyllysine
Dpr 2,3-Diaminopropionic acid
A2Bu 2,4-Diaminobutyric acid
Dbu (S)-2,3-Diaminobutyric acid
Abu γ-Aminobutyric acid (GABA)
Aha ε-Aminohexanoic acid
Aib α-Aminoisobutyric acid
Y(BzI) L-O-Benzyltyrosine
Bip L-(4-phenyl)phenylalanine
S(BzI) L-O-Benzylserine
T(BzI) L-O-Benzylthreonine hCha L-Homo-cyclohexylalanine hCys L-Homo-cysteine hSer L-Homo-serine hArg L-Homo-arginine hPhe L-Homo-phenylalanine
Bpa L-4-Benzoylphenylalanine
4-AmPyrrl (2S,4S)-4-Amino-pyrrolidine-L-carboxylic acid
4-AmPyrr2 (2S,4R)-4-Amino-pyrrolidine-L-carboxylic acid 4-PhePyrrl (2S,5R)-4-Phenyl-pyrrolidine-L-carboxylic acid
4-PhePyrr2 (2S,5S)-4-Phenyl-pyrrolidine-L-carboxylic acid
5-PhePyrrl (2S,5R)-5-Phenyl-pyrrolidine-L-carboxylic acid
5-PhePyrr2 (2S,5S)-5-Phenyl-pyrrolidine-L-carboxylic acid
Pro(4-OH)1 (4S)-L-Hydroxyproline
Pro(4-OH)2 (4R)-L-Hydroxyproline
Pip L-Pipecolic acid
DPip D-Pipecolic acid
OctG L-Octylglycine
NGIy N-Methylglycine
MePhe L-N-Methylphenylalanine
MeNIe L-N-Methylnorleucine
MeAIa L-N-Methylalanine
MeIIe L-N-Methylisoleucine
MeVaI L-N-Methylvaline
MeLeu L-N-Methylleucine
DimK L-(N' ,N'Dimethyl)-lysine
Lpzp L-Piperazinic acid
Dpzp D-Piperazinic acid
Isorn L-(N\N -diisobutyl)-ornithine
PipAla L-2-(4' -piperidinyl)-alanine
PirrAla L-2-(3 -pyrrolidinyl)-alanine
Ampc 4-Amino-piperidine-4-carboxylic acid
NMeR L-N-Methylarginine
NMeK L-N-Methyllysine
NMePhe L-N-Methylphenylalanine
IPegK L-2-Amino-6-{2-[2-(2-methoxy- ethoxy)ethoxy]acetylamino} -hexanoic acid
SPegK L-2-Amino-6-[2-(2methoxy-ethoxy)-acetylamino]- hexanoic acid
Dab L-2,4-Diamino-butyric acid
IPegDab L-2-Amino-4{2-[2-(2-methoxy-ethoxy)-ethoxy]- acetylaraino} -butyric acid
SPegDab L-2-Amino-4[2-(2-methoxy-ethoxy)-acetylamino] butyric acid
4-PyrAla L-2-(4Tyridyl)-alanine
OrnPyr L-2-Amino-5-[(2λcarbonylpyrazine)]amino-pentanoic acid
BnG N-Benzylglycine
AlIoT Allo-Threonin
Aoc 2-(S)-Aminooctanoic acid
Cpa L-Cyclo-Propylalanine
arly prefem ;d residues for group C are:
Ala L- Alanine
He L-Isoleucine
Leu L-Leucine
Met L-Methionine
VaI L-Valine tBuA L-t-Butylalanine t-BuG L-tert.-Butylglycine
Cha L-Cyclohexylalanine
C4al L-3-Cyclobutylalanine
C5al L-3 -Cyclopentylalanine
NIe L-Norleucine hCha L-Homo-cyclohexylalanine
OctG L-Octylglycine
MePhe L-N-Methylphenylalanine
MeNIe L-N-Methylnorleucine
MeAIa L-N-Methylalanine
MeIIe L-N-Methylisoleucine
MeVaI L-N-Methylvaline
MeLeu L-N-Methylleucine
Aoc 2-(S)-Aminooctanoic acid Cpa L-Cyclo-Propylalanine
arly preferrei i residues for group D are:
His L-Histidine
Phe L-Phenylalanine
Tip L-Tryptophan
Tyr L-Tyrosine
Phg L-Phenylglycine
2-Nal L-2-Naphthylalanine
1-Nal L- 1 -Naphthylalanine
4C1-Phe L-4-Chlorophenylalanine
3C1-Phe L-3-Chlorophenylalanine
2C1-Phe L-2-Chlorophenylalanine
3,4C12-Phe L-3,4-Dichlorophenylalanine
4F-Phe L-4-Fluorophenylalanine
3F-Phe L-3 -Fluorophenylalanine
2F-Phe L-2-Fluorophenylalanine
Thi L-β-2-Thienylalanine
Tza L-2-Thiazolylalanine
Y(BzI) L-O-Benzyltyrosine
Bip L-Biphenylalanine
S(BzI) L-O-Benzylserine
T(BzI) L-O-B enzylthreonine hPhe L-Homo-phenylalanine
Bpa L-4-Benzoylphenylalanine
PirrAla L-2-(3 ' -pyrrolidinyl)-alanine
NMePhe L-N-Methylphenylalanine
4-PyrAla L-2-(4Tyridyl)-alanine
Particularly preferred residues for group E are Arg L-Arginine Lys L-Lysine
Orn L-Ornithine
Dpr L-2,3-Diaminopropionic acid
A2Bu L-2,4-Diaminobutyric acid
Dbu (S)-2,3-Diaminobutyric acid
Phe(pNH2) L-para-Aminophenylalanine
Phe(mNH2) L-meta-Aminophenylalanine
Phe(oNH2) L-ortho-Aminophenylalanine hArg L-Homo-arginine
Phe(mC(NH2)=NH) L-meta-Amidinophenylalanine
Phe(pC(NH2)=NH) L-para-Amidinophenylalanine Phe(mNHC (NH2)=NH) L-meta-Guanidinophenylalanine Phe(pNHC (NH2)=NH) L-para-Guanidinophenylalanine DimK L-(N\N'Dimethyl)-lysine
Isorn L-(N' ,Nλ -diisobutyl)-ornithine
NMeR L-N-Methylarginine
NMeK L-N-Methyllysine
IPegK L-2-Amino-6-{2-[2-(2-rnethoxy- ethoxy)ethoxy] acetylamino } -hexanoic acid SPegK L-2-Amino-6-[2-(2methoxy-ethoxy)-acetylamino]-hexanoic acid
Dab L-2,4-Diamino-butyric acid IPegDab L-2-Amino-4{2-[2-(2-methoxy-ethoxy)-ethoxy]- acetylamino} -butyric acid
SPegDab L-2-Amino-4[2-(2-methoxy-ethoxy)-acetylamino] butyric acid
OrnPyr L-2-Amino-5-[(2"carbonylpyrazine)]aminopentanoic PipAla L-2-(4" -piperidinyl)-alanine
Particularly preferred residues for group F are Asn L-Asparagine
Asp L-Aspartic acid Cys L-Cysteine
GIn L-Glutamine
GIu L-Glutamic acid
Ser L-Serine
Thr L-Threonine
AlloThr AlIo Threonine
Cit L-Citrulline
Pen L-Penicillamine
AcLys L-Nε-Acetyllysine hCys L-Homo-cysteine hSer L-Homo-serine
Generally, the peptidic chain Z within the β-hairpin mimetics of the invention comprises 12 amino acid residues. The positions Pl to P12 of each amino acid residue in the chain Z are unequivocally defined as follows: Pl represents the first amino acid in the chain Z that is coupled with its N-terminus to the C-terminus of the templates (b)-(p), or of group -B-CO- in template (al), or of group -A-CO- in template (a2); and P12 represents the last amino acid in the chain Z that is coupled with its C-terminus to the N-terminus of the templates (b)-(p), or of group -A-CO- in template (al), or of group -B-CO- in template (a2). Each of the positions Pl to P12 will preferably contain an amino acid residue belonging to one of the above types C, D, E, F, H, or of formula -A-CO- or of formula -B-CO-, or being GIy, or Pro as follows:
The α-amino acid residues in positions 1 to 12 of the chain Z are preferably: - Pl : of type C or of type D or of type E or of type F;
P2: of type D;
P3 : of type C, or the residue is GIy or Pro;
P4: of type C or of type E or of type F, or the residue is GIy or Pro;
P5 : of type E, or the residue is GIy or Pro; - P6: of type E, of type C or of type F or of formula -A-CO-, or the residue is GIy or Pro;
P7: of type C or of type E or of type F or of formula -B-CO-; P8 : of type D, or of type F;
P9: oftype E or oftype F or oftype C;
PlO: of type E;
PI l: of type F or of type C, or the residue is GIy or Pro; and - P12: of type C or of type D or of type E, or of type F; or
P4 and P9 and/or P2 and Pl 1 , taken together, can form a group of type H; and at P6, PlO and PI l also D-isomers being possible; or, alternatively, within the less preferred embodiment mentioned earlier herein above: - Pl : of type C or of type D or of type E, or of type F;
P2: of type F or of type C, or the residue is GIy or Pro;
P3: of type E;
P4: of type E or of type F or of type C;
P5 : of type D, or of Type F; - P6: of type C or of type E or of type F or of formula -B-CO-;
P7 : of type C or of type F or of formula -A-CO-, or the residue is GIy or Pro;
P8: of type E, or the residue is GIy or Pro;
P9: of type C or of type E or of type F, or the residue is GIy or Pro; - PlO: of type C, or the residue is GIy or Pro;
PI l : oftype D; and
P12: of type C or of type D or of type E or of type F; or
P4 and P9 and/or P2 and PI l , taken together, can form a group of type H; and at P2, P3, and P7 also D-isomers being possible.
If n is 12, the α-amino acid residues in positions 1 to 12 are most preferably: Pl : Ala, Cit, Thr, Thr, Asp, GIu;
P2: Trp, Tyr; - P3: Ile, Val, Nle, Chg, Cha;
P4: Dab, Lys, GIn;
P5: Lys, Dab, Orn; P6: Dab, DDab; Lys;
P7: His, Lys, GIn, Dab;
P8: Tyr, Trp, Ser;
P9 Dab, Lys; - PlO: Dab, Lys;
Pl 1 : Ala, Abu, Thr, GIy, Pro, Hse, lie, Nva, 0AIa, 0VaI, Aib, NIe, Chg,
Cha, GIn, Asp, GIu, Cpa, t-BuG, Leu, VaI, Asn;
P12: Dab, Lys, GIn, Ser; at P6, PlO and Pl 1 are D-Isomers being possible.
Particularly preferred β-hairpin peptidomimetics of the invention include those described in Examples 1, 2, 6, 16, 19, 22, 24, 25, 28, 29, 32, 35, 40, 41, 49, 50.
The processes of the invention can advantageously be carried out as parallel array syntheses to yield libraries of template-fixed β-hairpin peptidomimetics of the above general formula I. Such parallel syntheses allow one to obtain arrays of numerous (normally 24 to 192, typically 96) compounds of general formula I in high yields and defined purities, minimizing the formation of dimeric and polymeric by-products. The proper choice of the functionalized solid-support (i.e. solid support plus linker molecule), templates and site of cyclization play thereby key roles.
The functionalized solid support is conveniently derived from polystyrene crosslinked with, preferably 1-5%, divinylbenzene; polystyrene coated with polyethyleneglycol spacers (TentagelR); and polyacrylamide resins (see also Obrecht, D.; Villalgordo, J. -M, "Solid- Supported Combinatorial and Parallel Synthesis of Small-Molecular- Weight Compound Libraries", Tetrahedron Organic Chemistry Series, Vol. 17, Pergamon, Elsevier Science, 1998).
The solid support is functionalized by means of a linker, i.e. a bifunctional spacer molecule which contains on one end an anchoring group for attachment to the solid support and on the other end a selectively cleavable functional group used for the subsequent chemical transformations and cleavage procedures. For the purposes of the present invention two types of linkers are used: Type 1 linkers are designed to release the amide group under acidic conditions (Rink H, Tetrahedron Lett. 1987, 28, 3783-3790). Linkers of this kind form amides of the carboxyl group of the amino acids; examples of resins functionalized by such linker structures include 4-[(((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) aminomethyl] PS resin, 4-[(((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) aminomethyl] -4- methylbenzydrylamine PS resin (Rink amide MBHA PS Resin), and 4-[(((2,4- dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) aminomethyl] benzhydrylamine PS-resin (Rink amide BHA PS resin). Preferably, the support is derived from polystyrene crosslinked with, most preferably 1-5%, divinylbenzene and functionalized by means of the 4- (((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) linker.
Type 2 linkers are designed to eventually release the carboxyl group under acidic conditions. Linkers of this kind form acid-labile esters with the carboxyl group of the amino acids, usually acid-labile benzyl, benzhydryl and trityl esters; examples of such linker structures include 2-methoxy-4-hydroxymethylphenoxy (SasrinR linker), 4-(2,4-dimethoxyphenyl- hydroxymethyl)-phenoxy (Rink linker), 4-(4-hydroxymethyl-3-methoxyphenoxy)butyric acid (HMPB linker), trityl and 2-chlorotrityl. Preferably, the support is derived from polystyrene crosslinked with, most preferably 1-5%, divinylbenzene and functionalized by means of the 2-chlorotrityl linker.
When carried out as parallel array syntheses the processes of the invention can be advantageously carried out as described herein below but it will be immediately apparent to those skilled in the art how these procedures will have to be modified in case it is desired to synthesize one single compound of the above formula I.
A number of reaction vessels (normally 24 to 192, typically 96), equal to the total number of compounds to be synthesized by the parallel method, are loaded with 25 to 1000 mg, preferably 100 mg, of the appropriate functionalized solid support, preferably 1 to 3% cross- linked polystyrene or Tentagel resin. The solvent to be used must be capable of swelling the resin and includes, but is not limited to, dichloromethane (DCM), dimethylformamide (DMF), N-methylpyrrolidone (NMP), dioxane, toluene, tetrahydrofuran (THF), ethanol (EtOH), trifluoroethanol (TFE), isopropylalcohol and the like. Solvent mixtures containing as at least one component a polar solvent (e. g. 20% TFE/DCM, 35% THF/NMP) are beneficial for ensuring high reactivity and solvation of the resin-bound peptide chains ( Fields, G. B., Fields, C. G., J. Am. Chem. Soc. 1991, 113, 4202-4207).
With the development of various linkers that release the C-terminal carboxylic acid group under mild acidic conditions, not affecting acid-labile groups protecting functional groups in the side chain(s), considerable progresses have been made in the synthesis of protected peptide fragments. The 2-methoxy-4-hydroxybenzylalcohol-derived linker (SasrinR linker, Mergler et al., Tetrahedron Lett. 1988, 29 4005-4008) is cleavable with diluted trifluoroacetic acid (0.5-1% TFA in DCM) and is stable to Fmoc deprotection conditions during the peptide synthesis, Boc/tBu-based additional protecting groups being compatible with this protection scheme. Other linkers which are suitable for the process of the invention include the super acid labile 4-(2,4-dimethoxyphenyl-hydroxymethyl)-phenoxy linker (Rink linker, Rink, H. Tetrahedron Lett. 1987, 28, 3787-3790), where the removal of the peptide requires 10% acetic acid in DCM or 0.2% trifluoroacetic acid in DCM; the 4-(4-hydroxymethyl-3- methoxyphenoxy)butyric acid-derived linker (HMPB-linker, Flδrsheimer & Riniker, Peptides 1991,1990 131) which is also cleaved with 1%TFA/DCM in order to yield a peptide fragment containing all acid labile side- chain protective groups; and, in particular, the 2- chlorotritylchloride linker (Barlos et al., Tetrahedron Lett. 1989, 30, 3943-3946), which allows the peptide detachment using a mixture of glacial acetic acid/trifluoroethanol/DCM (1:2:7) for 30 min.
Suitable protecting groups for amino acids and, respectively, for their residues are, for example,
- for the amino group (as is present e. g. also in the side-chain of lysine)
Cbz benzyloxycarbonyl
Boc tert-butyloxycarbonyl
Fmoc 9-fluorenylmethoxycarbonyl Alloc allyloxycarbonyl
Teoc trimethylsilylethoxycarbonyl
Tec trichloroethoxycarbonyl
Nps o-nitrophenylsulfonyl;
Trt triphenymethyl or trityl
for the carboxyl group (as is present e. g. also in the side-chain of aspartic and glutamic acid) by conversion into esters with the alcohol components
tBu tert. -butyl
Bn benzyl
Me methyl
Ph phenyl
Pac Phenacyl
Allyl
Tse trimethylsilylethyl
Tee trichloroethyl;
for the guanidino group (as is present e. g. in the side-chain of arginine)
Pmc 2,2,5, 7,8-pentamethylchroman-6-sulfonyl
Ts tosyl (i. e. p-toluenesulfonyl)
Cbz benzyloxycarbonyl
Pbf pentamethyldihydrobenzofuran-5-sulfonyl
for the hydroxy group (as is present e. g. in the side-chain of threonine and serine)
tBu tert-butyl Bn benzyl
Trt trityl
and for the mercapto group (as is present e. g. in the side-chain of cysteine) Acm acetamidomethyl tBu tert. -butyl
Bn benzyl
Trt trityl
Mtr 4-methoxytrityl.
The 9-fluorenylmethoxycarbonyl- (Fmoc)-protected amino acid derivatives are preferably used as the building blocks for the construction of the template-fixed β-hairpin loop mimetics of formula I. For the deprotection, i. e. cleaving off of the Fmoc group, 20% piperidine in DMF or 2% DBU/2% piperidine in DMF can be used.
The quantity of the reactant, i. e. of the amino acid derivative, is usually 1 to 20 equivalents based on the milliequivalents per gram (meq/g) loading of the functionalized solid support (typically 0.1 to 2.85 meq/g for polystyrene resins) originally weighed into the reaction tube. Additional equivalents of reactants can be used, if required, to drive the reaction to completion in a reasonable time. The reaction tubes, in combination with the holder block and the manifold, are reinserted into the reservoir block and the apparatus is fastened together. Gas flow through the manifold is initiated to provide a controlled environment, for example, nitrogen, argon, air and the like. The gas flow may also be heated or chilled prior to flow through the manifold. Heating or cooling of the reaction wells is achieved by heating the reaction block or cooling externally with isopropanol/dry ice and the like to bring about the desired synthetic reactions. Agitation is achieved by shaking or magnetic stirring (within the reaction tube). The preferred workstations (without, however, being limited thereto) are Labsource's Combi-chem station and MultiSyn Tech's-Syro synthesizer.
Amide bond formation requires the activation of the α-carboxyl group for the acylation step. When this activation is being carried out by means of the commonly used carbodiimides such as dicyclohexylcarbodiimide (DCC, Sheehan & Hess, J. Am. Chem. Soc. 1955, 77, 1067- 1068) or diisopropylcarbodiimide (DIC, Sarantakis et al Biochem. Biophys. Res. Commun.1976, 73, 336-342), the resulting dicyclohexylurea and diisopropylurea is insoluble and, respectively, soluble in the solvents generally used. In a variation of the carbodiimide method 1-hydroxybenzotriazole (HOBt, Konig & Geiger, Chem. Ber 1970, 103, 788-798) is included as an additive to the coupling mixture. HOBt prevents dehydration, suppresses racemization of the activated amino acids and acts as a catalyst to improve the sluggish coupling reactions. Certain phosphonium reagents have been used as direct coupling reagents, such as benzotriazol-l-yl-oxy-tris-(dimethylamino)-phosρhonium hexafluorophosphate (BOP, Castro et al., Tetrahedron Lett 1975, 14, 1219-1222; Synthesis, 1976, 751-752), or benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexaflurophoshate (Py-BOP, Coste et al., Tetrahedron Lett. 1990, 31, 205-208), or 2-(lH-benzotriazol-l-yl- )l,l,3,3-tetramethyluronium terafluoroborate (TBTU), or hexafluorophosphate (HBTU, Knorr et al., Tetrahedron Lett. 1989, 30, 1927-1930), or 1-benzotriazol-l- [bis(dimethylamino)methylene]-5-chloro-hexafluorophosphate- 1 , 3 -oxide (HCTU); these phosphonium reagents are also suitable for in situ formation of HOBt esters with the protected amino acid derivatives. More recently diphenoxyphosphoryl azide (DPPA) or O-(7- aza-benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TATU) or O-(7-aza- benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU)/7-aza-l- hydroxy benzotriazole (HOAt, Carpino et al., Tetrahedron Lett. 1994, 35, 2279-2281) have also been used as coupling reagents.
Due to the fact that near-quantitative coupling reactions are essential, it is desirable to have experimental evidence for completion of the reactions. The ninhydrin test (Kaiser et al., Anal. Biochemistry 1970, 34, 595), where a positive colorimetric response to an aliquot of resin- bound peptide indicates qualitatively the presence of the primary amine, can easily and quickly be performed after each coupling step. Fmoc chemistry allows the spectrophotometric detection of the Fmoc chromophore when it is released with the base (Meienhofer et al., Int. J. Peptide Protein Res. 1979, 13, 35-42).
The resin-bound intermediate within each reaction tube is washed free of excess of retained reagents, of solvents, and of by-products by repetitive exposure to pure solvents) by one of the two following methods:
1) The reaction wells are filled with solvent (preferably 5 ml), the reaction tubes, in combination with the holder block and manifold, are immersed and agitated for 5 to 300 minutes, preferably 15 minutes, and drained by gravity followed by gas pressure applied through the manifold inlet (while closing the outlet) to expel the solvent; 2) The manifold is removed from the holder block, aliquots of solvent
(preferably 5 ml) are dispensed through the top of the reaction tubes and drained by gravity through a filter into a receiving vessel such as a test tube or vial.
Both of the above washing procedures are repeated up to about 50 times (preferably about 10 times), monitoring the efficiency of reagent, solvent and by-product removal by methods such as TLC, GC, or inspection of the washings.
The above described procedure of reacting the resin-bound compound with reagents within the reaction wells followed by removal of excess reagents, by-products and solvents is repeated with each successive transformation until the final resin-bound fully protected linear peptide has been obtained.
Before this fully protected linear peptide is detached from the solid support, it is possible, if desired, to selectively deprotect one or several protected functional group(s) present in the molecule and to appropriately substitute the reactive group(s) thus liberated. To this effect, the functional group(s) in question must initially be protected by a protecting group which can be selectively removed without affecting the remaining protecting groups present. Alloc (allyloxycarbonyl) is an example for such an amino protecting group which can be selectively removed, e.g. by means of Pd° and phenylsilane in CH2CI2, without affecting the remaining protecting groups, such as Fmoc, present in the molecule. The reactive group thus liberated can then be treated with an agent suitable for introducing the desired substituent. Thus, for example, an amino group can be acylated by means of an acylating agent corresponding to the acyl substituent to be introduced. For the formation of pegylated amino acids such as
IPegK, or SPegK, preferably a solution of 5 equivalents of HATU (N-[(dimethylamino)-lH- l,2,3-triazolo[4,5-δ]pyridin-l-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide) in dry DMF and a solution of 10 equivalents of DIPEA (Diisopropyl ethaylamine) in dry DMF and 5 equivalents of 2-[2-(2-methoxyethoxy)ethoxy] acetic acid (IPeg) and, respectively, 2-(2-methoxyethoxy)acetic acid (sPeg), is applied to the liberated amino group of the appropiate amino acid side chain for 3 h. The procedure is thereafter repeated for another 3h with a fresh solution of reagents after filtering and washing the resin. Before this fully protected linear peptide is detached from the solid support , it is also possible, if desired, to form (an) interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β-strand region.
Interstrand linkages and their formation have been discussed above, in connection with the explanations made regarding groups of the type H which can, for example, be disulfide bridges formed by cysteine and homocysteine residues at opposite positions of the β-strand; or lactam bridges formed by glutamic and aspartic acid residues linking ornithine and, respectively, lysine residues, or by glutamic acid residues linking 2,4-diaminobutyric acid residues located at opposite β-strand positions by amide bond formation. The formation of such interstrand linkages can be effected by methods well known in the art.
For the formation of disulfide bridges preferably a solution of 10 equivalents of iodine solution is applied in DMF or in a mixture OfCH2Cl2 /MeOH for 1.5 h which is repeated for another 3h with a fresh iodine solution after filtering of the iodine solution, or in a mixture of DMSO and acetic acid solution, buffered with 5% with NaHCOsto pH 5-6 for 4h, or in water after having been adjusted to pH 8 with ammonium hydroxide solution by stirring for 24h or ammonium acetate buffer adjusted to pH 8 in the presence of air, or in a solution of NMP and tri-n- butylphosphine (preferably 50 eq.).
Detachment of the fully protected linear peptide from the solid support is achieved by immersion of the reaction tubes, in combination with the holder block and manifold, in reaction wells containing a solution of the cleavage reagent (preferably 3 to 5 ml). Gas flow, temperature control, agitation and reaction monitoring are implemented as described above and as desired to effect the detachment reaction. The reaction tubes, in combination with the holder block and manifold, are disassembled from the reservoir block and raised above the solution level but below the upper lip of the reaction wells, and gas pressure is applied through the manifold inlet (while closing the outlet) to efficiently expel the final product solution into the reservoir wells. The resin remaining in the reaction tubes is then washed 2 to 5 times as above with 3 to 5 ml of an appropriate solvent to extract (wash out) as much of the detached product as possible. The product solutions thus obtained are combined, taking care to avoid cross-mixing. The individual solutions/extracts are then manipulated as needed to isolate the final compounds. Typical manipulations include, but are not limited to, evaporation, concentration, liquid/liquid extraction, acidification, basification, neutralization or additional reactions in solution.
The solutions containing fully protected linear peptide derivatives which have been cleaved off from the solid support and neutralized with a base, are evaporated. Cyclization is then effected in solution using solvents such as DCM, DMF, dioxane, THF and the like. Various coupling reagents which were mentioned earlier can be used for the cyclization. The duration of the cyclization is about 6-48 hours, preferably about 16 hours. The progress of the reaction is followed, e. g. by RP-HPLC (Reverse Phase High Performance Liquid Chromatography). Then the solvent is removed by evaporation, the fully protected cyclic peptide derivative is dissolved in a solvent which is not miscible with water, such as DCM, and the solution is extracted with water or a mixture of water-miscible solvents, in order to remove any excess of the coupling reagent.
Finally, the fully protected peptide derivative is treated with 95% TFA, 2.5% H2O, 2.5% TIS or another combination of scavengers for effecting the cleavage of protecting groups. The cleavage reaction time is commonly 30 minutes to 12 hours, preferably about 2.5 hours. The volatiles are evaporated to dryness and the crude peptide is dissolved in 20% AcOH in water and extracted with isopropyl ether or other solvents which are suitable therefor. The aqueous layer is collected and evaporated to dryness, and the fully deprotected cyclic peptide derivative of formula I is obtained as end-product. Depending on its purity, this peptide derivative can be used directly for biological assays, or it has to be further purified, for example by preparative HPLC.
Alternatively the detachment, cyclisation and complete deprotection of the fully protected peptide from the solid support can be achieved manually in glass vessels.
As mentioned earlier, it is thereafter possible, if desired, to convert a fully deprotected product of formula I thus obtained into a pharmaceutically acceptable salt or to convert a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt. Any of these operations can be carried out by methods well known in the art.
The template starting materials of formula II used in the processes of the invention, pre- starting materials therefor, and the preparation of these starting and pre-starting materials are described in International Application PCT/EP02/01711, published as WO 02/070547 Al.
The β-hairpin peptidomimetics of the invention can be used in a wide range of applications in order to inhibit the growth of or to kill microorganisms. In particular they can be used to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa.
They can be used for example as disinfectants or as preservatives for materials such as foodstuffs, cosmetics, medicaments and other nutrient-containing materials. The β-hairpin peptidomimetics of the invention can also be used to treat or prevent diseases related to microbial infection in plants and animals.
For use as disinfectants or preservatives the β-hairpin peptidomimetics can be added to the desired material singly, as mixtures of several β-hairpin peptidomimetics or in combination with other antimicrobial agents. The β-hairpin peptidomimetics may be administered per se or may be applied as an appropriate formulation together with carriers, diluents or excipients well known in the art.
When used to treat or prevent infections or diseases related to such infections, particularly infections related to respiratory diseases such as cystic fibrosis, emphysema and asthma; infections related to skin or soft tissue diseases such as surgical wounds, traumatic wounds and burn wounds; infections related to gastrointestinal diseases such as epidemic diarrhea, necrotizing enterocolitis and typhlitis; infections related to eye diseases such as keratitis and endophthalmitis; infections related to ear diseases such as otitis, infections related to CNS diseases such as brain abscess and meningitis; infections related to bone diseases such as osteochondritis and osteomyelitis; infections related to cardiovascular diseases such as endocartitis and pericarditis; or infections related to gastrourinal diseases such as epididymitis, prostatitis and urethritis; the β-hairpin peptidomimetics can be administered singly, as mixtures of several β-hairpin peptidomimetics, in combination with other antimicrobial or antibiotic agents, or anti cancer agents, or antiviral (e. g. anti-HIV) agents, or in combination with other pharmaceutically active agents. The β-hairpin peptidomimetics can be administered per se or as pharmaceutical compositions.
Pharmaceutical compositions comprising β-hairpin peptidomimetics of the invention may be manufactured by means of conventional mixing, dissolving, granulating, coated tablet- making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active β-hairpin peptidomimetics into preparations which can be used pharmaceutically. Proper formulation depends upon the method of administration chosen.
For topical administration the β-hairpin peptidomimetics of the invention may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.
Systemic formulations include those designed for administration by injection, e.g. subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.
For injections, the β-hairpin peptidomimetics of the invention may be formulated in adequate solutions, preferably in physiologically compatible buffers such as Hink's solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the β-hairpin peptidomimetics of the invention may be in powder form for combination with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation as known in the art. For oral administration, the compounds can be readily formulated by combining the active β- hairpin peptidomimetics of the invention with pharmaceutically acceptable carriers well known in the art. Such carriers enable the β-hairpin peptidomimetics of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions etc., for oral ingestion of a patient to be treated. For oral formulations such as, for example, powders, capsules and tablets, suitable excipients include fillers such as sugars, such as lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired, desintegrating agents may be added, such as cross-linked polyvinylpyrrolidones, agar, or alginic acid or a salt thereof, such as sodium alginate. If desired, solid dosage forms may be sugar-coated or enteric-coated using standard techniques.
For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable carriers, excipients or diluents include water, glycols, oils, alcohols, etc. In addition, flavoring agents, preservatives, coloring agents and the like may be added.
For buccal administration, the composition may take the form of tablets, lozenges, etc. formulated as usual.
For administration by inhalation, the β-hairpin peptidomimetics of the invention are conveniently delivered in form of an aeorosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifmoromethane, trichlorofluromethane, carbon dioxide or another suitable gas. In the case of a pressurized aerosol the dose unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the β-hairpin peptidomimetics of the invention and a suitable powder base such as lactose or starch. The compounds may also be formulated in rectal or vaginal compositions such as suppositories together with appropriate suppository bases such as cocoa butter or other glycerides.
In addition to the formulations described previously, the β-hairpin peptidomimetics of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection. For the manufacture of such depot preparations the β-hairpin peptidomimetics of the invention may be formulated with suitable polymeric or hydrophobic materials (e.g. as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble salts.
In addition, other pharmaceutical delivery systems may be employed such as liposomes and emulsions well known in the art. Certain organic solvents such as dimethylsulfoxide also may be employed. Additionally, the β-hairpin peptidomimetics of the invention may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic agent, additional strategies for protein stabilization may be employed.
As the β-hairpin pepdidomimetics of the invention may contain charged residues, they may be included in any of the above-described formulations as such or as pharmaceutically acceptable salts. Pharmaceutically acceptable salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.
The β-hairpin peptidomimetics of the invention, or compositions thereof, will generally be used in an amount effective to achieve the intended purpose. It is to be understood that the amount used will depend on a particular application.
For example, for use as a desinfectant or preservative, an antimicrobially effective amount of a β-hairpin peptidomimetic of the invention, or a composition thereof, is applied or added to the material to be desinfected or preserved. By antimicrobially effective amount is meant an amount of a β-hairpin peptidomimetic of the invention, or a composition thereof, that inhibits the growth of, or is lethal to, a target microbe population. While the antimicrobially effective amount will depend on a particular application, for use as desinfectants or preservatives the β-hairpin peptidomimetics of the invention, or compositions thereof, are usually added or applied to the material to be desinfected or preserved in relatively low amounts. Typically, the β-hairpin peptidomimetics of the invention comprise less than about 5% by weight of a desinfectant solution or material to be preserved, preferably less than 1% by weight and more preferably less than 0.1% by weight. An ordinary skilled expert will be able to determine antimicrobially effective amounts of particular β-hairpin pepdidomimetics of the invention for particular applications without undue experimentation using, for example, the in vitro assays provided in the examples.
For use to treat or prevent microbial infections or diseases related to such infections, the β- hairpin pepidomimetics of the invention, or compositions thereof, are administered or applied in a therapeutically effective amount. By therapeutically effective amount is meant an amount effective in ameliorating the symptoms of, or in ameliorating, treating or preventing microbial infections or diseases related thereto. Determination of a therapeutically effective amount is well within the capacities of those skilled in the art, especially in view of the detailed disclosure provided herein.
As in the case of desinfectants and preservatives, for topical administration to treat or prevent bacterial infections a therapeutically effective dose can be determined using, for example, the in vitro assays provided in the examples. The treatment may be applied while the infection is visible, or even when it is not visible. An ordinary skilled expert will be able to determine therapeutically effective amounts to treat topical infections without undue experimentation.
For systemic administration, a therapeutically effective dose can be estimated initially from in vitro assays. For example, a dose can be formulated in animal models to achieve a circulating β-hairpin peptidomimetic concentration range that includes the IC50 as determined in the cell culture (i.e. the concentration of a test compound that is lethal to 50% of a cell culture), the MIC, as determined in cell culture (i.e. the concentration of a test compound that is lethal to 100% of a cell culture). Such information can be used to more accurately determine useful doses in humans.
Initial dosages can also be determined from in vivo data, e.g. animal models, using techniques that are well known in the art. One having ordinary skills in the art could readily optimize administration to humans based on animal data.
Dosage amount for applications as antimicrobial agents may be adjusted individually to provide plasma levels of the β-hairpin peptidomimetics of the invention which are sufficient to maintain the therapeutic effect. Therapeutically effective serum levels may be achieved by administering multiple doses each day.
In cases of local administration or selective uptake, the effective local concentration of the β- hairpin peptidomimetics of the invention may not be related to plasma concentration. One having the skills in the art will be able to optimize therapeutically effective local dosages without undue experimentation.
The amount of β-hairpin peptidomimetics administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgement of the prescribing physician.
The antimicrobial therapy may be repeated intermittently while infections are detectable or even when they are not detectable. The therapy may be provided alone or in combination with other drugs, such as for example antibiotics or other antimicrobial agents.
Normally, a therapeutically effective dose of the β-hairpin peptidomimetics described herein will provide therapeutic benefit without causing substantial toxicity.
Hemolysis of red blood cells is often employed for assessment of toxicity of related compounds such as protegrin or tachyplesin. Values are given as %-lysis of red blood cells observed at a concentration of lOOμg/ml. Typical values determined for cationic peptides such as protegrin and tachyplesin range between 30-40% with average MIC-values of 1- 5μg/ml over a wide range of pathogens. Normally, β-hairpin peptidomimetics of the invention will show hemolysis in a range of 0.5-10%, often in a range of 1-5%, at activity levels comparable to those mentioned above for protegrin and tachyplesin. Thus preferred compounds exhibit low MIC-values and low %-hemolysis of red blood cells observed at a concentration of lOOμg/ml.
Toxicity of the β-hairpin peptidomimetics of the invention herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD50 (the dose lethal to 50% of the population) or the LDioo (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a dosage range that is not toxic for use in humans. The dosage of the β-hairpin peptidomimetics of the invention lies preferably within a range of circulating concentrations that include the effective dose with little or no toxicity. The dosage may vary within the range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dose can be chosen by the individual physician in view of the patient's condition (see, e.g. Fingl et al. 1975, In : The Pharmacological Basis of Titer apeutics, Ch.1, p.l).
The following Examples illustrate the invention in more detail but are not intended to limit its scope in any way. The following abbreviations are used in these Examples:
HBTU: 1 -benzotriazol- 1 -yl-tetramethylurounium hexafluorophosphate
(Knorr et al. Tetrahedron Lett. 1989, 30, 1927-1930); HCTU: 1 -Benzotriazol l-[tø(dimethylamino)rnethylene]
-5chloro-hexafluorophosphate-l,3-oxide HOBt: 1-hydroxybenzotriazole; DIEA: diisopropylethylamine; HOAT: 7-aza- 1 -hydroxybenzotriazole; HATU: O-(7-aza-benzotriazole-l-yl)-N,N,N',N'-tetramethyluronoium hexafluorophosphate (Carpino et al. Tetrahedron Lett. 1994, 35, 2279-2281). Examples
1. Peptide synthesis
Coupling of the first protected amino acid residue to the resin
0.5 g of 2-chlorotritylchloride resin (Barlos et al. Tetrahedron Lett. 1989, 30, 3943-3946) (0.83 mMol/g, 0.415 mmol) was filled into a dried flask. The resin was suspended in CH2Cl2 (2.5 ml) and allowed to swell at room temperature under constant stirring for 30 min. The resin was treated with 0.415 mMol (leq) of the first suitably protected amino acid residue (see below) and 284 μl (4eq) of diisopropylethylamine (DIEA) in CH2Cl2 (2.5 ml), the mixture was shaken at 25°C for 4 hours. The resin was shaken (CH2Cl2 /MeOH/DIEA : 17/2/1), 30 ml for 30 min; then washed in the following order with CH2Cl2 (Ix), DMF (Ix), CH2Cl2 (Ix), MeOH (Ix), CH2Cl2(Ix), MeOH (Ix), CH2Cl2 (2x), Et2O (2x) and dried under vacuum for 6 hours.
Loading was typically 0.6-0.7 mMol/g.
The following preloaded resin was prepared: Fmoc-Pro-2-chlorotritylresin.
Synthesis of the fully protected peptide fragment
The synthesis was carried out using a Syro-peptide synthesizer (Multisyntech) using 24 to 96 reaction vessels. In each vessel were placed 60 mg (weight of the resin before loading) of the above resin. The following reaction cycles were programmed and carried out:
Step Reagent Time
1 CH2Cl2, wash and swell (manual) 3 x 1 min.
2 DMF, wash and swell 1 x 5 min 3 40 % piperidine/DMF 2 x 5 min.
4 DMF, wash 5 x 2 min.
5 5 equiv. Fmoc amino acid/DMF + 5 eq. HCTU
+ 5 eq. DIEA 2 x 60 min.
6 DMF, wash 4 x 2 min.
7 CH2CI2, wash (at the end of the synthesis) 3 x 2 min.
Steps 3 to 6 are repeated to add each amino-acid.
After the synthesis of the folly protected peptide fragment had been terminated, then subsequently the cleavage, cyclization and work up procedure as described hereinbelow, was used for the preparation of the peptides.
Analytical methods:
Method 1: Analytical HPLC retention times (RT, in minutes) were determined using an
Jupiter Proteo c<?/w?ra (90A, 15Ox 2.0 mm, cod. 00F4396-B0 - Phenomenex) Wύh the following solvents A (H2O + 0.1 % TFA) and B (CH3CN + 0.1 % TFA) and the gradient: 0 min: 95%A, 5%B; 20 min: 40%A 60%B; 21-23 min: 0%A, 100%B; 23.1-30 min: 95% A,
5%B.
Method 2: Analytical HPLC retention times (RT, in minutes) were determined using an
Aquity UPLC BEH C18 column (1.7 μm, 100 x 2.1 mm, cod. 186002352 - Waters) with the following solvents A (H2O + 0.1% TFA) and B (CH3CN + 0.085% TFA) and the gradient: 0 min: 95%A, 5%B; 0.2 min: 95%A 5%B; 4 min: 35%A, 65%B; 4.2 min: 5% A, 95%B; 4.25 min: 95%A, 5%B; 4.9 min: 95%A, 5%B.
Procedure: Cleavage, cyclization and work up of backbone cyclized peptides
Cleavage, backbone cyclization and purification of the peptide
After assembly of linear peptides, the resin was suspended in 1 ml (0.39 mMol) of 1% TFA in CH2Cl2 (v/v) for 3 minutes and filtered, and the filtrate was neutralized with ImI (1.17 mMol, 3eq.) of 20% DIEA in CH2Cl2 (v/v). This procedure was repeated twice to ensure completion of the cleavage. The resin was washed with 2ml OfCH2Cl2. The CH2Cl2 layer was evaporated to dryness. The fully protected linear peptide was solubilised in 8 ml of dry DMF. Then 2 eq. of HATU in dry DMF (ImI) and 4 eq. of DIPEA in dry DMF (1 ml) were added to the peptide, followed by stirring for 16 h. The volatiles were evaporated to dryness. The crude cyclic peptide was dissolved in 7 ml OfCH2Cl2 and extracted with 10% acetonitrile in water (4.5 ml) three times. The CH2Cl2 layer was evaporated to dryness. To fully deprotect the peptide, 3 ml of cleavage cocktail TFA:TIS:H2O (95:2.5:2.5) were added, and the mixture was stirred for 2.5 h. The volatile was evaporated to dryness and the crude peptide was dissolved in 20% AcOH in water (7 ml) and extracted with diisopropyl ether (4 ml) for three times. The aqueous layer was collected and evaporated to dryness, and the residue was purified by preparative reverse phase LC-MS.
After lyophilisation the products were obtained as white powders and analysed by HPLC- ESI-MS analytical methods as described above. The analytical data comprising purity after preparative HPLC and ESI-MS are shown in Table 1.
Examples 1-50, are shown in Table 1. The peptides were synthesized starting with the amino acid L-Pro which was grafted to the resin. Starting resin was Fmoc-Pro-2-chlorotrityl resin, which was prepared as described above. The linear peptides were synthesized on solid support according to the procedure described above in the following sequence: Resin-Pro- DPro-P12-Pl 1-P10-P9-P8-P7-P6-P5-P4-P3-P2-P1. Ex. 1-50, were cleaved from the resin, cyclized, deprotected and purified as indicated by preparative reverse phase LC-MS.
After lyophilisation the products were obtained as white powders and analysed by HPLC- ESI-MS methods as described above.
HPLC-retention times (minutes) were determined using the analytical methods as described above. Examples 1 to 39 were analysed with method I1 for Examples 40-50 method 2 was used:
Ex. 1 (8.87), Ex. 2 (9.26), Ex. 3 (9.34), Ex. 4 (9.45), Ex. 5 (9.48), Ex. 6 (9.44), Ex. 7 (10.11), Ex.8 (9.99), Ex.9 (10.22), Ex.10 (9.76), Ex.11 (10.56), Ex.12 (11.37), Ex.13 (9.13), Ex. 14 (9.34), Ex.15 (8.80), Ex.16 (9.23); Ex.17 (9.65), Ex.18 (9.18), Ex.19 (8.37), Ex.20 (8.86), Ex.21 (8.78), Ex.22 (9.32), Ex.23 (9.58), Ex.24 (9.27), Ex.25 (9.31), Ex.26 (9.24), Ex.27 (9.23), Ex.28 (9.34), Ex.29 (9.66), Ex.30 (9.88), Ex.31 (9.62), Ex.32(8.86), Ex.33 (9.73), Ex.34 (10.46), Ex.35 (9.21), Ex.36 (9.80), Ex.37 (9.73), Ex.38 (9.20), Ex. 39 (9.53), Ex.40 (2.07), Ex.41 (1.77), Ex.42 (1.66), Ex.43 (1.67), Ex.44 (1.81), Ex.45 (1.87), Ex.46 (1.81), Ex.47 (1.83), Ex.48 (1.79), Ex.49 (1.88), Ex.50 (2.17).
Figure imgf000091_0001
Table 1: Examples continued
Example Sequ.ID Pl P2 P3 P4 P5 P6 P7 P8 P9 PlO PIl P12 Template Purity%a) [M+ 2H]/2
31 SEQ ID NO:31 Thr Trp NIe Dab Lys Dab Dab Trp Dab Dab Ala Dab 13PrO1TrO 95 791.1
32 SEQ ID NO:32 Thr Trp VaI Dab Lys Dab Dab Trp Dab Dab Ala Dab 0PrO1TrO 95 784.0
33 SEQ ID NO:33 Thr Trp Chg Dab Lys Dab Dab Trp Dab Dab Ala Dab DProLPro 95 804.4
34 SEQ ID NO:34 Thr Trp Cha Dab Lys Dab Dab Trp Dab Dab Ala Dab 0PrO1TrO 95 811.5
35 SEQ ID NO:35 Thr Trp He Dab Lys Dab Dab Trp Dab Dab Hse Dab °ProLPro 95 806.4
36 SEQ ID NO:36 Thr Trp He Dab Lys Dab Dab Trp Dab Dab t-BuG Dab 1Tr0 1TrO 95 812.5
37 SEQ ID NO:37 Thr Trp He Dab Lys Dab Dab Trp Dab Dab Cpa Dab °ProLPro 89 811.3
38 SEQ ID NO:38 Thr Trp He Dab Lys Dab Dab Trp Dab Dab Asn Dab 0PrO1TrO 95 813.1
39 SEQ ID NO:39 Thr Trp He Dab Lys Dab GIn Trp Dab Dab Ala Dab 0PrO1Tr0 95 805.2 — *
40 SEQ ID NO:40 Thr Trp He GIn Lys Dab Dab Trp Dab Dab Ala GIn °ProLPro 95 819.6
41 SEQ ID NO:41 Thr Trp He Dab Lys °Dab Dab Trp Dab Dab Ala Dab °ProLPro 91 791.2
42 SEQ ID NO:42 Asp Tyr He Dab Lys °Dab Dab Trp Dab Dab Ala Dab °ProLPro 85 786.6
43 SEQ ID NO:43 Asp Tyr He Dab Orn °Dab Dab Trp Dab Dab Ala Dab °ProLPro 85 779.6
44 SEQ ID NO:44 GIu Trp He Dab Lys °Dab Dab Trp Dab Dab Ala Dab °ProLPro 78 805.1
45 SEQ ID NO:45 GIu Trp He Dab Lys °Dab Dab Trp Dab Dab Ala GIn 0PrO1TrO 82 819.2
46 SEQ IDNO:46 GIu Trp He Dab Lys °Dab Dab Trp Dab Dab Ala Dap °ProLPro 83 798.0
47 SEQ ID NO:47 GIu Trp He Dab Orn °Dab Dab Trp Dab Dab Ala Dab °ProLPro 85 798.3
48 SEQ ID NO:48 Thr Trp He Dab Orn °Dab Dab Trp Dab Dab Ala Dab °ProLPro 86 784.1
49 SEQ ID NO:49 Thr Trp He Dab Om °Dab Dab Trp Dab Dab Ala Ser °ProLPro 91 777.7
50 SEQ ID NO:50 GIu Trp He GIn Lys Dab Dab Ser Dab Dab Ala Ser °ProLPro 95 805.8
%-ρuritity of compounds after prep. HPLC.
2. Biological methods
2.1. Preparation of the peptide samples.
Lyophilized peptides were weighed on a Microbalance (Mettler MT5) and dissolved in sterile water to a final concentration of 1 mg/ml unless stated otherwise. Stock solutions were kept at +40C, light protected.
2.2. Antimicrobial activity of the peptides.
The selective antimicrobial activities of the peptides were determined in 96-well plates (Nunclon polystyrene) by the standard NCCLS broth microdilution method (see ref 1, below) with slight modifications. Innocula of the microorganisms were diluted into
Mueller-Hinton (MH) broth + 0.02% BSA and compared with a 0.5 Mcfarland standard to give appr. 10 colony forming units (CFU)/ml. Aliquots (50 μl) of inoculate were added to 50 μl of MH broth + 0.02% BSA containing the peptide in serial two-fold dilutions. The following microorganisms were used to determine antibiotic selectivity of the peptides: Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (P. aeruginosa ATCC 27853, P8191900, P1021903, P1021913, IMP 1 Livermore 3140). Antimicrobial activities of the peptides were expressed as the minimal inhibitory concentration (MIC) in μg/ml at which no visible growth was observed after 18-20 hours of incubation at 37°C.
2.3. Cytotoxicity assay
The cytotoxicity of the peptides to HELA cells (Acc57) and COS-7 cells (CRL-1651) was determined using the MTT reduction assay [see ref. 2 and 3, below]. Briefly the method was as follows: HELA cells and COS-7 cells were seeded at 7.OxIO3 and, respectively, 4.5x103 cells per well and grown in 96-well microtiter plates for 24 hours at 37°C at 5% CC"2. At this point, time zero (Tz) was determined by MTT reduction (see below). The supernatant of the remaining wells was discarded, and fresh medium and the peptides in serial dilutions of 12.5, 25 and 50 μM were dispensed into the wells. Each peptide concentration was assayed in triplicate. Incubation of the cells was continued for 48 hours at 37°C at 5% CO2. Wells were then washed once with phosphate buffered saline (PBS) and subsequently 100 μl MTT reagent (0.5 mg/ml in medium RPMI1640 and, respectively, DMEM) were added to the wells. This was incubated at 370C for 2 hours and subsequently the medium was aspirated and 100 μl isopropanol were added to each well. The absorbance at 595 nm of the solubilized product was measured (ODs95peptide). For each concentration averages were calculated from triplicates. The percentage of growth was calculated as follows: (OD595peptide-OD595Tz-OD595Empty well) / (OD595Tz- OD595Emρty well) x 100% and was plotted for each peptide concentration. The LC 50 values (Lethal Concentration, defined as the concentration that kills 50% of the cells) were determined for each peptide by using the trend line function of EXCEL (Microsoft Office 2000) for the concentrations (50, 25, 12.5 and 0 μM), the corresponding growth percentages and the value -50, (=TREND(C50:C0,%50:%0,-50)). The GI 50 (Growth Inhibition) concentrations were calculated for each peptide by using a trend line function for the concentrations (50, 25, 12.5 and 0 μg/ml), the corresponding percentages and the value 50, (=TREND (C5OiCo3 0Zo5O=0ZoO5SO).
2.4. Hemolysis The peptides were tested for their hemolytic activity against human red blood cells
(hRBC). Fresh hRBC were washed three times with phosphate buffered saline (PBS) by centrifugation for 10 min at 2000 x g. Peptides at a concentration of 100 μM were incubated with 20% v/v hRBC for 1 hour at 370C. The final erythrocyte concentration was approximately 0.9xl09 cells per ml. A value of 0% and, respectively,. 100% cell lysis was determined by incubation of the hRBC in the presence of PBS alone and, respectively, 0.1% Triton X-100 in H2O. The samples were centrifuged, the supernatant was 20-fold diluted in PBS buffer and the optical density (OD) of the sample at 540 nM was measured. The 100% lysis value (OD540HaO) gave an OD540 of approximately 1.3-1.8. Percent hemolysis was calculated as follows: (OD54opeptide/OD540H2θ) xlOO%.
2.5. Plasma stability
405 μl of plasma/albumin solution were placed in a polypropylene (PP) tube and spiked with 45 μl of compound from a 100 mM solution B, derived from 135 μl of PBS and 15 μl of 1 mM peptide in PBS, pH 7.4. 150 μl aliquots were transferred into individual wells of the 10 kDa filter plate (Millipore MAPPB 1010 Biomax membrane). For "0 minutes controls": 270 μl of PBS were placed in a PP tube and 30 μl of stock solution B was added and mixed. 150 μl of control solution were placed into one well of the filter plate and served as "filtered control". Further 150 μl of control solution were placed directly into a receiver well (reserved for filtrate) and served as "not-filtered control". The entire plate including evaporation lid was incubated for 60 min at 370C. Plasma samples (rat plasma: Harlan Sera lab UK, human plasma: Blutspendezentrum Zurich) were centrifuged at least for 2 h at 4300 rpm (3500 g) and 150C in order to yield 100 μl filtrate. For "serum albumin"-samples (freshly prepared human albumin: Sigma A-4327, rat albumin: Sigma A-6272, all at 40 mg/ml concentration in PBS) approximately 1 hour of centrifugation was sufficient. The filtrates in the receiver PP plate were analysed by LC/MS as follows: Column: Jupiter C18 (Phenomenex), mobile phases: (A) 0.1% formic acid in water and (B) acetonitrile, gradient: 5%-100% (B) in 2 minutes, electrospray ionization, MRM detection (triple quadrupole). The peak areas were determined and triplicate values were averaged. The binding was expressed in percent of the (filtered and not-filtered time point 0 min) control 1 and 2 by: 100-(100 x T6o/T0). The average from these values was then calculated.
2.6. Pharmacokinetic study (PK)
Pharmacokinetic study after single intravenous, subcutaneous and intraperitoneal administration in mice
Pharmacokinetic study after single intravenous (i.v.) and subcutaneous (s.c.) administration was performed for the compound of Example 1 ("Ex. 1"). CD-I mice (20- 25 g) were used in the study. Physiological saline was used a vehicle. The volume was 2 ml/kg i.v., and 5 ml/kg s.c. and the peptide Ex. 1 was injected to give a final intravenous dose of 1 mg/kg, and a subcutaneous dose of 5 mg/kg. Approximately 200-250 μl of blood was removed under light isoflurane anesthesia by cardiac puncture at predetermined time intervals (0, 5, 15, 30 min and 1, 2, 3, 4 and 5 hours for the i.v. study and 0, 15, 30 min and 1, 2, 4, 6, 8 and 10 hours for the s.c. study) and added to heparinized tubes. Plasma was removed from pelleted cells upon centrifugation and frozen at -8O0C prior to HPLC-MS analysis.
Preparation of the plasma calibration samples
"Blank" mouse plasma from untreated animals was used. Aliquots of plasma of 0.2 ml each were spiked with 50 ng of propranolol (Internal Standard, IS), (sample preparation by solid phase extraction on OASIS® HLB cartridges (Waters)) and with known amounts of Ex. 1 in order to obtain 9 plasma calibration samples in the range 10 - 5000 nM. The OASIS® HLB cartridges were conditioned with 1 ml of methanol and then with 1 ml of 1% NH3 in water. Samples were then diluted with 700 μl of 1% NH3 in water and loaded. The plate was washed with 1 ml of methanol/1% NH3 in water 5/95. Elution was performed using 1 ml of 0.1% TFA in methanol.
The plate containing eluates was introduced into the concentrator system and taken to dryness. The residues were dissolved in 100 μL of formic acid 0.1%/acetonitrile, 95/5 (v/v) and analysed in the HPLC/MS on a reverse phase analytical column (Jupiter C 18, 50 x 2.0 mm, 5 μm, Phenomenex), using gradient elution (mobile phases A: 0.1% formic acid in water, B: Acetonitrile; from 5%B to 100%B in 2 min.). Preparation of plasma samples
Samples coming from animal treatments were pooled in order to obtain an appropriate volume for the extraction. If the total volume obtained was less than 0.2 ml the appropriate amount of "blank" mouse plasma was added in order to keep the matrix identical to the calibration curve. Samples were than spiked with IS and processed as described for the calibration curve.
Pharmacokinetic evaluation
PK analysis was performed on pooled data (generally n=2 or 3) using the software Win Nonlin (Pharsight). The area under the curve AUC was calculated by the linear trapezoidal rule. Elimination half-life was calculated by the linear regression on at least three data points during the elimination phase. The time intervals selected for the half-life determinations were evaluated by the correlation coefficient (r2), which should be at least above 0.85 and most optimally above 0.96. In case of i.v. administration the initial concentration at tzero was determined by extrapolation of the curve through the first two time points. Finally bioavailability after i.p. administration was calculated from the normalised AUCinf_D_obs ration after s.c. versus i.v. administration.
2.7. In vivo Septicemia Assay Groups of 6 CD-I (CrI.) derived male mice weighing 24 ± 2 g were used. The mice were each inoculated intravenously (IV) with an LD90-100 of Pseudomonas aeruginosa (ATCC 27853) (9 x 106 CFU/0.5ml/mouse) in brain heart infusion broth without 5% mucin. Compound at doses of 5, 2.5, 1, 0.5, 0.25 and 0.1 mg/kg, vehicle (0.9% NaCl, 10 ml/kg) was administered subcutaneously (SC) to test animals at lhour after bacterial inoculation. Also, an additional group was treated twice with compound at a dose of
5mg/kg at 1 and 6 hours after bacterial inoculation. Mortality was recorded once daily for 7 days following the bacterial inoculation and an increase of survival of the animals by 50 percent or more (3 50 %) after the bacterial inoculation, relative to vehicle control, indicates significant antimicrobial effect. The MED (ED50) was determined by nonlinear regression using Graph-Pad Prism (Graph Pad Software, USA).
2.8. Results
The results of the experiments described in 2.2, 2.3 and 2.4, above, are indicated in Table 2, herein below Table 2: Minimal inhibitory concentrations (MIC in μg/ml) in Mueller-Hinton broth, cytotoxicity and percentage hemolyses at a concentration of 100 μg/ml of peptide
Figure imgf000097_0001
Figure imgf000098_0001
Table 2 continued
Figure imgf000099_0001
n.d. = not determined VD OO
The results of the experiment described in 2.5, above, are indicated in Table 3 herein below.
Table 3
Figure imgf000100_0001
The results of the experiment described in 2.6 (PK), above, are indicated in Table 4 herein below.
Table 4
Figure imgf000100_0002
After intravenous administration of Ex. 1 at a dose level of 1 mg/kg body weight, Ex. 1 followed intravenous kinetic characteristics. After PK analysis, Ex. 1 showed an extrapolated Cinitjai of 2174 ng/ml and a Cmax observed of 1268 ng/ml at 5 min. Plasma levels rapidly decreased to 575 and 177 ng/ml at 15 min and 1 hour respectively. From 0.5 to 2 h plasma levels decreased with an elimination half-life of 0.53 h to 10.6 ng/ml at
3 h. The AUCINF_obs amounted to 679.5 ng.h/ml.
After subcutaneous administration of Ex. 1 at a dose level of 5 mg/kg body weight, plasma levels of Ex. 1 increased the first 0.5-1 h and showed a Cmax of 2333 ng/ml. From
0.5 to 8 h plasma levels decreased with an elimination half-life of 0.95 h to 7.3 ng/ml at 8 h. The AUCINF_obs amounted to 4016.5 ng.h/ml.
As compared to the normalized AUC value after i.v. administration (100% absorbed, 679 ng.h/ml) of Ex. 1 absorbed after s.c. administration amounted to 118% (803 ng.h/ml). The value above 100% may partially reflect an impaired reliability caused by the limited number of points or is caused by a non-linearity in dose.
The results of the experiment described in 2.7 (Septicaemia Assay), above, are indicated in Table 5-7 herein below.
Septicaemia experiment in mice: LD90-100 of Pseudomonas aeruginosa (ATCC 27853) (9 x 106 CFU/0.5 ml/mouse IV and after 1 h Ex. 1 s.c.
Table 5
Figure imgf000101_0001
Septicaemia experiment in mice: LD90-100 of Pseudomonas aeruginosa
(ATCC 27853) (9 x 106 CFU/0.5 ml/mouse IV), and after 1 and 5h Ex. 40 s.c. Table 6
Figure imgf000102_0001
Septicaemia experiment in mice: LD90-100 of Ps eudomonas aeruginosa (ATCC 27853) (9 x 106 CFU/0.5 ml/mouse IV), and after I and 5h Ex. 50 s.c.
Table 7
Figure imgf000102_0002
References
1. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical laboratory standards, Villanova, Pa.
2. Mossman T. J Immunol Meth 1983, 65, 55-63
3. Berridge MV, Tan AS. Archives of Biochemistry & Biophysics 1993, 303, 474-482

Claims

1. Compounds of the general formula
wherein
Figure imgf000103_0001
is a group of one of the formulae
Figure imgf000103_0002
(a1) (a2)
Figure imgf000103_0003
Figure imgf000104_0001
Figure imgf000105_0001
(n) (o) (P)
wherein
Figure imgf000105_0002
is the residue of an L-α-amino acid with B being a residue of formula -NR20CH(R71)- or the enantiomer of one of the groups Al to A69 as defined hereinafter;
Figure imgf000105_0003
is a group of one of the formulae
Figure imgf000105_0004
A1 A2 A3 A4
Figure imgf000106_0001
A5 A6 A7 A8 A9
Figure imgf000106_0002
A10 A11 A12 A13 A14
Figure imgf000106_0003
A15 A16 A17 A18 A19
Figure imgf000106_0004
A20 A21 A22 A23 A24
Figure imgf000106_0005
A25 A26 A27 A28
Figure imgf000107_0001
A38 A39 A40 A41 A42
Figure imgf000107_0002
A48 A49 A50 A51 A52
Figure imgf000107_0003
A53 A54 A55 A56 A57
Figure imgf000108_0001
A67 A68 A69
Figure imgf000108_0002
A70 A71 A72 A73 A74
Figure imgf000108_0003
A75 A76 A77 A78 A79
Figure imgf000108_0004
A80 A81 A82 A83 A84
Figure imgf000109_0001
A95 A96 A97 A98 A99
Figure imgf000109_0002
A100 A101 A102 A103 A104
R1 is H; lower alkyl; or aryl-lower alkyl;
R2 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;
-(CH2)m(CHR61)sNR33R34; -(CH2)ra(CHR6I)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R3 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;
-(CH2)0(CHR61)SCONR58R59 ; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R4 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)ra(CHR6))sSR56;
-(CH2)ra(CHR61)sNR33R34;
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;
-(CH2)p(CHR61)sCOOR57; -(CH2)p(CHR61)sCONR5SR59; -(CH2)P(CHR61)SPO(OR60)2;
-(CH2)P(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R5 is alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)o(CHR61)sNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)0(CHR61)SCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R6 is H; alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)O(CHR61)SNR33R34; -(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R7 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sNR33R34; -(CH2)q(CHR61)sOCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82;
-(CH2)r(CHR61)sCOOR57; -(CH2)r(CHR61)sCONR58R59;
-(CH2)r(CHR61)sPO(OR60)2;
-(CH2)r(CHR61)sSO2R62; or -(CH2)r(CHR61)s C6H4R8;
R8 is H; Cl; F; CF3; NO2; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)NR33R34 ;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR6I)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)SSO2R62; or -(CH2)0(CHR61)SCOR64; R9 is alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)0(CHR61)sCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R10 is alkyl; alkenyl; -(CH2)O(CHR6')SOR55; -(CH2)O(CHR61)sSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)0(CHR61)SCOOR57; -(CH2)0(CHR61)SCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R11 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)SSO2R62; or -(CH2)O(CHR61)S C6H4R8; R12 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)r(CHR61)sCOOR57; -(CH2)r(CHR61)sCONR58R59;
-(CH2)r(CHR61)sPO(OR60)2; -(CH2)r(CHR61)s SO2R62; or -(CH2)r(CHR61)sC6H4R8; R13 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sSR56; -(CH2)q(CHR61)sNR33R34;
-(CH2)q(CHR61)sOCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82; -(CH2)q(CHR61)sCOOR57; -(CH2)q(CHR61)sCONR58R59; -
(CH2)q(CHR61)sPO(OR60)2;
-(CH2)q(CHR61)s SO2R62; Or-(CH2X(CHR61) sC6H4R8; R14 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82; -(CH2)q(CHR61)sCOOR57; -(CH2)q(CHR61)sCONR58R59;
Figure imgf000111_0001
R15 is alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)O(CHR61)SSR56;
-(CH2)O(CHR61)SNR33R34; -(CH2)O(CHR61)SOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)O(CHR61)SCOOR57; -(CH2)O(CHR61)SCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R16 is alkyl; alkenyl; -(CH2)o(CHR6l)sOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34; -(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)O(CHR61XCOOR57; -(CH2)0(CHR6I)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R17 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sSR56; -(CH2)q(CHR61)sNR33R34;
-(CH2)q(CHR61)sOCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82; -(CH2)q(CHR61)sCOOR57; -(CH2)q(CHR61)sCONR58R59; -(CH2)q(CHR61)sPO(OR60)2; -(CH2)q(CHR61)s SO2R62; or -(CH2X1(CHR61XC6H4R8;
R18 is alkyl; alkenyl; -(CH2)P(CHR61)SOR55; -(CH2)P(CHR61)SSR56; -(CH2)p(CHR61)sNR33R34;
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82; -(CH2)p(CHR61)sCOOR57; -(CH2)p(CHR61)sCONR58R59; -(CH2)P(CHR61)SPO(OR60)2;
-(CH2)p(CHR61)s SO2R62; or -(CH2)O(CHR61XC6H4R8; R19 is lower alkyl; -(CH2)P(CHR61)SOR55; -(CH2)P(CHR61)SSR56; -(CH2)P(CHR61)SNR33R34;
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82; -(CH2)p(CHR61)sCOOR57; -(CH2)P(CHR61)SCONR58R59;
-(CH2)P(CHR61)SPO(OR60)2;
-(CH2)P(CHR61)S SO2R62; or -(CH2MCm61XC6H4R8; or R18 and R19 taken together can form: -(CHj)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NRS7(CH2)2-; R20 is H; alkyl; alkenyl; or aryl-lower alkyl;
R21 is H; alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)0(CHR61)SCOOR57; -(CH2)0(CHR61)SCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61X SO2R62; or -(CH2)O(CHR61)SC6H4R8; R22 is H; alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34; -(CH2)O(CHR61XOCONR33R75; -(CH2)O(CHR61XNR20CONR33R82; -(CH2)O(CHR61)SCOOR57; -(CH2)O(CHR61)SCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61XC6H4R8; R23 is alkyl; alkenyl; -(CH2)0(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)o(CHR61)sNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;
-(CH2)0(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R24 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)O(CHR61)SSR56;
-(CH2)o(CHR61)sNR33R34;
-(CH2)o(CE[R61)sOCONR33R75; -(CH2)o(CHR61)sNR2()CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)0(CHR61)sCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8;
R25 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)SSO2R62; or -(CH2)O(CHR61 XC6H4R8;
R26 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;
-(CH2)O(CHR61)SCONR58R59; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; or
R25 and R26 taken together can form: -(CH2)2.6-; -(CH2)rO(CH2)r-; -(CH2)rS(CH2)r-; or
-(CH2)rNR57(CH2)r-;
R27 is H; alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)0(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR5SR59; -(CH2)o(CHR61)sOCONR33R75;
-(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sPO(OR60)2; -(CH2)O(CHR61)S SO2R62; or -(CH2)0(CHR61) sC6iH.R8; R28 is alkyl; alkenyl; -(CH2)O(CHR61)S-OR55; -(CH2)O(CHR61)S SR56; -(CH2)O(CHR61)S NR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)O(CHR61)S COOR57; -(CH2)O(CHR61)S CONR58R59; -(CH2)O(CHR61)S PO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)S C6H4R8; R29 is alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR6I)SSR56; -(CH2)O(CHR6I)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)0(CHR61)SCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8; R30 is H; alkyl; alkenyl; or aryl-lower alkyl;
R31 is H; alkyl; alkenyl; -(CH2)P(CHR61)SOR55; -(CH2)P(CHR61)SNR33R34; -(CH2)p(CHR61)sOCONR33R75; -(CH2)P(CHR61)SNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)0(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)SSO2R62; or -(CH2)O(CHR61)S C6H4R8; R32 is H; lower alkyl; or aryl-lower alkyl; R33 is H; alkyl, alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR34R63; -(CH2)m(CHR61)sOCONR75R82; -(CH2)m(CHR61)sNR20CONR78R82; -(CH2)o(CHR61)sCOR64; -(CH2)0(CHR61)s-CONR58R59, -(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)s SO2R62; or -(CH2)O(CHR61)SC6H4RS; R34 is H; lower alkyl; aryl, or aryl-lower alkyl;
R33 and R34 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-;
R35 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; -(CH2)in(CHR61)sNR20CONR33R82; -(CH2)p(CHR61)sCOOR57; -(CH2)P(CHR61)SCONR58R59;
-(CH2)P(CHR61)SPO(OR60)2;
-(CH2)P(CHR61)SSO2R62; or -(CH2)P(CHR61)S C6H4R8; R36 is H, alkyl; alkenyl; -(CH2)O(CHR61)sOR55; -(CH2)P(CHR61)SNR33R34; -(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR6l)sNR20CONR33R82; -(CH2)P(CHR61)SCOOR57; -(CH2)P(CHR61)SCONR58R59;
-(CH2)P(CHR61)SPO(OR60)2;
-(CH2)P(CHR61)SSO2R62; or -(CH2)O(CHR61)S C6H4R8; R37 is H; F; Br; Cl; NO2; CF3; lower alkyl; -(CH2)P(CHR61)SOR55; -(CH2)p(CHR61)sNR33R34;
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR(il)sNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)SSO2R62; or -(CH2)O(CHR61)S C6H4R8; R38 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)P(CHR61)SOR55;
-(CH2)P(CHR61)SNR33R34;
-(CH2)P(CHR61)SOCONR33R75; -(CH2)P(CHR61)SNR20CONR33R82;
-(CH2)0(CHR61)SCOOR57; -(CH2)0(CHR61)SCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2; -(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR6I)sC6H4R8;
R ,39 is H; alkyl; alkenyl; or aryl-lower alkyl; R40 is H; alkyl; alkenyl; or aryl-lower alkyl; R41 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)P(CHR61)SOR55;
-(CH2)P(CHR61)SNR33R34; -(CH2)p(CHR61)sOCONR33R75; -(CH2)P(CHR61)SNR20CONR33R82;
-(CH2)o(CHR61)sCOOR57; -(CH2)0(CHR61)sCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)0(CHR61)sSO2R62; or -(CH2)O(CHR61)S C6H4R8; R42 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)P(CHR61)SOR55; -(CH2)P(CHR61)SNR33R34;
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR6I)sNR20CONR33R82;
-(CH2)O(CHR61)SCOOR57; -(CH2)O(CHR61)SCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)O(CHR61)SSO2R62; or -(CH2)O(CHR61)S C6H4R8; R43 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR5S; -(CH2)m(CHR61)sNR33R34;
-(CH2)ra(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;
-(CH2)O(CHR61)SCOOR57; -(CH2)O(CHR61)SCONR58R59;
-(CH2)o(CHR61)sPO(OR60)2;
-(CH2)o(CHR6l)sSO2R62; or -(CH2)O(CHR61)S C6H4R8; R44 is alkyl; alkenyl; -(CH2)t(CHR61)sOR55; -(CH2)r(CHR61)sSR56; -(CH2)r(CHR61)sNR33R34;
-(CH2)r(CHR61)sOCONR33R75; -(CH2)r(CHR61)sNR20CONR33R82; -(CH2)r(CHR61)sCOOR57; -(CH2)r(CHR61)sCONR58R59; -(CH2)r(CHR61)sPO(OR60)2;
-(CH2)r(CHR61)s SO2R62; or -(CH2)r(CHR61)sC6H4R8; R45 is H; alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)O(CHR61)SSR56; -(CH2)O(CHR61)SNR33R34;
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82; -(CH2)O(CHR61)SCOOR57; -(CH2)S(CHR61)SCONR58R59;
-(CH2)S(CHR61)SPO(OR60)2;
-(CH2)S(CHR61)S SO2R62; or -(CH2)S(CHR61)SC6H4R8; R46 is H; alkyl; alkenyl; or -(CH2)O(CHR61)PC6H4R8; R47 is H; alkyl; alkenyl; or -(CH2)0(CHR61)SOR55; R48 is H; lower alkyl; lower alkenyl; or aryl-lower alkyl;
R49 is H; alkyl; alkenyl; -(CHR61)SCOOR57; (CHR61)SCONR58R59; (CHR61)SPO(OR60)2;
-(CHR61)SSOR62; or -(CHR61)SC6H4R8; R50 is H; lower alkyl; or aryl-lower alkyl;
R51 is H; alkyl; alkenyl; -(CH2)ra(CHR61)sOR55; -(CH2)m(CHR61)sSR56; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)pPO(OR60)2; -(CH2)P(CHR61)S SO2R62; or -(CH2)P(CHR61)SC6H4R8; R52 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56; -(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;
-(CH2)ra(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)pPO(OR60)2; -(CH2)P(CHR61)S SO2R62; or -(CH2)P(CHR61)SC6H4R8; R53 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56; -(CH2)m(CHR61)sNR33R34;
-(CH2)ra(CHR61)sOCONR33R75;
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR6I)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)pPO(OR60)2; -(CH2)p(CHR61)s SO2R62; or -(CH2)P(CHR61)SC6H4R8; R54 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR6I)sNR33R34; -(CH2)m(CHR61)sOCONR33R75; .(CH2)m(CHR61)sNR20CONR33R82; -(CH2)O(CHR61)COOR57; -(CH2)O(CHR61)SCONR58R59; or -(CH2)O(CHR61)S C6H4R8;
R55 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH2)m(CHR61)sOR57; -(CH2)ra(CHR61)sNR34R63; -(CH2)m(CHR61)sOCONR75R82;
-(CH2)m(CHR61)sNR20CONR78R82; -(CH2)o(CHR61)s-COR64; -(CH2)0(CHR61)COOR57; or -(CH2)O(CHR61)SCONR58R59;
R56 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH2)m(CHR61)sOR57; -(CH2)m(CHR61)sNR34R63; -(CH2)m(CHR61)sOCONR75R82;
-(CH2)m(CHR61)sNR20CONR78R82; -(CH2)O(CHR61)S-COR64; or -(CH2)0(CHR61)SCONR58R59;
R57 is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl; R58 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl- lower alkyl;
R59 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl- lower alkyl; or
R58 and R59 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or
-(CH2)2NR57(CH2)2-; R60 is H; lower alkyl; lower alkenyl; aryl; or aryl-lower alkyl;
R61 is H, alkyl; alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; -(CH2)POR55;
-(CH2)PNR33R34; -(CH2)POCONR75R82; -(CH2)PNR20CONR78R82; -(CH2)0COOR57; or -(CH2)oPO(OR60)2; R62 is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl-lower alkyl;
R63 is H; lower alkyl; lower alkenyl; aryl, heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl;
-COR64; -COOR57; -CONR58R59; -SO2R62; or -PO(OR60)2;
R34and R63 taken together can form: -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-;
R64 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl;
-(CH2)P(CHR61)SOR65; -(CH2)P(CHR61)SSR66; or -(CH2)P(CHR61)SNR34R63; -(CH2)p(CHR6l)sOCONR75R82; -(CH2)P(CHR61)SNR20CONR78R82; R65 is H; lower alkyl; lower alkenyl; aryl, aryl-lower alkyl; heteroaryl-lower alkyl; -
COR57;
-COOR57; or -CONR58R59;
R66 is H; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; heteroaryl-lower alkyl; or - CONR58R59; m is 2-4; o is 0-4; p is 1-4; q is 0-2; r is 1 or 2; s is O or 1; R67 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; R68 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; R69 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; and R70 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; with the proviso that at least two of R67, R68, R69 and R70 are H; and
Z is a chain of 12 α-amino acid residues, the positions of said amino acid residues in said chain being counted starting from the N-terminal amino acid, whereby these amino acid residues are, depending on their position in the chain, GIy or Pro, or of formula -A-CO-, or of formula -B-CO-, or of one of the types
C: -NR20CH(R72)CO-;
D: -NR20CH(R73)CO-; E: -NR20CH(R74)CO-;
F: -NR20CH(R84)CO-; and
H: -NR20-CH(CO-)-(CH2)4-7-CH(CO-)-NR20-;
-NR20-CH(CO-)-(CH2)pSS(CH2)p-CH(CO-)-NR20-; -NR20-CH(CO-)-(-(CH2)pNR20CO(CH2)p-CH(CO-)-NR20-; and -NR20-CH(CO-)-(-(CH2)pNR20CONR20(CH2)p-CH(CO-)-NR20-;
R71 is H; lower alkyl; lower alkenyl; -(CX2)P(CHR61)SOR75; -(CX2)P(CHR61)SSR75; -(CX2)p(CHR61)sNR33R34; -(CX2)p(CXR61)sOCONR33R75; -(CX2)p(CHR61)sNR20CONR33R82;
-(CX2)0(CHR61)SCOOR75; -(CX2)PCONR58R59; -(CX2)PPO(OR62)2; -(CX2)PSO2R62; or -(CX2)O-C6R67R68R69R70R76;
R72 is H; lower alkyl; lower alkenyl; -(CX2)P(CHR86)SOR85; or
Figure imgf000118_0001
R73 is -(CX2)OR77; -(CX2)rO(CH2)oR77; -(CX2)rS(CH2)0R77; or -(CX2)rNR20(CH2)oR77; R74 is -(CX2)PNR78R79; -(CX2)PNR77R80; -(CX2)PC(=NR80)NR78R79; - (CX2)pC(=NOR50)NR78R79;
-(CX2)pC(=NNR78R79)NR78R79; -(CX2)pNR80C(=NR80)NR78R79; -(CX2)pN=C(NR78R80)NR79R80;-(CX2)pC6H4NR78R79; -(CX2)PC6H4NR77R80; -(CX2)pC6H4C(=NR80)NR78R79; -(CX2)pC6H4C(=NORS0)NR7sR79;
-(CX2)pC6H4C(=NNR78R79)NR78R79; -(CX2)PC6H4NR80C(=NR80)NR78R79; -(CX2)pC6H4N=C(NR78R80)NR79R80; -(CX2)rO(CX2)mNR78R79; - (CX2)rO(CX2)mNR77R80;
-(CX2)rO(CX2)pC(=NR80)NR78R79; -(CX2)rO(CX2)pC(=NOR50)NR78R79; -(CX2)rO(CX2)pC(=NNR78R79)NR78R79; -(CX2)rO(CH2)mNR80C(=NR80)NR78R79;
-(CX2)rO(CX2)mN=C(NR78R80)NR79R80; -(CX2XO(CX2)PC6H4CNR78R79; -(CX2)rO(CX2)pC5H4C(=NR80)NR78R79; -(CX2)rO(CX2)pC6H4C(=NOR50)NR78R79; -(CX2)rO(CX2)pC6H4C(=NNR78R79)NR78R79;
-(CX2)rO(CX2)pC6H4NR80C(=NR80)NR78R79; -(CX2)rS(CX2)mNR78R79; -(CX2)rS(CX2)mNR77R80;-(CX2)rS(CX2)pC(=NR80)NR78R79;
-(CX2)rS(CX2)pC(=NOR50)NR78R79; -(CX2)rS(CX2)pC(=NNR78R79)NR78R79; -(CX2)rS(CX2)mNR80C(=NR80)NR78R79; -(CX2)rS(CX2)mN=C(NR78R80)NR79R80; -(CX2)rS(CX2)pC6H4CNR78R79; -(CX2)rS(CX2)pC6H4C(=NR80)NR78R79; -(CX2)rS(CX2)pC6H4C(=NOR50)NR78R79; - (CX2)rS(CX2)pC6H4C(=NNR78R79)NR78R79;
-(CX2)rS(CX2)pC6H4NR80C(=NR80)NR78R79; -(CX2)pNRs0COR64; - (CX2)PNR80COR77;
-(CX2)PNR80CONR78R79; -(CX2)PC6H4NR80CONR78R79; or -(CX2)PNR20CO-[(CX2)U- XX]1-CH3 where XX is -O-; -NR20-, or -S-; u is 1-3, and t is 1-6;
R75 is lower alkyl; lower alkenyl; or aryl-lower alkyl;
R33 and R75 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-;
R75 and R82 taken together can form: -(CX2)2.6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or -(CX2)2NR57(CX2)2-;
R76 isH; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CX2)OOR72; -(CX2)OSR72; -(CX2)ONR33R34; -(CX2)0OCONR33R75; -(CX2)oNR20CONR33R82; -(CX2)OCOOR75; -(CX2)OCONR58R59; -(CX2)oPO(OR60)2; -(CX2)PSO2R62; or -(CX2)OCOR64;
Figure imgf000120_0001
Figure imgf000121_0001
H42 H43 H44 H45
Figure imgf000121_0002
H46 H47 H48 H49
Figure imgf000121_0003
H50 H51 H52 H53 H54
R78 is H; lower alkyl; aryl; or aryl-lower alkyl;
R78 and R82 taken together can form: -(CX2)2-6-; -(CX2)2θ(CX2)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-; R79 is H; lower alkyl; aryl; or aryl-lower alkyl; or
R78 and R79, taken together, can be -(CX2)2-7-; -(CX2)2O(CX2)2-; or -(CX2)2NRS7(CX2)2-;
R80 Js H; or lower alkyl; R81 Is H; lower alkyl; or aryl-lower alkyl; R is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl; R33 and R82 taken together can form: -(CX2)2.6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or -(CX2)2NR57(CX2)2-;
R83 is H; lower alkyl; aryl; or -NR78R79; R84 is -(CX2)m(CHR6I)sOH; -(CX2)pCONR78R79; -(CX2)PNR80CONR78R79;
-(CX2)PC6H4CONR78R79; or -(CX2)PC6H4NR80CONR78R79; R85 is lower alkyl; or lower alkenyl;
R86 is H, alkyl; alkenyl; -(CX2)POR85J-(CX2)PSR85
R87 is H; alkyl; alkenyl; heteroaryl, aryl-lower alkyl; -(CX2)POR55; -(CX2)POCONR75R82;
-(CX2)PNR20CONR78R82; -(CX2)PCOOR57, or -(CX2)PPO(OR60)2;
X is H; or optionally halogen;R71 is H; lower alkyl; lower alkenyl; -(CX2)P(CHR61)SOR75; - (CX2)p(CHR61)sSR75;
-(CX2)p(CHR61)sNR33R34; -(CH2)p(CHR61)sOCONR33R75; -(CX2)P(CHR61)SNR20CONR33R82;
-(CX2)0(CHR61)SCOOR75; -(CH2)PCONR58R59; -(CH2)PPO(OR62)2; -(CH2)PSO2R62; or -(CX2)O-C6R67R68R69R70R76; R72 is H; lower alkyl; lower alkenyl; -(CX2)P(CHR86)SOR85; or
-(CX2)p(CHR86)sSR85; R73 is -(CX2)OR77; -(CH2)rO(CH2)oR77; -(CX2)rS(CH2)0R77; or
-(CX2)rNR20(CH2)oR77;
R74 is -(CX2)PNR78R79; -(CX2)PNR77R80; -(CX2)pC(=NR80)NR78R79; - (CX2)pC(=NOR50)NR78R79;
-(CX2)pC(=NNR7SR79)NR78R79; -(CX2)pNR80C(=NR80)NR78R79; -(CX2)pN=C(NR78R80)NR79R80;-(CX2)pC6H4NR78R79; -(CH2)PC6H4NR77R80; -(CX2)PC6H4C(=NR80)NR78R79; -(CX2)PC6H4C(=NOR50)NR78R79; -(CX2)pC6H4C(=NNR7SR79)NR78R79; -(CX2)pC6H4NR80C(=NR80)NR7SR79; -(CX2)pC6H4N=C(NR78R80)NR79R80; -(CH2)rO(CX2)mNR78R79; -
(CH2)rO(CX2)mNR77R80;
-(CX2)rO(CX2)pC(=NR80)NR78R79; -(CX2)rO(CX2)pC(=NOR50)NR78R79; -(CX2)rO(CX2)pC(=NNR78R79)NR7SR79; -(CX2)rO(CH2)mNR80C(=NR80)NR78R79; -(CX2)rO(CX2)mN=C(NR78R80)NR79R80; -(CX2)ACX2)PC6H4CNR78R79; -(CX2)IO(CX2)pC6H4C(=NR80)NR78R79; -(CX2)rO(CX2)pC6H4C(=NOR50)NR78R79;
-(CX2)rO(CX2)pC6H4C(=NNR78R79)NR78R79;
-(CX2)rO(CX2)pC6H4NR80C(=NR80)NR78R79; -(CX2)rS(CX2)mNR78R79; -(CX2)rS(CX2)raNR77RS0;-(CX2)rS(CX2)pC(=NR80)NR78R79; -(CX2)rS(CX2)pC(=NOR50)NR78R79; -(CX2)rS(CX2)pC(=NNR78R79)NR78R79; -(CX2)rS(CX2)mNR80C(=NR80)NR78R79; -(CX2)rS(CX2)raN=C(NR78R80)NR79R80; -(CX2XS(CX2)PC6H4CNR78R79; -(CX2)rS(CX2)pC6H4C(=NR80)NR78R79; -(CX2)rS(CX2)pC6H4C(=NOR50)NR78R79; - (CX2)rS(CX2)pC6H4C(=NNR78R79)NR78R79; -(CX2)rS(CX2)pC6H4NR80C(=NR80)NR78R79; -(CX2)PNR80COR64; - (CX2)PNR80COR77;
-(CX2)PNR80CONR78R79; -(CX2)PC6H4NR80CONR78R79; or -(CX2)PNR20CO-[(CX2)U- X]1-CH3 where X is -O-; -NR20-, or -S-; u is 1-3, and t is 1-6;
R75 is lower alkyl; lower alkenyl; or aryl-lower alkyl; R33 and R75 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-; R75 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-;
R76 isH; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CX2)OOR72; -(CX2)OSR72; -(CX2)ONR33R34; -(CX2)OOCONR33R75; -(CX2)ONR20CONR33R82;
-(CX2)OCOOR75; -(CX2)OCONR58R59; -(CX2)oPO(OR60)2; -(CX2)PSO2R62; or
-(CX2)OCOR64;
R77 is -C6R67R68R69R70R76; or a heteroaryl group of one of the formulae
Figure imgf000123_0001
H1 H2 H3 H4 H5
Figure imgf000123_0002
H6 H7 H8 H9 H10
Figure imgf000123_0003
H11 H12 H13 H14 H15
Figure imgf000124_0001
H16 H17 H18 H19 H20
Figure imgf000124_0002
H21 H22 H23 H24 H25
Figure imgf000124_0003
H26 H27 H28 H29
Figure imgf000124_0004
H30 H31 H32 H33
Figure imgf000124_0005
H34 H35 H36 H37
Figure imgf000124_0006
H38 H39 H40 H41
Figure imgf000124_0007
H42 H43 H44 H45
Figure imgf000125_0001
H46 H47 H48 H49
Figure imgf000125_0002
H50 H51 H52 H53 H54
R78 Is H; lower alkyl; aryl; or aryl-lower alkyl; R78 and R82 taken together can form: -(CX2W; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-; R79 is H; lower alkyl; aryl; or aryl-lower alkyl; or
R78 and R79, taken together, can be -(CX2W; -(CX2)2O(CX2)2-; or -(CX2)2NR57(CX2)2-; Rso is H; or lower alkyl;
R81 is H; lower alkyl; or aryl-lower alkyl;
R82 is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl; R33 and R82 taken together can form: -(CX2W; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or
-(CX2)2NR57(CX2)2-;
R83 is H; lower alkyl; aryl; or -NR78R79; R84 is -(CX2)m(CHR61)sOH; -(CX2)PCONR78R79; -(CX2)PNR80CONR78R79;
-(CX2)PC6H4CONR78R79; or -(CX2)PC6H4NR80CONR78R79; R85 is lower alkyl; or lower alkenyl;
R86 is H, alkyl; alkenyl; -(CX2)POR8V(CX2)PSR85
R87 is H; alkyl; alkenyl; heteroaryl, aryl-lower alkyl; -(CX2)POR55; -(CX2)POCONR75R82;
-(CX2)PNR20CONR78R82; -(CX2)PCOONR57, or -(CX2)PPO(OR60); X is H, or optionally halogen;
with the proviso that in said chain of 12 α-amino acid residues Z the amino acid residues in positions 1 to 12 are:
Pl : of type C or of type D or of type E or of type F, or the residue is Pro; P2: oftype D oroftype E;
P3 : of type C or of type D, or the residue is GIy or Pro;
P4: oftype C or oftype E or oftype F; or the residue is Gly Gly or
Pro; P5: of type E or of type D or of type C, or the residue is GIy or Pro;
P6: of type E or of type F or of type C or of formula -A-CO-, or the residue is GIy or Pro;
P7: of type C or of type E or of type F or of formula -B-CO-;
P8: of type D or of type C, or type F, or the residue is Pro; - P9: of type C or of type E or of type D or of type F;
PlO: of type E;
PI l: of type C or of type F5 or the residue is Pro or GIy ; and
P 12 : of type C or of type D or of type E or of type F, or the residue is Pro; or - P4 and P9 and/or P2 and PIl, taken together, can form a group of type H; and at P6, PlO and PIl also D-isomers being possible; or, alternatively,
Pl: of type C or of type D or of type E or of type F, or the residue is Pro;
P2: of type C or of type F, or the residue is Pro or GIy ;
P3: of type E;
P4: of type C or of type E or of type D or of type F;
P5 : of type D or of type C, or of type F5 or the residue is Pro; - P6: of type C or of type E or of type F or of formula -B-CO-;
P7: of type E or of type F or of type C or of formula -A-CO-, or the residue is GIy or Pro;
P8: of type E or of type D or of type C5 or the residue is GIy or Pro;
P9: of type C or of type E or of type F; - PlO: of type C or of type D, or the residue is GIy or Pro;
PIl: oftype D oroftype E; and
P12: of type C or of type D or of type E or of type F, or the residue is Pro; or
P4 and P9 and/or P2 and PIl5 taken together, can form a group of type H; and at P2, P3 and P7 also D-isomers being possible;
and pharmaceutically acceptable salts thereof.
2. Compounds according to claim I wherein in the claim of 12 α-amino acids residues Z the amino acid residue in position P4 is of type C, or of type E or of type F; P8 is of type D or of type C, or the residue is Pro; and at PlO and Pl 1 also D isomers are possible; or alternatively, the amino acid residue on position P5 is of type D or of type C or the residue is Pro; P9 is of type C or of type E or of type F and at none of the positions Pl to P 12 D-isomers are possible.
3. Compounds according to claims 1 or 2 wherein
Figure imgf000127_0001
is a group of formula (al) or (a2).
4. Compounds according to claim 3 wherein A is a group of one of the formulae Al to A69;
R1 is hydrogen or lower alkyl;
R2 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl); -CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); - (CH2)mOCONR33R75 (where R33 is H; lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)mNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)oN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);
(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2S or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R3 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CBb)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or
R33 and R82 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);
-(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where
R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2^C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). R4 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)r; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)inOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or
R33 and R82 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);
-(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: isH; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2XC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy). R5 is lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); (CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2W; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is alkyl; alkenyl; aryl; aryl- lower alkyl; or heteroaryl-lower alkyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is
H; or lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy):
R6 is H; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)0OCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -
(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2X1C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R7 is lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)qSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CHa)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); - (CH2)qOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)MS -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)qNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2- 6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)qN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)rCOOR57 (where R57 is lower alkyl; or lower alkenyl);
-(CH2)qCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2)2-5-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2^C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)0OCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2.6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);
-(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)OC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); R9 is lower alkyl; lower alkenyl; -(CHa)0OR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -
(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -
(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)oN(R20)COR64(where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)C1C6H4R8 (where R8 is H; F; CI; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R10 is lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H is or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -
(CH2)M-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oN(R20)COR64(where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where
R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2XC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R11 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together ar -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or
R33 and R82 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)r; where R57 is H; or lower alkyl);
-(CH2)mN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);
-(CH2)0COOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR5SR59 (where
R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2.6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); R12 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)M-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)inOCONR33R75 (where R33is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or - (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);
-(CH2)rCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)rCONR58R59 (where
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)rPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2^C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy): R13 is lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55 isis lower alkyl; or lower alkenyl);
-(CH2)qSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -
(CH2)2-5-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)qOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CHz)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)qNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are - (CH2)2.6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)qN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)rCOOR57 (where R57 is lower alkyl; or lower alkenyl); - (CH2)qCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2^C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R14 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl);
~(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)JSIR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are - (CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl is R82: H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is H; lower alkyl; R64 is lower alkyl; or lower alkenyl);
-(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)(JC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R15 is lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl); -(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are
-(CHb)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2J2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -NR20COlower alkyl (R20=H; or lower alkyl); being particularly favoured;
-(CH2)0COOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where
R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl);
-(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or (CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); R16 is lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -
(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CHz)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R is H; or lower alkyl; or R and R taken together are
-(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)0CONR58R59 (where R5S is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken together are -(CHz)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); and
R17 is lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)qSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)M-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)qOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)qNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2. 6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)qN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)rCOOR57 (where R57 is lower alkyl; or lower alkenyl); - (CH2)qCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2^C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
5. Compounds according to claim 3 or 4 wherein A is a group of one of the formulae A5 (with R2 being H); A8; A22; A25; A38 (with R2 being H); A42; and A50.
6. Compounds according to claim 5 wherein A is a group of formula
Figure imgf000137_0001
A81 wherein R20 is H or lower alkyl; and R64 is alkyl; alkenyl; aryl; aryl-lower alkyl; or heteroaryl-lower alkyl.
7. Compounds according to claim 6 wherein R64 is n-hexyl; n-heptyl; A- (phenyl)benzyl; diphenylmethyl, 3-amino-propyl; 5-amino-pentyl; methyl; ethyl; isopropyl; isobutyl; n-propyl; cyclohexyl; cyclohexylmethyl; n-butyl; phenyl; benzyl; (3- indolyl)methyl; 2-(3-indolyl)ethyl; (4-phenyl)phenyl; or n-nonyl.
8. Compounds according to claim 3 wherein A is a group of one of the formulae A70 to A104;
R20 is H; or lower alkyl;
R18 is lower alkyl;
R19 is lower alkyl; lower alkenyl; -(CH2)POR55 (where R55 is lower alkyl; or lower alkenyl); -(CH2)PSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are
-(CH2)M-; -(CH2)2O(CH2)r;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)POCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -
(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)PN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); (CH2)PCOOR57 (where R57: lower alkyl; or lower alkenyl); (CH2)PCONR58R59
(where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R5S and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)PSO2R62 (where R62 is lower alkyl; or lower alkenyl); or (CH2)OC6H4R8
(where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R21 is H; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl); -(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -
(CH2)2.6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl) ;
-(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)r; where R57 is H; or lower alkyl);
-(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)0N(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -
(CH2)0CONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CHOqC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); R22 is lower alkyl; lower alkenyl; -(CH2)0OR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)0OCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-
6-; -(CH2)2O(CH2)2s -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oN(R20)COR64(where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl);
-(CH2)OCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl);
-(CH2)oSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)C1C6H4R8 (where R8 is H; F; Cl; CF; lower alkyl; lower alkenyl; or lower alkoxy); R23 is H; lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -
(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-
6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -NR20COlower alkyl (R20=H; or lower alkyl) being particularly favoured; -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where
R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where
R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl);
-(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2^C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R24 is lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -
(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CHj)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are
-(CEb)2-6-; -(CHj)2O(CHa)2S
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -NR20COlower alkyl (R20=H ; or lower alkyl) being particularly favoured;
-(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where
R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)WS -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2s where
R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2^C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R25 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2.6-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mOCONR33R75 (where R33 is
H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CK2U-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or
R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)0COOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-;
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC5H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R26 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or
R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2)M-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and RS2 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)0COOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); or, alternatively, R25 and R26 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR34(CH2)2-;
R27 is H; lower alkyl; lower alkenyl; -(CH2)0OR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are
-(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -
(CH2)2-6-; -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl);
-(CH2)OCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);
R28 is lower alkyl; lower alkenyl; -(CH2)OOR55 (where R55 is lower alkyl; or lower alkenyl); -(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -
(CH2)W-; -(CH2)2O(CH2)r;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CHz)2-6-; -(CH2)2O(CH2)r; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2.
6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl);
-(CH2)OCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl);
-(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); and
R29 is lower alkyl; lower alkenyl; -(CH2)0OR55 (where R55 is lower alkyl; or lower alkenyl); -(CH2)OSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)ONR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -
(CH2)WS -(CH2)2O(CH2)2-;
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are
-(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-
6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -NR20COlower-alkyl (R20=H; or lower alkyl) being particularly favoured; -(CH2)0COOR57 (where R57 is lower alkyl; or lower alkenyl);
-(CH2)oCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)M-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl);
-(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2^C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
9. Compounds according to claim 8 wherein R23, R24 and R29 are -NR20-CO-lower alkyl where R20 is H; or lower alkyl.
10. Compounds according to claim 8 or 9 wherein A is a group of one of the formulae A74 (with R22 being H); A75; A76; KIl (with R22 being H); A78; and A79.
11. Compounds according to any one of claims 3 to 10 wherein B is a group of formula
-NR20CH(R71)- or an enantiomer of one of the groups A5 (with R2 being H); A8; A22; A25; A38 (with R2 being H); A42; A47; and A50.
12. Compounds according to claim 11 wherein B-CO is Ala; Arg; Asn; Cys; GIn; GIy; His; He; Leu; Lys; Met; Phe; Pro; Ser; Thr; Trp; Tyr; VaI; Cit; Orn; tBuA; Sar; t-BuG; 4AmPhe; 3AmPhe; 2AmPhe; Phe(mC(NH2)=NH; Phe(pC(NH2)=NH; Phe(niNHC (NH2)=NH; Phe(pNHC (NH2)=NH; Phg; Cha; C4al; C5al; NIe; 2-Nal; 1-Nal; 4C1-Phe; 3C1-Phe; 2C1-Phe; 3,4Cl2Phe; 4F-Phe; 3F-Phe; 2F-Phe; Tic; Thi; Tza; Mso; AcLys; Dpr; A2Bu; Dbu; Abu; Aha; Aib; Y(BzI); Bip; S(BzI); T(BzI); hCha; hCys; hSer, hArg; hPhe; Bpa; Pip; OctG; MePhe; MeNIe; MeAIa; MeIIe; MeVaI; or MeLeu.
13. Compounds according to claim 11 or 12 wherein B is a group, having (L)- configuration, of formula
Figure imgf000144_0001
A8" wherein R20 is H; or lower alkyl; and R64 is alkyl; alkenyl; aryl; aryl-lower alkyl; or heteroaryl-lower alkyl.
14. Compounds according to claim 13 wherein R64 is n-hexyl; n-heptyl; 4- (phenyl)benzyl; diphenylmethyl, 3-amino-propyl; 5-amino-pentyl; methyl; ethyl; isopropyl; isobutyl; n-propyl; cyclohexyl; cyclohexylmethyl; n-butyl; phenyl; benzyl; (3- indolyl)methyl; 2-(3-indolyl)ethyl; (4-phenyl)phenyl; or n-nonyl.
15. Compounds according to claim 1 wherein
Figure imgf000145_0001
is a group of formula (bl) or (cl);
R1 is H; or lower alkyl;
R20 is H; or lower alkyl; R30 is H; or methyl;
R31 is H; lower alkyl; lower alkenyl; -(CH2)POR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)pNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or
R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)POCONR33R75 (where R33 is
H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -
(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)PN(R20)COR64 (where: R20 is
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)0COOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2XC6EjR8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); most preferably -CH2CONR58R59 (where R58 is H; or lower alkyl; and R59 is lower alkyl; or lower alkenyl); R32 is H; or methyl; R33 is lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)mNR34R63 (where R34 is lower alkyl; or lower alkenyl; R63 is H; or lower alkyl; or R34 and R63 taken together are -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mOCONR75R82 (where R75 is lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R75 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR78R82 (where R20 is H; or lower alkyl; R78 is H; or lower alkyl ; or lower alkenyl; R82 is H; or lower alkyl; or R78 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is H; or tower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2W; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);
R34 is H; or lower alkyl;
R33: isH; lower alkyl; lower alkenyl; (CH2)mOR55 (where R55: lower alkyl; or lower alkenyl);
-(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)JS[R20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)0COOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
R36: lower alkyl; lower alkenyl; or aryl-lower alkyl;
R37 is H; lower alkyl; lower alkenyl; -(CH2)POR55 (where R55 is lower alkyl; or lower alkenyl);
-(CH2)PNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);- (CH2)POCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)PN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2.β-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)OSO2R62 (where R62 is lower alky; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); and
R38 is H; lower alkyl; lower alkenyl; -(CH2)POR55 (where R55 is lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together sre -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)POCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are - (CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)PNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2.6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)r; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)PN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)OCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)0SO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2X1C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).
16. Compounds according to claim 15 wherein R1 is H; R20 is H; R30 is H; R31 is carboxymethyl; or lower alkoxycarbonylmethyl; R32 is H; R35 is methyl; R36 is methoxy; R37 is H and R38 is H.
17. Compounds according to any one of claims 1 to 16 wherein the α-amino acid residues in positions 1 to 12 of the chain Z are:
Pl : of type C or of type D or of type E or of type F; - P2: of type D;
P3: of type C, or the residue is GIy or Pro;
P4: of type C or of type E or of type F, or the residue is GIy or Pro;
P5: of type E, or the residue is GIy or Pro;
P6: oftype E or of type F or of formula -A-CO-, or the residue is GIy or Pro;
P7: of type C or oftype E or of type F or of formula -B-CO-;
P8: of type D, or of type F;
P9: of type E or of type F or of type C;
PlO: of type E; - PI l: of type F or of type C, or the residue is GIy or Pro; and
P12: of type C or of type D or of type E, or of type F; or
P4 and P9 and/or P2 and PI l , taken together, can form a group of type
H; and at P6, PlO and PIl also D-isomers being possible; or, alternatively,
Pl : of type C or of type D or of type E, or of type F;
P2: of type F or of type C, or the residue is GIy or Pro;
P3: of type E;
P4: of type E or of type F or of type C; - P5: of type D, or of Type F; P6: of type C or of type E or of type F or of formula -B-CO-;
P7 : of type C or of type F or of formula -A-CO-, or the residue is
GIy or Pro;
P8: of type E, or the residue is GIy or Pro; P9 : of type C or of type E or of type F, or the residue is GIy or Pro;
PlO: of type C, or the residue is GIy or Pro; PI l: oftype D; and
P12: of type C or of type D or of type E or of type F; or P4 and P9 and/or P2 and PI l , taken together, can form a group of type H; and at P2, P3, and P7 also D-isomers being possible.
18. Compounds according to claim 16 wherein the α-amino acid residues in positions 1 to 12 of the chain Z are: - Pl: Ala, Cit, Thr, Thr, Asp, GIu;
P2: Trp, Tyr;
P3: Ile, Val, Nle, Chg, Cha;
P4: Dab, Lys, GIn;
P5: Lys, Dab, Orn; - P6: Dab, DDab; Lys;
P7: His, Lys, GIn, Dab;
P8: Tyr, Trp, Ser;
P9 Dab, Lys;
PlO: Dab, Lys; - PI l: Ala, Abu, Thr, GIy, Pro, Hse, He, Nva, DAla, DVal, Aib, NIe,
Chg, Cha, GIn, Asp, GIu, Cpa, t-BuG, Leu, VaI, Asn;
P12: Dab, Lys, GIn, Ser;
19. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: He;
P4: Dab; - P5: Lys; P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab; i - PlO: Dab;
PIl: Ala; and
P12: Dab
20. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: He;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PI l: GIy; and
P12: Dab
,
21. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are: Pl: Thr;
P2: Trp;
P3: He;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab; PlO: Dab; PI l: Abu; and P12: Dab
22. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: He;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Thr; and
P 12: Dab
23. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Tyr;
P3: lie;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: Dab
24. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Ala;
P2: Trp; - P3:l Ie;
P4: Dab
P5: Lys;
P6: Dab;
P7: Dab; - P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: Dab
25. A compound of formula I according to claim 1 wherein the template is Pro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: He;
P4: Lys;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: Dab
26. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr; - P2: Trp; P3: He;
P4: Dab;
P5: Lys;
P6: Lys; i - P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Ala; and
) - P12: Dab
27. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: lie;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: Lys
28. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr; - P2: Trp;
P3: He;
P4: GIn;
P5: Lys;
P6: Dab; - P7: Dab; P8: Tip;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: Dab
29. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: VaI;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: TΦ;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: Dab
30. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: He;
P4: Dab;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PIl: Hse; and P12: Dab
31. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: He;
P4: GIn;
P5: Lys;
P6: Dab;
P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: GIn
32. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: GIu;
P2: Trp;
P3: lie;
P4: Dab;
P5: Lys;
P6: DDab;
P7: Dab;
P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: GIn
33. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: Thr;
P2: Trp;
P3: He; P4: Dab;
P5: Orn;
P6: DDab;
P7: Dab; - P8: Trp;
P9: Dab;
PlO: Dab;
PI l: Ala; and
P12: Ser
34. A compound of formula I according to claim 1 wherein the template is DPro-LPro and the amino acid residues in position 1 - 12 are:
Pl: GIu;
P2: Trp; - P3: He;
P4: GIn;
P5: Lys;
P6: Dab;
P7: Dab; - P8: Ser;
P9: Dab;
PlO: Dab;
PIl: Ala; and
P12: Ser
35. Enantiomers of the compounds of formula I as defined in claim 1.
36. Compounds according to any one of claims 1 to 35 for use as therapeutically active substances.
37. Compounds according the claims 36 having selective antimicrobial activity being in particular against Pseudomonas aeruginosa.
38. A pharmaceutical composition containing a compound according to any one of claims 1 to 35 and a pharmaceutically inert carrier.
39. Compositions according to claim 38 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary or inhalation administration.
40. Compositions according to claim 38 or 39 in form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.
41. The use of compounds according to any one of claims 1 to 35 for the manufacture of a medicament for treating or preventing infections or diseases related to such infections.
42. The use according to claim 41 wherein said infections are related to respiratory diseases such as cystic fibrosis, emphysema and asthma; related to skin or soft tissue diseases such as surgical wounds, traumatic wounds or burn wounds; related to gastrointestinal diseases such as epidemic diarrhea, necrotizing enterocolitis or typhlitis; related to eye diseases such as keratitis or endophthalmitis; related to ear diseases such as otitis; related to CNS diseases such as brain abscess or meningitis; related to bone diseases such as osteochondritis or osteomyelitis; related to cardiovascular diseases such as endocartitis or pericarditis; related to gastrourinal diseases such as epididymitis, prostatitis or urethritis; related to cancer; or related to HIV.
43. The use of compounds according to any one of claims 1 to 35 as disinfectants or preservatives for foodstuffs, cosmetics, medicaments and other nutrient-containing materials.
44. A process for the manufacture of compounds according to any one of claims 1-34 which process comprises
(a) coupling an appropriately functionalized solid support with an appropriately N- protected derivative of that amino acid which in the desired end-product is in position 5, 6 or 7, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(b) removing the N-protecting group from the product thus obtained;
(c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position nearer the N-terminal amino acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(d) removing the N-protecting group from the product thus obtained;
(e) repeating steps (c) and (d) until the N-terminal amino acid residue has been introduced;
(f) coupling the product thus obtained with a compound of the general formula
Figure imgf000158_0001
wherein
Figure imgf000158_0002
is as defined in claim 1 and X is an N-protecting group or, if
Figure imgf000158_0003
is to be group (al) or (a2), as defined in claim 1, alternatively
(fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula
HOOC-B-H III or HOOC-A-H IV wherein B and A are as defined in claim 1, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected; (fb) removing the N-protecting group from the product thus obtained; and
(fc) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, HI, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected; (g) removing the N-protecting group from the product obtained in step (f) or (fc);
(h) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected; y
(i) removing the N-protecting group from the product thus obtained;
(j) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(k) removing the N-protecting group from the product thus obtained;
(1) repeating steps Q) and (k) until all amino acid residues have been introduced; (m) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
(o) detaching the product thus obtained from the solid support;
(p) cyclizing the product cleaved from the solid support;
(q) if desired, forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β-strand region;
(r) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule; and
(s) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.
45. A process for the manufacture of compounds according to any one of claims 1-34 which process comprises
(a1) coupling an appropriately functionalized solid support with a compound of the general formula
Figure imgf000159_0001
wherein
Figure imgf000159_0002
is as defined in claim 1 and X is an N-protecting group or, if
Figure imgf000160_0001
is to be group (al) or (a2), as defined in claim 1, alternatively (a'a) coupling said appropriately functionalized solid support with an appropriately N-protected derivative of an amino acid of the general formula
HOOC-B-H III or HOOC-A-H IV wherein B and A are as defined in claim 1, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(a'b) removing the N-protecting group from the product thus obtained; and (a'c) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, IH, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(b1) removing the N-protecting group from the product obtained in step (a1) or (a'c); (c1) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(d!) removing the N-protecting group from the product thus obtained; (e1) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
(f ) removing the N-protecting group from the product thus obtained; (g?) repeating steps (e1) and (f ) until all amino acid residues have been introduced; (h1) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated; (i1) detaching the product thus obtained from the solid support; (j1) cyclizing the product cleaved from the solid support; (k1) if desired forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β-strand region; (I1) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule; and
(m1) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.
46. A modification of the process of claim 44 or 45 for the manufacture of compounds according to claim 35 in which enantiomers of all chiral starting materials are used.
PCT/CH2007/000017 2006-01-16 2007-01-15 Template-fixed peptidomimetics with antimicrobial activity WO2007079605A2 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
ES07700115T ES2381846T3 (en) 2006-01-16 2007-01-15 Peptidomimetics attached to a matrix
AT07700115T ATE538131T1 (en) 2006-01-16 2007-01-15 STENCIL-FIXED PEPTIDOMIMETICS
CA2637377A CA2637377C (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics
KR1020087020026A KR101352829B1 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics with antimicrobial activity
PL07700115T PL1979374T3 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics
AU2007204547A AU2007204547B2 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics with antimicrobial activity
US12/161,065 US8685922B2 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics with antimicrobial activity
JP2008549738A JP5237826B2 (en) 2006-01-16 2007-01-15 Template-immobilized peptide mimetic
BRPI0707144-2A BRPI0707144B1 (en) 2006-01-16 2007-01-15 COMPOUNDS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS, AND PROCESS FOR THE MANUFACTURE OF COMPOUNDS
EA200801710A EA015991B1 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics
CN2007800080521A CN101395173B (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics with antimicrobial activity
SI200730882T SI1979374T1 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics
DK07700115.4T DK1979374T3 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics
NZ570245A NZ570245A (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics with antimicrobial activity
EP07700115A EP1979374B1 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics
IL192816A IL192816A (en) 2006-01-16 2008-07-15 Template-fixed peptidomimetics, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
NO20083485A NO341875B1 (en) 2006-01-16 2008-08-12 Template-fixed peptide mimics
HK09105497.8A HK1127957A1 (en) 2006-01-16 2009-06-19 Template-fixed peptidomimetics with antimicrobial activity
US14/074,251 US9521846B2 (en) 2006-01-16 2013-11-07 Template-fixed peptidomimetics with antimicrobial activity
US14/175,160 US9538752B2 (en) 2006-01-16 2014-02-07 Template-fixed peptidomimetics with antimicrobial activity
US14/175,193 US9596852B2 (en) 2006-01-16 2014-02-07 Template-fixed peptidomimetics with antimicrobial activity
US15/392,586 US10730912B2 (en) 2006-01-16 2016-12-28 Template-fixed peptidomimetics with antimicrobial activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CH2006/000036 WO2007079597A1 (en) 2006-01-16 2006-01-16 Template - fixed peptidomimetics with antimicrobial activity
CHPCT/CH2006/000036 2006-01-16

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US12/161,065 A-371-Of-International US8685922B2 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics with antimicrobial activity
US14/074,251 Division US9521846B2 (en) 2006-01-16 2013-11-07 Template-fixed peptidomimetics with antimicrobial activity
US14/175,160 Division US9538752B2 (en) 2006-01-16 2014-02-07 Template-fixed peptidomimetics with antimicrobial activity
US14/175,193 Division US9596852B2 (en) 2006-01-16 2014-02-07 Template-fixed peptidomimetics with antimicrobial activity

Publications (2)

Publication Number Publication Date
WO2007079605A2 true WO2007079605A2 (en) 2007-07-19
WO2007079605A3 WO2007079605A3 (en) 2007-08-30

Family

ID=36992526

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CH2006/000036 WO2007079597A1 (en) 2006-01-16 2006-01-16 Template - fixed peptidomimetics with antimicrobial activity
PCT/CH2007/000017 WO2007079605A2 (en) 2006-01-16 2007-01-15 Template-fixed peptidomimetics with antimicrobial activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CH2006/000036 WO2007079597A1 (en) 2006-01-16 2006-01-16 Template - fixed peptidomimetics with antimicrobial activity

Country Status (21)

Country Link
US (5) US8685922B2 (en)
EP (1) EP1979374B1 (en)
JP (1) JP5237826B2 (en)
KR (1) KR101352829B1 (en)
CN (2) CN102796179B (en)
AT (1) ATE538131T1 (en)
AU (1) AU2007204547B2 (en)
CA (1) CA2637377C (en)
CY (1) CY1117252T1 (en)
DK (1) DK1979374T3 (en)
EA (1) EA015991B1 (en)
ES (1) ES2381846T3 (en)
HK (2) HK1127957A1 (en)
IL (1) IL192816A (en)
NO (1) NO341875B1 (en)
NZ (1) NZ570245A (en)
PL (1) PL1979374T3 (en)
PT (1) PT1979374E (en)
SI (1) SI1979374T1 (en)
WO (2) WO2007079597A1 (en)
ZA (1) ZA200806564B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012016595A1 (en) 2010-08-05 2012-02-09 Polyphor Ag β-HAIRPIN PEPTIDOMIMETICS
WO2014023757A1 (en) 2012-08-08 2014-02-13 Polyphor Ag Combinations with a backbone-cyclized peptide
WO2014161781A1 (en) * 2013-03-30 2014-10-09 Polyphor Ag Beta-hairpin peptidomimetics
CN104684924A (en) * 2012-08-08 2015-06-03 波利弗尔股份公司 Combinations with a backbone-cyclized peptide
US20160060298A1 (en) * 2013-03-30 2016-03-03 Polyphor Ag Beta-hairpin peptidomimetics
WO2016050360A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
WO2016050361A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
WO2016150576A1 (en) 2015-03-23 2016-09-29 Polyphor Ag Beta-hairpin peptidomimetics
WO2019091601A1 (en) 2017-11-10 2019-05-16 Polyphor Ag Beta-hairpin peptidomimetics
WO2022106063A2 (en) 2020-11-23 2022-05-27 Polyphor Ag Compositions of a beta-hairpin peptidomimetic and aerosol dosage forms thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556747A (en) * 2005-02-17 2009-09-25 Polyphor Ltd Template-fixed beta-hairpin peptidomimetics with protease inhibitory acitivity
WO2007079597A1 (en) 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
CA2676865C (en) 2007-01-29 2018-09-25 Polyphor Ltd. Template - fixed peptidomimetics
EA017583B1 (en) 2007-02-28 2013-01-30 Полифор Лтд. Template-fixed peptidomimetics
WO2010015287A2 (en) * 2008-08-08 2010-02-11 Polyphor Ag Template-fixed peptidomimetics
US8541556B1 (en) 2012-03-02 2013-09-24 Empire Technology Development Llc Lignin derivatives and uses thereof
US9095142B2 (en) 2012-06-28 2015-08-04 Empire Technology Development Llc Lignin derivatives having polycations and uses thereof
US9688723B2 (en) * 2012-11-08 2017-06-27 Phi Pharma Sa C4S proteoglycan specific transporter molecules
CN104478993B (en) * 2013-06-20 2017-10-10 重庆理工大学 A kind of non-protein amino acid antibacterial peptide and its application
CN104371002B (en) * 2013-06-20 2017-10-10 重庆理工大学 A kind of non-protein amino acid antibacterial peptide and its application
CN103319568B (en) * 2013-06-20 2015-01-21 重庆理工大学 Non-protein amino acid antibacterial peptide and application for same
CN112457314A (en) * 2020-11-19 2021-03-09 烟台大学 Chiral indoloindolizidine compound and preparation method thereof
CN112876537B (en) * 2021-01-29 2022-01-04 西南科技大学 Method for enriching and purifying cyclopeptide Xylastrimide A from xylaria longilineans

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916872A (en) 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
WO2002070547A1 (en) 2001-02-23 2002-09-12 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
WO2004018503A1 (en) 2002-08-20 2004-03-04 Polyphor Ltd. Template-fixed peptidomimetics with antibacterial activity
WO2004033489A1 (en) 2002-10-02 2004-04-22 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
WO2001016161A1 (en) * 1999-08-30 2001-03-08 Universität Zürich SYNTHESIS OF TEMPLATE-FIXED β-HAIRPIN LOOP MIMETICS
CN101157924A (en) * 2001-12-11 2008-04-09 人体基因组科学有限公司 Neutrophil leukocyte gene alpha
US7855179B2 (en) 2002-10-02 2010-12-21 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
AU2003232253A1 (en) * 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
US7838496B2 (en) * 2003-05-02 2010-11-23 Polyphor Ag/Ltd. Template-fixed peptidomimetics as medicaments against HIV and cancer
CA2545590C (en) 2003-11-15 2013-08-20 Polyphor Ltd. Template fixed beta-hairpin loop mimetics and their use in phage display
NZ556747A (en) * 2005-02-17 2009-09-25 Polyphor Ltd Template-fixed beta-hairpin peptidomimetics with protease inhibitory acitivity
WO2006117011A1 (en) 2005-05-02 2006-11-09 Polyphor Ltd. Dye conjugates of template-fixed peptidomimetics
WO2007079597A1 (en) 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
CA2676865C (en) 2007-01-29 2018-09-25 Polyphor Ltd. Template - fixed peptidomimetics
EA017583B1 (en) 2007-02-28 2013-01-30 Полифор Лтд. Template-fixed peptidomimetics
WO2010015287A2 (en) 2008-08-08 2010-02-11 Polyphor Ag Template-fixed peptidomimetics
WO2010060479A1 (en) 2008-11-26 2010-06-03 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
WO2010127704A1 (en) 2009-05-07 2010-11-11 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
CN102471349B (en) 2009-08-05 2016-08-24 波利弗尔股份公司 Conformationally constrained, fully synthetic macrocyclic compounds
WO2011060832A1 (en) 2009-11-20 2011-05-26 Polyphor Ag Template-fixed peptidomimetics with ccr10 antagonistic activity
US8716242B2 (en) 2009-12-04 2014-05-06 Polyphor Ag β-hairpin peptidomimetics
AU2010344997B2 (en) 2010-02-05 2015-09-10 Polyphor Ag Template - fixed peptidomimetics with CXCR7 modulating activity
WO2011095218A1 (en) 2010-02-05 2011-08-11 Polyphor Ag Template-fixed pep tidomime tics with cxcr7 modulating activity
WO2012016595A1 (en) 2010-08-05 2012-02-09 Polyphor Ag β-HAIRPIN PEPTIDOMIMETICS
ES2552944T3 (en) 2011-06-07 2015-12-03 Polyphor Ag Beta fork peptidomimetics as CXCR4 antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916872A (en) 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
WO2002070547A1 (en) 2001-02-23 2002-09-12 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
WO2004018503A1 (en) 2002-08-20 2004-03-04 Polyphor Ltd. Template-fixed peptidomimetics with antibacterial activity
WO2004033489A1 (en) 2002-10-02 2004-04-22 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity

Non-Patent Citations (60)

* Cited by examiner, † Cited by third party
Title
"Approved standard M7-A3", 1993, NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS, article "Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically"
A. AUMELAS, M. MANGONI, C. ROUMESTAND, L. CHICHE, E. DESPAUX, G. GRASSY, B. CALAS, A. CHAVANIEU, A., EUR. J. BIOCHEM., vol. 237, 1996, pages 575 - 583
A. TOSSI, L. SANDRI, A. GIANGASPERO, A., BIOPOLYMERS, vol. 55, 2000, pages 4 - 30
A. TOSSI, L. SANDRI, A. GIANGASPERO, BIOPOLYMERS, vol. 55, 2000, pages 4 - 30
BARLOS ET AL., TETRAHEDRON LETT., vol. 30, 1989, pages 3943 - 3946
BERRIDGE MV, TAN AS, ARCHIVES OF BIOCHEMISTRY & BIOPHYSICS, vol. 303, 1993, pages 474 - 482
C. A. DEMKO, P. J. BIARD, P. B. DAVIES, J. CLIN. EPIDEMIOL., vol. 48, 1995, pages 1041 - 1049
C. MCINNES, L. H. KONDEJEWSKI, R. S. HODGES, B. D. SYKES, J. BIOL. CHEM., vol. 275, 2000, pages 14287 - 14294
CARPINO ET AL., TETRAHEDRON LETT., vol. 35, 1994, pages 2279 - 2281
CASTRO ET AL., TETRAHEDRON LETT., vol. 14, 1975, pages 1219 - 1222
COSTE ET AL., TETRAHEDRON LETT., vol. 31, 1990, pages 205 - 208
D, OBRECHT, M. ALTORFER, J. A. ROBINSON, ADV. MED. CHEM., vol. 4, 1999, pages 1 - 68
E. M. KEREM, R. GOLD, H. LEVINSON, J. PEDIATR., vol. 116, 1990, pages 714 - 719
FIELDS, G. B., FIELDS, C. G., J. AM. CHEM. SOC., vol. 113, 1991, pages 4202 - 4207
FINGL ET AL.: "The Pharmacological Basis of Therapeutics", 1975, pages: 1
FLORSHEIMER, RINIKER, PEPTIDES, vol. 1990, 1991, pages 131
H. BREITHAUPT, NAT. BIOTECHNOL., vol. 17, 1999, pages 1165 - 1169
H. TAMAMURA, R. IKOMA, M. NIWA, S. FUNAKOSHI, T. MURAKAMI, N. FUJII, CHEM. PHARM. BULL., vol. 41, 1993, pages 978 - 980
H. TAMAMURA, T. MURAKAMI, S. NORIUCHI, K. SUGIHARA, A. OTAKA, W. TAKADA, T. IBUKA, M. WAKI, N. TAMAMOTO, N. FUJII, CHEM. PHARM. BULL., vol. 43, 1995, pages 853 - 858
H. W. HUANG, BIOCHEMISTRY, vol. 39, 2000, pages 8347 - 8352
J. A. ROBINSON, SYN. LETT., vol. 4, 2000, pages 429 - 441
J. CHEN, T. J. FALLA, H. J. LIU, M. A. HURST, C. A. FUJII, D. A. MOSCA, J. R. EMBREE, D. J. LOURY, P. A. RADEL, C. C. CHANG, BIOPOLYMERS, vol. 55, 2000, pages 88 - 98
J. P. TAM, C. WU, J.-L. YANG, EUR. J. BIOCHEM., vol. 267, 2000, pages 3289 - 3300
J. P. TAM, Y.-A. LU, J.-L. YANG, BIOCHEMISTRY, vol. 39, 2000, pages 7159 - 7169
J.-P. TAM, C. WU, J.-L. YANG, EUR. J. BIOCHEM., vol. 267, 2000, pages 3289 - 3300
J.-P. TAM, Y.-A. LU, J.-L. YANG, BIOCHEMISTRY, vol. 39, 2000, pages 7159 - 7169
K. KAWANO, T. YONEYA, T. MIYATA, K. YOSHIKAWA, F. TOKUNAGA, Y. TERADA, S. J. IWANAGA, S., J. BIOL. CHEM., vol. 265, 1990, pages 15365 - 15367
KAISER ET AL., ANAL. BIOCHEMISTRY, vol. 34, 1970, pages 595
KNORR ET AL., TETRAHEDRON LETT., vol. 30, 1989, pages 1927 - 1930
KONIG, GEIGER, CHEM. BER, vol. 103, 1970, pages 788 - 798
L. H. KONDEJEWSKI, M. JELOKHANI-NIARAKI, S. W. FARMER, B. LIX, M. KAY, B. D. SYKES, R. E. HANCOCK, R. S. HODGES, J. BIOL. CHEM., vol. 274, 1999, pages 13181 - 13192
L. H. KONDEJEWSKI, S. W. FARMER, D. S. WISHART, R. E. HANCOCK, R. S. HODGES, INT. J. PEPTIDE PROT. RES., vol. 47, 1996, pages 460 - 466
L. JIANG, K. MOEHLE, B. DHANAPAL, D. OBRECHT, J. A. ROBINSON, HELV. CHIM. ACTA., vol. 83, 2000, pages 3097 - 3112
L. SAIMAN, S. TABIBI, T. D. STARNER, P. SAN GABRIEL, P. L. WINOKUR, H. P. JIA, P. B. MCGRAY, JR., B. F. TACK, ANTIMICROB. AGENTS AND CHEMOTHER., vol. 45, 2001, pages 2838 - 2844
M. E. MANGONI, A. AUMELAS, P. CHAMET, C. ROUMESTAND, L. CHICHE, E. DESPAUX, G. GRASSY, B. CALAS, A. CHAVANIEU, FEBS LETT., vol. 383, 1996, pages 93 - 98
M. WU, E. MAIER, R. BENZ, R. E. HANCOCK, BIOCHEMISTRY, vol. 38, 1999, pages 7235 - 7242
MEIENHOFER ET AL., INT. J. PEPTIDE PROTEIN RES., vol. 13, 1979, pages 35 - 42
MOSSMAN T., J IMMUNOL METH, vol. 65, 1983, pages 55 - 63
N. SITARAM, R. NAGARAIJ, BIOCHEM. BIOPHYS. RES. COMM., vol. 267, 2000, pages 783 - 790
N. SITARAM, R. NAGARAJ, BIOCHIM. BIOPHYS. ACTA, vol. 1462, 1999, pages 29 - 54
OBRECHT, D., VILLALGORDO, J.-M: "Tetrahedron Organic Chemistry Series", vol. 17, 1998, PERGAMON, ELSEVIER SCIENCE, article "Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries"
R. E. W. HANCOCK, R. LEHRER, TRENDS BIOTECHNOL., vol. 16, 1998, pages 82 - 88
R. I. LEHRER, A. K. LICHTENSTEIN, T. GANZ, ANNU. REV. IMMUNOL., vol. 11, 1993, pages 105 - 128
R. L. FAHRNER, T. DIECKMANN, S. S. L. HARWIG, R. I. LEHRER, D. EISENBERG, J. FEIGON, J., CHEM. BIOL., vol. 3, 1996, pages 543 - 550
R. M. EPAND, H. J. VOGEL, BIOCHIM. BIOPHYS. ACTA, vol. 1462, 1999, pages 11 - 28
RINK H, TETRAHEDRON LETT., vol. 28, 1987, pages 3783 - 3790
RINK LINKER, RINK, H., TETRAHEDRON LETT., vol. 28, 1987, pages 3787 - 3790
S. E. HULL, R. KARLSSON, P. MAIN, M. M. WOOLFSON, E. J. DODSON, NATURE, vol. 275, 1978, pages 206 - 275
S. L. HARWIG, A. WARING, H. J. YANG, Y. CHO, L. TAN, R. I. LEHRER, R. J., EUR. J. BIOCHEM., vol. 240, 1996, pages 352 - 357
S. THENNARASU, R. NAGARAJ, BIOCHEM. BIOPHYS. RES. COMM., vol. 254, 1999, pages 281 - 283
SARANTAKIS ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 73, 1976, pages 336 - 342
SASRINR LINKER, MERGLER ET AL., TETRAHEDRON LETT., vol. 29, 1988, pages 4005 - 4008
SHEEHAN, HESS, J. AM. CHEM. SOC., vol. 77, 1955, pages 1067 - 1068
SYNTHESIS, 1976, pages 751 - 752
T. GANZ, R. I. LEHRER, MOL. MEDICINE TODAY, vol. 5, 1999, pages 292 - 297
T. NAKAMURA, H. FURUNAKA, T. MIYATA, F. TOKUNAGA, T. MUTA, S. IWANAGA, M. NIWA, T. TAKAO, Y. SHIMONISHI, Y. J. BIOL. CHEM., vol. 263, 1988, pages 16709 - 16713
V. N.. M., O. V. SHAMOVA, H. A. KOMEVA, R. I. LEHRER, FEBS LETT., vol. 327, 1993, pages 231 - 236
W. T. HELLER, A. J. WARING, R. I. LEHRER, W. HUANG, BIOCHEMISTRY, vol. 37, 1998, pages 17331 - 17338
Y.H. YAU, B. HO, N.S. TAN, M.L. NG, J.L. DING, ANTIMICROB. AGENTS AND CHEMOTHER., vol. 45, 2001, pages 2820 - 2825
Y.-Q. TANG, J. YUAN, G. OSAPAY, K. OSAPAY, D. TRAN, C. J. MILLER, A. J. OELLETTE, M. E. SELSTED, SCIENCE, vol. 286, 1999, pages 498 - 502

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012016595A1 (en) 2010-08-05 2012-02-09 Polyphor Ag β-HAIRPIN PEPTIDOMIMETICS
AU2013301576B2 (en) * 2012-08-08 2017-10-19 Polyphor Ag Combinations with a backbone-cyclized peptide
US9775877B2 (en) * 2012-08-08 2017-10-03 Polyphor Ag Combinations with a backbone-cyclized peptide
US9814754B2 (en) * 2012-08-08 2017-11-14 Polyphor Ag Combinations with a backbone-cyclized peptide
CN104684925A (en) * 2012-08-08 2015-06-03 波利弗尔股份公司 Combinations with a backbone-cyclized peptide
CN104684925B (en) * 2012-08-08 2021-11-30 波利弗尔股份公司 Combinations comprising backbone cyclized peptides
US20150224168A1 (en) * 2012-08-08 2015-08-13 Polyphor Ag Combinations with a backbone-cyclized peptide
US20150216927A1 (en) * 2012-08-08 2015-08-06 Polyphor Ag Combinations with a backbone-cyclized peptide
CN104684924A (en) * 2012-08-08 2015-06-03 波利弗尔股份公司 Combinations with a backbone-cyclized peptide
WO2014023757A1 (en) 2012-08-08 2014-02-13 Polyphor Ag Combinations with a backbone-cyclized peptide
US9938322B2 (en) 2013-03-30 2018-04-10 Polyphor Ag β-hairpin peptidomimetics
AU2014247188B2 (en) * 2013-03-30 2018-12-13 Polyphor Ag Beta-hairpin peptidomimetics
US9850284B2 (en) * 2013-03-30 2017-12-26 Polyphor Ag Beta-hairpin peptidomimetics
WO2014161781A1 (en) * 2013-03-30 2014-10-09 Polyphor Ag Beta-hairpin peptidomimetics
US20160060298A1 (en) * 2013-03-30 2016-03-03 Polyphor Ag Beta-hairpin peptidomimetics
EA034926B1 (en) * 2013-03-30 2020-04-07 Полифор Аг Beta-hairpin peptidomimetics
AU2014247189B2 (en) * 2013-03-30 2018-12-13 Polyphor Ag Beta-hairpin peptidomimetics
US10370411B2 (en) 2013-03-30 2019-08-06 Polyphor Ag Beta-hairpin peptidomimetics
AU2014247188C1 (en) * 2013-03-30 2019-04-04 Polyphor Ag Beta-hairpin peptidomimetics
US10370412B2 (en) 2013-03-30 2019-08-06 Polyphor Ag Beta-hairpin peptidomimetics
AU2014247189C1 (en) * 2013-03-30 2019-05-16 Polyphor Ag Beta-hairpin peptidomimetics
WO2016050360A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
WO2016050361A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
WO2016150576A1 (en) 2015-03-23 2016-09-29 Polyphor Ag Beta-hairpin peptidomimetics
WO2019091601A1 (en) 2017-11-10 2019-05-16 Polyphor Ag Beta-hairpin peptidomimetics
WO2022106063A2 (en) 2020-11-23 2022-05-27 Polyphor Ag Compositions of a beta-hairpin peptidomimetic and aerosol dosage forms thereof

Also Published As

Publication number Publication date
AU2007204547B2 (en) 2012-09-20
WO2007079597A1 (en) 2007-07-19
EA015991B1 (en) 2012-01-30
CN101395173A (en) 2009-03-25
JP2009523713A (en) 2009-06-25
US9538752B2 (en) 2017-01-10
US8685922B2 (en) 2014-04-01
ATE538131T1 (en) 2012-01-15
US9596852B2 (en) 2017-03-21
ZA200806564B (en) 2010-05-26
DK1979374T3 (en) 2012-04-10
PT1979374E (en) 2012-03-29
US10730912B2 (en) 2020-08-04
US20100240592A1 (en) 2010-09-23
HK1127957A1 (en) 2009-10-09
US9521846B2 (en) 2016-12-20
US20170107259A1 (en) 2017-04-20
NO20083485L (en) 2008-10-14
CY1117252T1 (en) 2017-04-26
NO341875B1 (en) 2018-02-12
CN102796179A (en) 2012-11-28
IL192816A (en) 2013-06-27
EA200801710A1 (en) 2009-02-27
CN102796179B (en) 2015-09-02
EP1979374A2 (en) 2008-10-15
CN101395173B (en) 2013-03-13
US20140087994A1 (en) 2014-03-27
SI1979374T1 (en) 2012-06-29
JP5237826B2 (en) 2013-07-17
AU2007204547A1 (en) 2007-07-19
ES2381846T3 (en) 2012-06-01
CA2637377A1 (en) 2007-07-19
IL192816A0 (en) 2009-02-11
US20140187472A1 (en) 2014-07-03
KR101352829B1 (en) 2014-02-17
NZ570245A (en) 2011-02-25
KR20090010022A (en) 2009-01-28
CA2637377C (en) 2016-03-22
BRPI0707144A2 (en) 2011-04-19
WO2007079605A3 (en) 2007-08-30
HK1175478A1 (en) 2013-07-05
PL1979374T3 (en) 2012-07-31
EP1979374B1 (en) 2011-12-21
US20140187471A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
US10730912B2 (en) Template-fixed peptidomimetics with antimicrobial activity
AU2002247724B2 (en) Template-fixed peptidomimetics with antimicrobial activity
US8895499B2 (en) β-hairpin peptidomimetics
AU2002247724A1 (en) Template-fixed peptidomimetics with antimicrobial activity
IL171530A (en) Template- fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
EP1856140A1 (en) Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
EP1532164A1 (en) Template-fixed peptidomimetics with antibacterial activity
US20110312879A1 (en) Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
WO2011066869A1 (en) Beta-hairpin peptidomimetics
US7855179B2 (en) Template-fixed peptidomimetics with antimicrobial activity
EP1549670B1 (en) Template-fixed peptidomimetics with antimicrobial activity
BRPI0707144B1 (en) COMPOUNDS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS, AND PROCESS FOR THE MANUFACTURE OF COMPOUNDS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/009033

Country of ref document: MX

Ref document number: 2008549738

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 192816

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2637377

Country of ref document: CA

Ref document number: 2007700115

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007204547

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 570245

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 3352/KOLNP/2008

Country of ref document: IN

Ref document number: 1020087020026

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200801710

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2007204547

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200780008052.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12161065

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0707144

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080716